{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Import packages"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "from collections import defaultdict\n",
    "from copy import deepcopy\n",
    "from tqdm import tqdm\n",
    "from pathlib import Path\n",
    "import random\n",
    "import json\n",
    "from sklearn.model_selection import train_test_split\n",
    "\n",
    "import matplotlib as mpl\n",
    "import matplotlib.pyplot as plt\n",
    "import numpy as np\n",
    "import pandas as pd\n",
    "\n",
    "from matplotlib.cm import ScalarMappable\n",
    "from matplotlib.lines import Line2D\n",
    "from mpl_toolkits.axes_grid1.inset_locator import inset_axes\n",
    "from textwrap import wrap\n",
    "\n",
    "import seaborn as sns\n",
    "import matplotlib.pyplot as plt\n",
    "sns.set(style=\"darkgrid\")\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Read CSV, Split train-test"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "989\n",
      "Number of Unique Contexts   : 144\n",
      "Ratio of QA Pair-to-Context : 6.868055555555555\n"
     ]
    }
   ],
   "source": [
    "df = pd.read_csv('../data/otquad-v1.0 - editing.csv')[['title', 'context',\n",
    "                                                      'question', 'answer']]\n",
    "\n",
    "print(len(df))\n",
    "print(f\"Number of Unique Contexts   : {df['context'].nunique()}\")\n",
    "print(f\"Ratio of QA Pair-to-Context : {len(df)/df['context'].nunique()}\")\n",
    "\n",
    "df['context_length'] = df['context'].apply(len)\n",
    "df['question_length'] = df['question'].apply(len)\n",
    "df['answer_length'] = df['answer'].apply(len)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [],
   "source": [
    "# dff = df.sample(100, random_state=42)\n",
    "# dff.to_csv('../data/sample_data.csv', index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "df_copy = deepcopy(df)\n",
    "df_copy.drop_duplicates(subset='context', keep=\"last\", inplace = True)\n",
    "df_copy.reset_index(drop=True)\n",
    "train_unique_context, test_unique_context = train_test_split(df_copy, \n",
    "                                                             test_size=0.2,\n",
    "                                                             random_state=42)\n",
    "train = pd.merge(train_unique_context, df, on=\"context\")\n",
    "test = pd.merge(test_unique_context, df, on=\"context\")\n",
    "\n",
    "assert np.array_equal(sorted(train_unique_context['context'].values),\n",
    "                      sorted(np.unique(train['context'].values)))\n",
    "assert np.array_equal(sorted(test_unique_context['context'].values),\n",
    "                      sorted(np.unique(test['context'].values)))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [],
   "source": [
    "# for i in range(len(train)):\n",
    "#   for j in range(len(train)):\n",
    "#     if i!=j:\n",
    "#       if train['question_y'].values[i]==train['question_y'].values[j]:\n",
    "#         print(train['question_y'].values[i])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(765, 224)"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(train['context'].values), len(test['context'].values)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "def df_to_json(df, data_path, json_filename):\n",
    "  start_index = [df['context'].values[i].lower().find(df['answer_y'].values[i].lower())\n",
    "                 for i in range(len(df))]\n",
    "  df['start_index_y'] = start_index\n",
    "\n",
    "  for i in range(len(df)):\n",
    "      print(i, start_index[i])\n",
    "      print('Original : ',df['answer_y'].values[i].lower())\n",
    "      print('Extracted: ', df['context'].values[i].lower()[start_index[i]:start_index[i]+len(df['answer_y'].values[i])])\n",
    "      assert df['answer_y'].values[i].lower() == df['context'].values[i].lower()[\n",
    "        start_index[i]:start_index[i]+len(df['answer_y'].values[i])]\n",
    "\n",
    "  print(f'Unique Contexts: {len(np.unique(df.context.values))}\\n Ratio of QA Pair-to-Contexts: {len(df)/len(np.unique(df.context.values))}')\n",
    "\n",
    "  squad_entries= []\n",
    "  for i in tqdm(range(len(df))):\n",
    "    id_num      = i\n",
    "    context     = df['context'].values[i]\n",
    "    question    = df['question_y'].values[i]\n",
    "    answer_text = df['answer_y'].values[i]\n",
    "    start       = df['start_index_y'].values[i]\n",
    "    title       = df['title_y'].values[i]\n",
    "\n",
    "    if start!=-1:\n",
    "      answer={\"text\":answer_text,\"answer_start\":int(start)}\n",
    "    else:\n",
    "      continue\n",
    "    new_entry={\n",
    "               \"qas\": [\n",
    "                 {\n",
    "                  \"id\": int(id_num),\n",
    "                  \"question\": question,\n",
    "                  \"answers\": [answer]\n",
    "                 }\n",
    "                 ],\n",
    "               \"context\": context\n",
    "               }\n",
    "    squad_entries.append({\"title\":title,\n",
    "                          \"paragraphs\":[new_entry]})\n",
    "        \n",
    "\n",
    "  squad_json={\"data\": squad_entries,\n",
    "            \"version\":1.0}\n",
    "\n",
    "  with open(data_path/json_filename, \"w\") as writer:\n",
    "      writer.write(json.dumps(squad_json, indent=4) + \"\\n\")\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0 94\n",
      "Original :  age\n",
      "Extracted:  age\n",
      "1 79\n",
      "Original :  general clinicians or specialists\n",
      "Extracted:  general clinicians or specialists\n",
      "2 113\n",
      "Original :  to study and consider the latest information on opioid therapy (ot) and how and whether to incorporate that information or recommendations into their practice\n",
      "Extracted:  to study and consider the latest information on opioid therapy (ot) and how and whether to incorporate that information or recommendations into their practice\n",
      "3 0\n",
      "Original :  this guideline\n",
      "Extracted:  this guideline\n",
      "4 291\n",
      "Original :  provide specific information\n",
      "Extracted:  provide specific information\n",
      "5 358\n",
      "Original :  looking up the dosing of a medication used less frequently or the meaning of the urine drug testing (udt) result\n",
      "Extracted:  looking up the dosing of a medication used less frequently or the meaning of the urine drug testing (udt) result\n",
      "6 476\n",
      "Original :  section on tapering and its accompanying appendix\n",
      "Extracted:  section on tapering and its accompanying appendix\n",
      "7 703\n",
      "Original :  to educate themselves and better understand their care\n",
      "Extracted:  to educate themselves and better understand their care\n",
      "8 796\n",
      "Original :  to assure that its clinicians and patients have the resources available to compassionately, effectively, and safely evaluate and deliver lot in a timely, culturally sensitive manner\n",
      "Extracted:  to assure that its clinicians and patients have the resources available to compassionately, effectively, and safely evaluate and deliver lot in a timely, culturally sensitive manner\n",
      "9 0\n",
      "Original :  further studies\n",
      "Extracted:  further studies\n",
      "10 65\n",
      "Original :  ongoing risk mitigation strategies, assessment for opioid use disorder, and consideration for tapering when risks exceed benefits\n",
      "Extracted:  ongoing risk mitigation strategies, assessment for opioid use disorder, and consideration for tapering when risks exceed benefits\n",
      "11 199\n",
      "Original :  recommend against\n",
      "Extracted:  recommend against\n",
      "12 417\n",
      "Original :  close monitoring, including engagement in substance use disorder treatment, and discontinuation of opioid therapy for pain with appropriate tapering\n",
      "Extracted:  close monitoring, including engagement in substance use disorder treatment, and discontinuation of opioid therapy for pain with appropriate tapering\n",
      "13 238\n",
      "Original :  15 mg every 10 days\n",
      "Extracted:  15 mg every 10 days\n",
      "14 343\n",
      "Original :  4 tablets = 60 mg in the morning, 3 tablets = 45 mg in the afternoon, 4 tablets = 60 mg in the evening\n",
      "Extracted:  4 tablets = 60 mg in the morning, 3 tablets = 45 mg in the afternoon, 4 tablets = 60 mg in the evening\n",
      "15 472\n",
      "Original :  3 tablets = 45 mg in the morning, 3 tablets = 45 mg in the afternoon, 4 tablets = 60 mg in the evening\n",
      "Extracted:  3 tablets = 45 mg in the morning, 3 tablets = 45 mg in the afternoon, 4 tablets = 60 mg in the evening\n",
      "16 601\n",
      "Original :  3 tablets = 45 mg in the morning, 3 tablets = 45 mg in the afternoon, 3 tablets = 45 mg in the evening\n",
      "Extracted:  3 tablets = 45 mg in the morning, 3 tablets = 45 mg in the afternoon, 3 tablets = 45 mg in the evening\n",
      "17 29\n",
      "Original :  bio-psycho-social model e.g., phi’s “whole health” approach\n",
      "Extracted:  bio-psycho-social model e.g., phi’s “whole health” approach\n",
      "18 59\n",
      "Original :  phi’s “whole health” approach\n",
      "Extracted:  phi’s “whole health” approach\n",
      "19 139\n",
      "Original :  cognitive behavioral therapy (cbt) or acceptance and commitment therapy (act) for pain\n",
      "Extracted:  cognitive behavioral therapy (cbt) or acceptance and commitment therapy (act) for pain\n",
      "20 352\n",
      "Original :  acupuncture, meditation, yoga\n",
      "Extracted:  acupuncture, meditation, yoga\n",
      "21 287\n",
      "Original :  complementary and integrative health\n",
      "Extracted:  complementary and integrative health\n",
      "22 407\n",
      "Original :  slow tapering of opioids to reduce opioid risks while not “cutting off” the veteran\n",
      "Extracted:  slow tapering of opioids to reduce opioid risks while not “cutting off” the veteran\n",
      "23 6\n",
      "Original :  there is currently no evidence in the literature documenting the benefit of lot that demonstrates  improvement in pain and function\n",
      "Extracted:  there is currently no evidence in the literature documenting the benefit of lot that demonstrates  improvement in pain and function\n",
      "24 352\n",
      "Original :  a careful assessment of benefits and risks should be made to ensure that  the benefits are expected to outweigh the well-documented risks\n",
      "Extracted:  a careful assessment of benefits and risks should be made to ensure that  the benefits are expected to outweigh the well-documented risks\n",
      "25 536\n",
      "Original :  multimodal\n",
      "Extracted:  multimodal\n",
      "26 643\n",
      "Original :  all opioid risk mitigation strategies outlined in this guideline (see recommendation 7) should be put into  place\n",
      "Extracted:  all opioid risk mitigation strategies outlined in this guideline (see recommendation 7) should be put into  place\n",
      "27 452\n",
      "Original :  the va/dod sud cpg\n",
      "Extracted:  the va/dod sud cpg\n",
      "28 13\n",
      "Original :  tapering to reduced dose or to discontinuation of long-term opioid therapy\n",
      "Extracted:  tapering to reduced dose or to discontinuation of long-term opioid therapy\n",
      "29 88\n",
      "Original :  when risks of long-term opioid therapy outweigh benefits\n",
      "Extracted:  when risks of long-term opioid therapy outweigh benefits\n",
      "30 152\n",
      "Original :  abrupt discontinuation\n",
      "Extracted:  abrupt discontinuation\n",
      "31 294\n",
      "Original :  risk assessment and patient needs and characteristics\n",
      "Extracted:  risk assessment and patient needs and characteristics\n",
      "32 0\n",
      "Original :  all patients who take opioids chronically\n",
      "Extracted:  all patients who take opioids chronically\n",
      "33 91\n",
      "Original :  those who are  younger than 30 years of age\n",
      "Extracted:  those who are  younger than 30 years of age\n",
      "34 58\n",
      "Original :  oud and overdose\n",
      "Extracted:  oud and overdose\n",
      "35 136\n",
      "Original :  seven\n",
      "Extracted:  seven\n",
      "36 0\n",
      "Original :  there may be some variation\n",
      "Extracted:  there may be some variation\n",
      "37 31\n",
      "Original :  patient values and preferences\n",
      "Extracted:  patient values and preferences\n",
      "38 68\n",
      "Original :  appropriate mechanism and condition specific non-opioid pharmacologic agents\n",
      "Extracted:  appropriate mechanism and condition specific non-opioid pharmacologic agents\n",
      "39 226\n",
      "Original :  gabapentin in neuropathic pain states\n",
      "Extracted:  gabapentin in neuropathic pain states\n",
      "40 270\n",
      "Original :  potential contraindications and long-term  risks of use\n",
      "Extracted:  potential contraindications and long-term  risks of use\n",
      "41 395\n",
      "Original :  these also can carry risk  of harm, depending on the specific patient and chosen medication\n",
      "Extracted:  these also can carry risk  of harm, depending on the specific patient and chosen medication\n",
      "42 0\n",
      "Original :  a paradigm shift in the use of ot for chronic non-terminal pain\n",
      "Extracted:  a paradigm shift in the use of ot for chronic non-terminal pain\n",
      "43 141\n",
      "Original :  rarely used outside of severe acute injury or post-surgical pain, primarily due to concern for tolerance, physical dependence, and addiction\n",
      "Extracted:  rarely used outside of severe acute injury or post-surgical pain, primarily due to concern for tolerance, physical dependence, and addiction\n",
      "44 236\n",
      "Original :  tolerance, physical dependence, and addiction\n",
      "Extracted:  tolerance, physical dependence, and addiction\n",
      "45 283\n",
      "Original :  as the hospice and palliative care  movement began defining end-of-life care in the u.s. during the 1980s and emphasizing the importance of  pain relief\n",
      "Extracted:  as the hospice and palliative care  movement began defining end-of-life care in the u.s. during the 1980s and emphasizing the importance of  pain relief\n",
      "46 504\n",
      "Original :  efforts to destigmatize the use of prescription opioids for chronic non-terminal pain\n",
      "Extracted:  efforts to destigmatize the use of prescription opioids for chronic non-terminal pain\n",
      "47 741\n",
      "Original :  chronic pain management\n",
      "Extracted:  chronic pain management\n",
      "48 792\n",
      "Original :  in the 1990s and the first decade of the 2000s\n",
      "Extracted:  in the 1990s and the first decade of the 2000s\n",
      "49 920\n",
      "Original :  absence\n",
      "Extracted:  absence\n",
      "50 1187\n",
      "Original :  in the decade of the 2010s\n",
      "Extracted:  in the decade of the 2010s\n",
      "51 1038\n",
      "Original :  as observational and epidemiologic data of harm from lot accumulated\n",
      "Extracted:  as observational and epidemiologic data of harm from lot accumulated\n",
      "52 46\n",
      "Original :  assist primary care providers in determining if an opioid taper is necessary for a specific patient, in performing the taper, and in providing follow-up and support during the taper\n",
      "Extracted:  assist primary care providers in determining if an opioid taper is necessary for a specific patient, in performing the taper, and in providing follow-up and support during the taper\n",
      "53 31\n",
      "Original :  methadone\n",
      "Extracted:  methadone\n",
      "54 166\n",
      "Original :  the heart rate’s corrected time interval from the start of the q wave to the end of the t wave\n",
      "Extracted:  the heart rate’s corrected time interval from the start of the q wave to the end of the t wave\n",
      "55 299\n",
      "Original :  a dangerous or fatal cardiac arrhythmia\n",
      "Extracted:  a dangerous or fatal cardiac arrhythmia\n",
      "56 278\n",
      "Original :  torsades de pointes\n",
      "Extracted:  torsades de pointes\n",
      "57 97\n",
      "Original :  unique pharmacodynamic properties that can prolong the qtc interval (the heart rate’s corrected time interval from the start of the q wave to the end of the t wave) and precipitate torsades de pointes, a dangerous or fatal cardiac arrhythmia\n",
      "Extracted:  unique pharmacodynamic properties that can prolong the qtc interval (the heart rate’s corrected time interval from the start of the q wave to the end of the t wave) and precipitate torsades de pointes, a dangerous or fatal cardiac arrhythmia\n",
      "58 340\n",
      "Original :  patients who may be at risk include those with other risk factors for qtc prolongation, current or prior electrocardiograms (ecgs) with a prolonged qtc >450 ms, or a history of syncope.\n",
      "Extracted:  patients who may be at risk include those with other risk factors for qtc prolongation, current or prior electrocardiograms (ecgs) with a prolonged qtc >450 ms, or a history of syncope.\n",
      "59 376\n",
      "Original :  those with other risk factors for qtc prolongation, current or prior electrocardiograms (ecgs) with a prolonged qtc >450 ms, or a history of syncope\n",
      "Extracted:  those with other risk factors for qtc prolongation, current or prior electrocardiograms (ecgs) with a prolonged qtc >450 ms, or a history of syncope\n",
      "60 3\n",
      "Original :  2010\n",
      "Extracted:  2010\n",
      "61 9\n",
      "Original :  the va and dod\n",
      "Extracted:  the va and dod\n",
      "62 150\n",
      "Original :  evidence reviewed through march 2009\n",
      "Extracted:  evidence reviewed through march 2009\n",
      "63 194\n",
      "Original :  the release of that guideline\n",
      "Extracted:  the release of that guideline\n",
      "64 194\n",
      "Original :  the release of that guideline\n",
      "Extracted:  the release of that guideline\n",
      "65 263\n",
      "Original :  an epidemic of opioid misuse and opioid use disorder (oud) in america, including among america’s veterans\n",
      "Extracted:  an epidemic of opioid misuse and opioid use disorder (oud) in america, including among america’s veterans\n",
      "66 49\n",
      "Original :  more frequent monitoring for adverse events including opioid use disorder and overdose\n",
      "Extracted:  more frequent monitoring for adverse events including opioid use disorder and overdose\n",
      "67 0\n",
      "Original :  as opioid dosage and risk increase\n",
      "Extracted:  as opioid dosage and risk increase\n",
      "68 179\n",
      "Original :  at any dose\n",
      "Extracted:  at any dose\n",
      "69 204\n",
      "Original :  in a dose dependent manner\n",
      "Extracted:  in a dose dependent manner\n",
      "70 298\n",
      "Original :  20- 50 mg morphine equivalent daily dose\n",
      "Extracted:  20- 50 mg morphine equivalent daily dose\n",
      "71 232\n",
      "Original :  risks for overdose and death\n",
      "Extracted:  risks for overdose and death\n",
      "72 120\n",
      "Original :  should patients be prescribed additional (or different) opioids if prior administration of opioids led to serious adverse effects or was not tolerated\n",
      "Extracted:  should patients be prescribed additional (or different) opioids if prior administration of opioids led to serious adverse effects or was not tolerated\n",
      "73 319\n",
      "Original :  patients who already have had an adequate opioid trial (of sufficient dose and duration to determine whether or not it will optimize benefit) without a  positive response\n",
      "Extracted:  patients who already have had an adequate opioid trial (of sufficient dose and duration to determine whether or not it will optimize benefit) without a  positive response\n",
      "74 46\n",
      "Original :  a systematic review of both clinical and epidemiological evidence\n",
      "Extracted:  a systematic review of both clinical and epidemiological evidence\n",
      "75 126\n",
      "Original :  a panel of multidisciplinary experts\n",
      "Extracted:  a panel of multidisciplinary experts\n",
      "76 167\n",
      "Original :  provides a clear explanation of the logical relationships between various care options and health outcomes while rating both the quality of the evidence and the strength of the recommendation\n",
      "Extracted:  provides a clear explanation of the logical relationships between various care options and health outcomes while rating both the quality of the evidence and the strength of the recommendation\n",
      "77 63\n",
      "Original :  when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice\n",
      "Extracted:  when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice\n",
      "78 214\n",
      "Original :  every healthcare professional making use of these guidelines\n",
      "Extracted:  every healthcare professional making use of these guidelines\n",
      "79 294\n",
      "Original :  evaluating the appropriateness of applying them in the setting of any particular clinical situation\n",
      "Extracted:  evaluating the appropriateness of applying them in the setting of any particular clinical situation\n",
      "80 91\n",
      "Original :  the best information available at the time of publication\n",
      "Extracted:  the best information available at the time of publication\n",
      "81 171\n",
      "Original :  provide information and assist decision making\n",
      "Extracted:  provide information and assist decision making\n",
      "82 244\n",
      "Original :  define a standard of care \n",
      "Extracted:  define a standard of care \n",
      "83 251\n",
      "Original :  a standard of care\n",
      "Extracted:  a standard of care\n",
      "84 341\n",
      "Original :  as prescribing an exclusive course of management\n",
      "Extracted:  as prescribing an exclusive course of management\n",
      "85 250\n",
      "Original :  concurrent benzodiazepine and lot use\n",
      "Extracted:  concurrent benzodiazepine and lot use\n",
      "86 318\n",
      "Original :  unintentional overdose death\n",
      "Extracted:  unintentional overdose death\n",
      "87 250\n",
      "Original :  concurrent benzodiazepine and lot use\n",
      "Extracted:  concurrent benzodiazepine and lot use\n",
      "88 81\n",
      "Original :  benzodiazepines\n",
      "Extracted:  benzodiazepines\n",
      "89 526\n",
      "Original :  due to symptoms related to benzodiazepine dependence, exacerbations of ptsd, and/or anxiety\n",
      "Extracted:  due to symptoms related to benzodiazepine dependence, exacerbations of ptsd, and/or anxiety\n",
      "90 634\n",
      "Original :  abrupt discontinuation of benzodiazepines\n",
      "Extracted:  abrupt discontinuation of benzodiazepines\n",
      "91 634\n",
      "Original :  abrupt\n",
      "Extracted:  abrupt\n",
      "92 695\n",
      "Original :  as it can lead to serious adverse  effects including seizures and death\n",
      "Extracted:  as it can lead to serious adverse  effects including seizures and death\n",
      "93 813\n",
      "Original :  with caution and  within a team environment when possible (see recommendation 26 in the va/dod sud cpg)\n",
      "Extracted:  with caution and  within a team environment when possible (see recommendation 26 in the va/dod sud cpg)\n",
      "94 768\n",
      "Original :  tapering benzodiazepines\n",
      "Extracted:  tapering benzodiazepines\n",
      "95 919\n",
      "Original :  due to the  difficulty of tapering or discontinuing benzodiazepines\n",
      "Extracted:  due to the  difficulty of tapering or discontinuing benzodiazepines\n",
      "96 988\n",
      "Original :  particular caution should be used\n",
      "Extracted:  particular caution should be used\n",
      "97 1070\n",
      "Original :  veterans with ptsd who have co-occurring chronic pain\n",
      "Extracted:  veterans with ptsd who have co-occurring chronic pain\n",
      "98 1125\n",
      "Original :  the va/dod ptsd  cpg\n",
      "Extracted:  the va/dod ptsd  cpg\n",
      "99 1146\n",
      "Original :  recommends against\n",
      "Extracted:  recommends against\n",
      "100 1125\n",
      "Original :  the va/dod ptsd  cpg\n",
      "Extracted:  the va/dod ptsd  cpg\n",
      "101 1262\n",
      "Original :  benzodiazepines to treat acute anxiety symptoms after trauma\n",
      "Extracted:  benzodiazepines to treat acute anxiety symptoms after trauma\n",
      "102 1343\n",
      "Original :  a  higher incidence of ptsd symptoms\n",
      "Extracted:  a  higher incidence of ptsd symptoms\n",
      "103 1547\n",
      "Original :  although  anxiety may initially improve with benzodiazepines, the improvement is short-lived and may result in  tolerance to increasing doses and eventual failure of the treatment.\n",
      "Extracted:  although  anxiety may initially improve with benzodiazepines, the improvement is short-lived and may result in  tolerance to increasing doses and eventual failure of the treatment.\n",
      "104 1777\n",
      "Original :  exacerbation of severe ptsd symptoms\n",
      "Extracted:  exacerbation of severe ptsd symptoms\n",
      "105 1733\n",
      "Original :  gradual benzodiazepine taper\n",
      "Extracted:  gradual benzodiazepine taper\n",
      "106 1815\n",
      "Original :  concomitant use of benzodiazepines\n",
      "Extracted:  concomitant use of benzodiazepines\n",
      "107 89\n",
      "Original :  primary care physicians\n",
      "Extracted:  primary care physicians\n",
      "108 117\n",
      "Original :  march 15, 2016\n",
      "Extracted:  march 15, 2016\n",
      "109 164\n",
      "Original :  assist primary care providers in offering safe and effective treatment for patients with chronic pain in the outpatient setting (not including active cancer treatment, palliative care, or end-of-life care). it is also aimed at improving communication between providers and patients and decreasing adverse outcomes associated with lot.\n",
      "Extracted:  assist primary care providers in offering safe and effective treatment for patients with chronic pain in the outpatient setting (not including active cancer treatment, palliative care, or end-of-life care). it is also aimed at improving communication between providers and patients and decreasing adverse outcomes associated with lot.\n",
      "110 574\n",
      "Original :  initiation and continuation of ot, management of  ot, and risk assessment and use of risk mitigation strategies\n",
      "Extracted:  initiation and continuation of ot, management of  ot, and risk assessment and use of risk mitigation strategies\n",
      "111 704\n",
      "Original :  grade system\n",
      "Extracted:  grade system\n",
      "112 792\n",
      "Original :  assessment of the quality of the evidence and consideration of the balance of desirable and undesirable outcomes, patient values and preferences,  and other considerations (e.g., resource use, equity) during recommendation development\n",
      "Extracted:  assessment of the quality of the evidence and consideration of the balance of desirable and undesirable outcomes, patient values and preferences,  and other considerations (e.g., resource use, equity) during recommendation development\n",
      "113 13\n",
      "Original :  alternatives to opioids\n",
      "Extracted:  alternatives to opioids\n",
      "114 41\n",
      "Original :  mild-to-moderate acute pain\n",
      "Extracted:  mild-to-moderate acute pain\n",
      "115 155\n",
      "Original :  when opioids are used for acute pain\n",
      "Extracted:  when opioids are used for acute pain\n",
      "116 88\n",
      "Original :  multimodal pain care including non-opioid medications as indicated\n",
      "Extracted:  multimodal pain care including non-opioid medications as indicated\n",
      "117 248\n",
      "Original :  immediate-release opioids are used at the lowest effective dose with opioid therapy reassessment no later than 3-5 days to determine if adjustments or continuing opioid therapy is indicated\n",
      "Extracted:  immediate-release opioids are used at the lowest effective dose with opioid therapy reassessment no later than 3-5 days to determine if adjustments or continuing opioid therapy is indicated\n",
      "118 290\n",
      "Original :  lowest effective\n",
      "Extracted:  lowest effective\n",
      "119 345\n",
      "Original :  no later than 3-5 days\n",
      "Extracted:  no later than 3-5 days\n",
      "120 368\n",
      "Original :  to determine if adjustments or continuing opioid therapy is indicated\n",
      "Extracted:  to determine if adjustments or continuing opioid therapy is indicated\n",
      "121 453\n",
      "Original :  education about opioid risks and alternatives to opioid therapy\n",
      "Extracted:  education about opioid risks and alternatives to opioid therapy\n",
      "122 20\n",
      "Original :  over days\n",
      "Extracted:  over days\n",
      "123 551\n",
      "Original :  by 20 to 50% of first dose if needed, then reduce by 10 to 20% every day\n",
      "Extracted:  by 20 to 50% of first dose if needed, then reduce by 10 to 20% every day\n",
      "124 774\n",
      "Original :  60 mg sr (15 mg x 4) q8h\n",
      "Extracted:  60 mg sr (15 mg x 4) q8h\n",
      "125 851\n",
      "Original :  45 mg sr (15 mg x 3) q8h\n",
      "Extracted:  45 mg sr (15 mg x 3) q8h\n",
      "126 887\n",
      "Original :  30 mg sr (15 mg x 2) q8h\n",
      "Extracted:  30 mg sr (15 mg x 2) q8h\n",
      "127 923\n",
      "Original :  15 mg sr q8h\n",
      "Extracted:  15 mg sr q8h\n",
      "128 947\n",
      "Original :  15 mg sr q12h\n",
      "Extracted:  15 mg sr q12h\n",
      "129 947\n",
      "Original :  15 mg sr q12h\n",
      "Extracted:  15 mg sr q12h\n",
      "130 947\n",
      "Original :  15 mg sr q12h\n",
      "Extracted:  15 mg sr q12h\n",
      "131 974\n",
      "Original :  15 mg sr qhs\n",
      "Extracted:  15 mg sr qhs\n",
      "132 974\n",
      "Original :  15 mg sr qhs\n",
      "Extracted:  15 mg sr qhs\n",
      "133 974\n",
      "Original :  15 mg sr qhs\n",
      "Extracted:  15 mg sr qhs\n",
      "134 974\n",
      "Original :  15 mg sr qhs\n",
      "Extracted:  15 mg sr qhs\n",
      "135 1021\n",
      "Original :  after day 11\n",
      "Extracted:  after day 11\n",
      "136 1051\n",
      "Original :  morphine ir 15 mg ½ tablet (7.5 mg) twice daily\n",
      "Extracted:  morphine ir 15 mg ½ tablet (7.5 mg) twice daily\n",
      "137 31\n",
      "Original :  rapid tapers\n",
      "Extracted:  rapid tapers\n",
      "138 54\n",
      "Original :  withdrawal effects\n",
      "Extracted:  withdrawal effects\n",
      "139 77\n",
      "Original :  patients should be treated with adjunctive medications\n",
      "Extracted:  patients should be treated with adjunctive medications\n",
      "140 180\n",
      "Original :  admitting the patient for inpatient care\n",
      "Extracted:  admitting the patient for inpatient care\n",
      "141 383\n",
      "Original :  medical history, mental health diagnoses, and patient preference\n",
      "Extracted:  medical history, mental health diagnoses, and patient preference\n",
      "142 222\n",
      "Original :  if patients are prescribed both long-acting and short-acting opioids\n",
      "Extracted:  if patients are prescribed both long-acting and short-acting opioids\n",
      "143 0\n",
      "Original :  psychological therapies (e.g., cognitive behavioral interventions such as cognitive behavioral therapy  [cbt], biofeedback)\n",
      "Extracted:  psychological therapies (e.g., cognitive behavioral interventions such as cognitive behavioral therapy  [cbt], biofeedback)\n",
      "144 146\n",
      "Original :  effective for pain reduction in multiple pain conditions\n",
      "Extracted:  effective for pain reduction in multiple pain conditions\n",
      "145 31\n",
      "Original :  cognitive behavioral interventions such as cognitive behavioral therapy  [cbt], biofeedback\n",
      "Extracted:  cognitive behavioral interventions such as cognitive behavioral therapy  [cbt], biofeedback\n",
      "146 211\n",
      "Original :  exercise treatments, including yoga\n",
      "Extracted:  exercise treatments, including yoga\n",
      "147 402\n",
      "Original :  exercise and  psychological therapies may each exert their influence through multiple mechanisms including but not  limited to the reduction in fear-avoidance, reduction in catastrophizing, and/or enhancing mood.\n",
      "Extracted:  exercise and  psychological therapies may each exert their influence through multiple mechanisms including but not  limited to the reduction in fear-avoidance, reduction in catastrophizing, and/or enhancing mood.\n",
      "148 631\n",
      "Original :  multidisciplinary biopsychosocial rehabilitation (described as a combination of a physical  intervention such as graded exercise and a psychological, social, or occupational intervention)\n",
      "Extracted:  multidisciplinary biopsychosocial rehabilitation (described as a combination of a physical  intervention such as graded exercise and a psychological, social, or occupational intervention)\n",
      "149 681\n",
      "Original :  described as a combination of a physical  intervention such as graded exercise and a psychological, social, or occupational intervention\n",
      "Extracted:  described as a combination of a physical  intervention such as graded exercise and a psychological, social, or occupational intervention\n",
      "150 631\n",
      "Original :  multidisciplinary biopsychosocial rehabilitation (described as a combination of a physical  intervention such as graded exercise and a psychological, social, or occupational intervention)\n",
      "Extracted:  multidisciplinary biopsychosocial rehabilitation (described as a combination of a physical  intervention such as graded exercise and a psychological, social, or occupational intervention)\n",
      "151 1042\n",
      "Original :  exercise and psychological therapies\n",
      "Extracted:  exercise and psychological therapies\n",
      "152 1042\n",
      "Original :  exercise and psychological therapies\n",
      "Extracted:  exercise and psychological therapies\n",
      "153 1000\n",
      "Original :  in light of the low harms associated with exercise and psychological therapies when compared with lot\n",
      "Extracted:  in light of the low harms associated with exercise and psychological therapies when compared with lot\n",
      "154 1000\n",
      "Original :  in light of the low harms associated with exercise and psychological therapies when compared with lot\n",
      "Extracted:  in light of the low harms associated with exercise and psychological therapies when compared with lot\n",
      "155 1250\n",
      "Original :  insufficient\n",
      "Extracted:  insufficient\n",
      "156 1339\n",
      "Original :  the choice of which to try first should be individualized based on patient  assessment and a shared decision making process\n",
      "Extracted:  the choice of which to try first should be individualized based on patient  assessment and a shared decision making process\n",
      "157 13\n",
      "Original :  assessing suicide risk and intervening when necessary\n",
      "Extracted:  assessing suicide risk and intervening when necessary\n",
      "158 67\n",
      "Original :  when considering initiating or continuing long-term opioid therapy\n",
      "Extracted:  when considering initiating or continuing long-term opioid therapy\n",
      "159 239\n",
      "Original :  at least every three months\n",
      "Extracted:  at least every three months\n",
      "160 148\n",
      "Original :  evaluating benefits of continued opioid therapy and risk for opioid-related adverse events\n",
      "Extracted:  evaluating benefits of continued opioid therapy and risk for opioid-related adverse events\n",
      "161 200\n",
      "Original :  risk for opioid-related adverse events\n",
      "Extracted:  risk for opioid-related adverse events\n",
      "162 159\n",
      "Original :  benefits of continued opioid therapy\n",
      "Extracted:  benefits of continued opioid therapy\n",
      "163 321\n",
      "Original :  lowest dose of opioids as indicated by patient-specific risks and benefits\n",
      "Extracted:  lowest dose of opioids as indicated by patient-specific risks and benefits\n",
      "164 360\n",
      "Original :  patient-specific risks and benefits\n",
      "Extracted:  patient-specific risks and benefits\n",
      "165 415\n",
      "Original :  absolutely safe\n",
      "Extracted:  absolutely safe\n",
      "166 37\n",
      "Original :  prochlorperazine 5 to 10 mg every 4 hours as needed, promethazine 25 mg orally or rectally every 6 hours as needed, ondansetron 4 mg every 6 hours as needed\n",
      "Extracted:  prochlorperazine 5 to 10 mg every 4 hours as needed, promethazine 25 mg orally or rectally every 6 hours as needed, ondansetron 4 mg every 6 hours as needed\n",
      "167 242\n",
      "Original :  dicyclomine 20 mg every 6 to 8 hours as needed\n",
      "Extracted:  dicyclomine 20 mg every 6 to 8 hours as needed\n",
      "168 329\n",
      "Original :  loperamide 4 mg orally initially, then 2 mg with each loose stool, not to exceed 16 mg daily; bismuth subsalicylate 524 mg every 0.5 to 1 hour orally, not to exceed 4192 mg/day\n",
      "Extracted:  loperamide 4 mg orally initially, then 2 mg with each loose stool, not to exceed 16 mg daily; bismuth subsalicylate 524 mg every 0.5 to 1 hour orally, not to exceed 4192 mg/day\n",
      "169 18\n",
      "Original :  the comprehensive addiction and recovery act\n",
      "Extracted:  the comprehensive addiction and recovery act\n",
      "170 3\n",
      "Original :  july 22, 2016\n",
      "Extracted:  july 22, 2016\n",
      "171 98\n",
      "Original :  addressing the epidemic of overdoses from prescription opioids and other prescription drugs and heroin\n",
      "Extracted:  addressing the epidemic of overdoses from prescription opioids and other prescription drugs and heroin\n",
      "172 242\n",
      "Original :  opioid abuse treatment and prevention\n",
      "Extracted:  opioid abuse treatment and prevention\n",
      "173 224\n",
      "Original :  any co-occurring condition that significantly affects respiratory rate or function such as chronic obstructive pulmonary disease (copd), asthma, pneumonia, sleep apnea, or a neuromuscular condition (e.g., amyotrophic lateral sclerosis)\n",
      "Extracted:  any co-occurring condition that significantly affects respiratory rate or function such as chronic obstructive pulmonary disease (copd), asthma, pneumonia, sleep apnea, or a neuromuscular condition (e.g., amyotrophic lateral sclerosis)\n",
      "174 461\n",
      "Original :  two large observational studies of patients with a  history of copd and sleep apnea who were prescribed opioids\n",
      "Extracted:  two large observational studies of patients with a  history of copd and sleep apnea who were prescribed opioids\n",
      "175 0\n",
      "Original :  opioid\n",
      "Extracted:  opioid\n",
      "176 46\n",
      "Original :  an assessment of current suicide risk should be made\n",
      "Extracted:  an assessment of current suicide risk should be made\n",
      "177 99\n",
      "Original :  at every phase of treatment\n",
      "Extracted:  at every phase of treatment\n",
      "178 128\n",
      "Original :  the va/dod suicide cpg\n",
      "Extracted:  the va/dod suicide cpg\n",
      "179 211\n",
      "Original :  patients considered to be at intermediate or high acute risk of suicide (determined by presence and severity of suicidal ideation, level of intention to act, existence of risk factors, limited or absent protective factors, etc.)\n",
      "Extracted:  patients considered to be at intermediate or high acute risk of suicide (determined by presence and severity of suicidal ideation, level of intention to act, existence of risk factors, limited or absent protective factors, etc.)\n",
      "180 298\n",
      "Original :  presence and severity of suicidal ideation, level of intention to act, existence of risk factors, limited or absent protective factors, etc.\n",
      "Extracted:  presence and severity of suicidal ideation, level of intention to act, existence of risk factors, limited or absent protective factors, etc.\n",
      "181 454\n",
      "Original :  suicidality\n",
      "Extracted:  suicidality\n",
      "182 49\n",
      "Original :  pain assessment, patient functional goals, impact of pain on family, work, life, review of previous diagnostic studies, additional consultations and referrals, coexisting illness and treatments and effect on pain, significant psychological, social, or behavioral factors that may affect treatment, family history of chronic pain, collateral of family involvement, patient beliefs/knowledge of the cause of their pain and their treatment preferences along with the perceived efficacy of various treatment options\n",
      "Extracted:  pain assessment, patient functional goals, impact of pain on family, work, life, review of previous diagnostic studies, additional consultations and referrals, coexisting illness and treatments and effect on pain, significant psychological, social, or behavioral factors that may affect treatment, family history of chronic pain, collateral of family involvement, patient beliefs/knowledge of the cause of their pain and their treatment preferences along with the perceived efficacy of various treatment options\n",
      "183 612\n",
      "Original :  psychological factors related to continuing vs. tapering ot\n",
      "Extracted:  psychological factors related to continuing vs. tapering ot\n",
      "184 758\n",
      "Original :  history, physical exam, comorbidities, previous treatment and medications, duration of symptoms, onset and triggers\n",
      "Extracted:  history, physical exam, comorbidities, previous treatment and medications, duration of symptoms, onset and triggers\n",
      "185 703\n",
      "Original :  beliefs, expectations, fears\n",
      "Extracted:  beliefs, expectations, fears\n",
      "186 964\n",
      "Original :  true life-threatening allergy to opioids, active sud, elevated suicide risk, concomitant use of benzodiazepines\n",
      "Extracted:  true life-threatening allergy to opioids, active sud, elevated suicide risk, concomitant use of benzodiazepines\n",
      "187 1091\n",
      "Original :  long-term opioid therapy\n",
      "Extracted:  long-term opioid therapy\n",
      "188 928\n",
      "Original :  opioid therapy\n",
      "Extracted:  opioid therapy\n",
      "189 1161\n",
      "Original :  prescription drug monitoring program\n",
      "Extracted:  prescription drug monitoring program\n",
      "190 1213\n",
      "Original :  substance use disorder\n",
      "Extracted:  substance use disorder\n",
      "191 1251\n",
      "Original :  urine drug test\n",
      "Extracted:  urine drug test\n",
      "192 1297\n",
      "Original :  va/dod clinical practice guideline for the assessment and management of patients at risk for suicide\n",
      "Extracted:  va/dod clinical practice guideline for the assessment and management of patients at risk for suicide\n",
      "193 42\n",
      "Original :  to improve the patient’s health and well-being by providing evidence-based guidance to providers who are taking care of patients on or being considered for lot\n",
      "Extracted:  to improve the patient’s health and well-being by providing evidence-based guidance to providers who are taking care of patients on or being considered for lot\n",
      "194 89\n",
      "Original :  by providing evidence-based guidance to providers who are taking care of patients on or being considered for lot\n",
      "Extracted:  by providing evidence-based guidance to providers who are taking care of patients on or being considered for lot\n",
      "195 274\n",
      "Original :  to assess the patient’s condition, provide education, and determine the best treatment methods in collaboration with the patient and a multidisciplinary care team, optimize the patient’s health outcomes and function and improve quality of life, minimize preventable complications and morbidity, emphasize the use of patient-centered care\n",
      "Extracted:  to assess the patient’s condition, provide education, and determine the best treatment methods in collaboration with the patient and a multidisciplinary care team, optimize the patient’s health outcomes and function and improve quality of life, minimize preventable complications and morbidity, emphasize the use of patient-centered care\n",
      "196 0\n",
      "Original :  given the increasing use of cannabis among patients with chronic pain and the lack of rcts comparing  outcomes of prescribing lot versus other therapies for patients with and without cannabis use and  cannabis use disorder\n",
      "Extracted:  given the increasing use of cannabis among patients with chronic pain and the lack of rcts comparing  outcomes of prescribing lot versus other therapies for patients with and without cannabis use and  cannabis use disorder\n",
      "197 96\n",
      "Original :  from  18.9% to 33.4%, an increase of 76.7%\n",
      "Extracted:  from  18.9% to 33.4%, an increase of 76.7%\n",
      "198 198\n",
      "Original :  women and young adults (i.e., 18-34 years old)\n",
      "Extracted:  women and young adults (i.e., 18-34 years old)\n",
      "199 379\n",
      "Original :  44%\n",
      "Extracted:  44%\n",
      "200 410\n",
      "Original :  15%\n",
      "Extracted:  15%\n",
      "201 531\n",
      "Original :  poorer physical function, independent of comorbid mental health concerns\n",
      "Extracted:  poorer physical function, independent of comorbid mental health concerns\n",
      "202 766\n",
      "Original :  over 90%\n",
      "Extracted:  over 90%\n",
      "203 819\n",
      "Original :  nearly 80%\n",
      "Extracted:  nearly 80%\n",
      "204 992\n",
      "Original :  approximately 65%\n",
      "Extracted:  approximately 65%\n",
      "205 1151\n",
      "Original :  age, marital status, race,  geography, mental health comorbidity, and dosage\n",
      "Extracted:  age, marital status, race,  geography, mental health comorbidity, and dosage\n",
      "206 1249\n",
      "Original :  those who were aged 50-65 years,  were married, were of a race other than african american, and who lived in a rural setting\n",
      "Extracted:  those who were aged 50-65 years,  were married, were of a race other than african american, and who lived in a rural setting\n",
      "207 1418\n",
      "Original :  veterans on higher doses of opioids\n",
      "Extracted:  veterans on higher doses of opioids\n",
      "208 1504\n",
      "Original :  those with mental health diagnoses\n",
      "Extracted:  those with mental health diagnoses\n",
      "209 20\n",
      "Original :  returning unused opioid medications\n",
      "Extracted:  returning unused opioid medications\n",
      "210 169\n",
      "Original :  70%\n",
      "Extracted:  70%\n",
      "211 88\n",
      "Original :  to reduce the amount of opioids in  the community\n",
      "Extracted:  to reduce the amount of opioids in  the community\n",
      "212 142\n",
      "Original :  it has been estimated that 70% of opioid prescriptions are left unused\n",
      "Extracted:  it has been estimated that 70% of opioid prescriptions are left unused\n",
      "213 233\n",
      "Original :  the national drug control strategy\n",
      "Extracted:  the national drug control strategy\n",
      "214 0\n",
      "Original :  take back programs\n",
      "Extracted:  take back programs\n",
      "215 300\n",
      "Original :  an effective tool\n",
      "Extracted:  an effective tool\n",
      "216 399\n",
      "Original :  3,633 containers containing 345  different prescription medications\n",
      "Extracted:  3,633 containers containing 345  different prescription medications\n",
      "217 550\n",
      "Original :  pain relievers\n",
      "Extracted:  pain relievers\n",
      "218 46\n",
      "Original :  a systematic approach considering four domains as per the grading of recommendations assessment, development and evaluation (grade) approach\n",
      "Extracted:  a systematic approach considering four domains as per the grading of recommendations assessment, development and evaluation (grade) approach\n",
      "219 104\n",
      "Original :  grading of recommendations assessment, development and evaluation\n",
      "Extracted:  grading of recommendations assessment, development and evaluation\n",
      "220 211\n",
      "Original :  confidence in the quality of the evidence, balance of desirable and undesirable outcomes (i.e., benefits and harms), patient or provider values and preferences, and other implications, as appropriate (e.g., resource use, equity, acceptability)\n",
      "Extracted:  confidence in the quality of the evidence, balance of desirable and undesirable outcomes (i.e., benefits and harms), patient or provider values and preferences, and other implications, as appropriate (e.g., resource use, equity, acceptability)\n",
      "221 74\n",
      "Original :  intermediate to high acute suicide risk, severe depression, unstable bipolar disorder, or unstable psychotic disorder\n",
      "Extracted:  intermediate to high acute suicide risk, severe depression, unstable bipolar disorder, or unstable psychotic disorder\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "222 285\n",
      "Original :  a  diagnosis of a mood disorder\n",
      "Extracted:  a  diagnosis of a mood disorder\n",
      "223 551\n",
      "Original :  those with bipolar disorder\n",
      "Extracted:  those with bipolar disorder\n",
      "224 583\n",
      "Original :  2.9 times\n",
      "Extracted:  2.9 times\n",
      "225 660\n",
      "Original :  3.2  times\n",
      "Extracted:  3.2  times\n",
      "226 784\n",
      "Original :  the va/dod suicide cpg\n",
      "Extracted:  the va/dod suicide cpg\n",
      "227 849\n",
      "Original :  the  va/dod clinical practice guideline for management of bipolar disorder in adults (va/dod bd  cpg)\n",
      "Extracted:  the  va/dod clinical practice guideline for management of bipolar disorder in adults (va/dod bd  cpg)\n",
      "228 1028\n",
      "Original :  high dose chronic opioid therapy for pain\n",
      "Extracted:  high dose chronic opioid therapy for pain\n",
      "229 1110\n",
      "Original :  treatment for chronic pain with movement, exercise, and cognitive-behavioral therapy for pain\n",
      "Extracted:  treatment for chronic pain with movement, exercise, and cognitive-behavioral therapy for pain\n",
      "230 0\n",
      "Original :  there is moderate quality evidence\n",
      "Extracted:  there is moderate quality evidence\n",
      "231 40\n",
      "Original :  intensification of monitoring\n",
      "Extracted:  intensification of monitoring\n",
      "232 76\n",
      "Original :  mitigate the risk of suicide among patients on lot\n",
      "Extracted:  mitigate the risk of suicide among patients on lot\n",
      "233 128\n",
      "Original :  im et al. (2015) found moderate quality evidence\n",
      "Extracted:  im et al. (2015) found moderate quality evidence\n",
      "234 484\n",
      "Original :  patients on long-acting opioids within the facilities providing more follow-up after new prescriptions\n",
      "Extracted:  patients on long-acting opioids within the facilities providing more follow-up after new prescriptions\n",
      "235 314\n",
      "Original :  decreased risk of suicide attempt\n",
      "Extracted:  decreased risk of suicide attempt\n",
      "236 0\n",
      "Original :  the increasing use of opioids, as well as the accompanying rise in morbidity and mortality associated with opioid use\n",
      "Extracted:  the increasing use of opioids, as well as the accompanying rise in morbidity and mortality associated with opioid use\n",
      "237 0\n",
      "Original :  the increasing use of opioids\n",
      "Extracted:  the increasing use of opioids\n",
      "238 0\n",
      "Original :  the increasing use of opioids\n",
      "Extracted:  the increasing use of opioids\n",
      "239 444\n",
      "Original :  curtailing illicit drug consumption in america and improving the health and safety of the american people by reducing the consequences of drug abuse\n",
      "Extracted:  curtailing illicit drug consumption in america and improving the health and safety of the american people by reducing the consequences of drug abuse\n",
      "240 723\n",
      "Original :  october 2015\n",
      "Extracted:  october 2015\n",
      "241 633\n",
      "Original :  presidential memorandum on preventing prescription drug abuse and heroin use\n",
      "Extracted:  presidential memorandum on preventing prescription drug abuse and heroin use\n",
      "242 814\n",
      "Original :  by calling for change in a number of key areas including preventing drug use in communities, seeking early intervention opportunities, and integrating sud treatment and supporting recovery\n",
      "Extracted:  by calling for change in a number of key areas including preventing drug use in communities, seeking early intervention opportunities, and integrating sud treatment and supporting recovery\n",
      "243 13\n",
      "Original :  assessing suicide risk\n",
      "Extracted:  assessing suicide risk\n",
      "244 0\n",
      "Original :  synthetic opioids such as fentanyl analogs, potent opioid receptor agonists\n",
      "Extracted:  synthetic opioids such as fentanyl analogs, potent opioid receptor agonists\n",
      "245 26\n",
      "Original :  fentanyl analogs, potent opioid receptor agonists\n",
      "Extracted:  fentanyl analogs, potent opioid receptor agonists\n",
      "246 128\n",
      "Original :  fentanyl analogs that may be used to create counterfeit opioid analgesic pills\n",
      "Extracted:  fentanyl analogs that may be used to create counterfeit opioid analgesic pills\n",
      "247 218\n",
      "Original :  a toxidrome characterized by significant cns and profound respiratory depression requiring multiple  naloxone doses for reversal\n",
      "Extracted:  a toxidrome characterized by significant cns and profound respiratory depression requiring multiple  naloxone doses for reversal\n",
      "248 83\n",
      "Original :  untreated sud, unstable mental health disorder, medical condition that acutely increases opioid risks (e.g., compromised or worsening cognitive or cardiopulmonary status), other factors that acutely increase risk of overdose (recent overdose, current sedation, recent motor vehicle accident), acutely elevated suicide risk\n",
      "Extracted:  untreated sud, unstable mental health disorder, medical condition that acutely increases opioid risks (e.g., compromised or worsening cognitive or cardiopulmonary status), other factors that acutely increase risk of overdose (recent overdose, current sedation, recent motor vehicle accident), acutely elevated suicide risk\n",
      "249 309\n",
      "Original :  recent overdose, current sedation, recent motor vehicle accident\n",
      "Extracted:  recent overdose, current sedation, recent motor vehicle accident\n",
      "250 462\n",
      "Original :  increase in all-cause mortality, increase risk of unintentional overdose death, increase risk of developing oud, risk of developing or worsening - depression, falls, fractures, sleep disordered breathing, worsening pain, motor vehicle accidents hypogonadism, prolonged pain, nausea, constipation, dry mouth, sedation, cognitive dysfunction, immune system dysfunction, reduction in function, reduction in quality of life\n",
      "Extracted:  increase in all-cause mortality, increase risk of unintentional overdose death, increase risk of developing oud, risk of developing or worsening - depression, falls, fractures, sleep disordered breathing, worsening pain, motor vehicle accidents hypogonadism, prolonged pain, nausea, constipation, dry mouth, sedation, cognitive dysfunction, immune system dysfunction, reduction in function, reduction in quality of life\n",
      "251 929\n",
      "Original :  modest short-term improvement in pain, possible short-term improvement in function\n",
      "Extracted:  modest short-term improvement in pain, possible short-term improvement in function\n",
      "252 1097\n",
      "Original :  “doctors used to think that opioids were safe and effective when used for long periods of time to treat chronic pain.”, “new information has taught us that long-term opioid use can lead to multiple problems including loss of pain relieving effects, increased pain, unintentional death, oud, and problems with sleep, mood, hormonal dysfunction, and immune dysfunction,”, “we now know that the best treatments for chronic pain are not opioids. the best treatments for chronic pain are non-drug treatments such as psychological therapies and rehabilitation therapies and non-opioid medications.”\n",
      "Extracted:  “doctors used to think that opioids were safe and effective when used for long periods of time to treat chronic pain.”, “new information has taught us that long-term opioid use can lead to multiple problems including loss of pain relieving effects, increased pain, unintentional death, oud, and problems with sleep, mood, hormonal dysfunction, and immune dysfunction,”, “we now know that the best treatments for chronic pain are not opioids. the best treatments for chronic pain are non-drug treatments such as psychological therapies and rehabilitation therapies and non-opioid medications.”\n",
      "253 49\n",
      "Original :  lung disease, sleep apnea, liver disease, renal disease, fall risk, advanced age\n",
      "Extracted:  lung disease, sleep apnea, liver disease, renal disease, fall risk, advanced age\n",
      "254 131\n",
      "Original :  consider tapering opioids\n",
      "Extracted:  consider tapering opioids\n",
      "255 314\n",
      "Original :  ptsd, depression, anxiety\n",
      "Extracted:  ptsd, depression, anxiety\n",
      "256 382\n",
      "Original :  the risks of continued use, along with possible benefits\n",
      "Extracted:  the risks of continued use, along with possible benefits\n",
      "257 619\n",
      "Original :  alcohol use disorder (aud), opioid use disorder (oud), and/or a use disorder involving other substances\n",
      "Extracted:  alcohol use disorder (aud), opioid use disorder (oud), and/or a use disorder involving other substances\n",
      "258 228\n",
      "Original :  benzodiazepines\n",
      "Extracted:  benzodiazepines\n",
      "259 108\n",
      "Original :  that drug diversion is a crime and constitutes an absolute contraindication to prescribing additional medications\n",
      "Extracted:  that drug diversion is a crime and constitutes an absolute contraindication to prescribing additional medications\n",
      "260 113\n",
      "Original :  drug diversion\n",
      "Extracted:  drug diversion\n",
      "261 223\n",
      "Original :  because suspicion is subjective and may be based on impression, bias, or prejudice\n",
      "Extracted:  because suspicion is subjective and may be based on impression, bias, or prejudice\n",
      "262 384\n",
      "Original :  objective\n",
      "Extracted:  objective\n",
      "263 432\n",
      "Original :  by a negative mass spectrometry/liquid chromatography udt for the substance being prescribed in the absence of withdrawal symptoms in someone who is receiving opioids\n",
      "Extracted:  by a negative mass spectrometry/liquid chromatography udt for the substance being prescribed in the absence of withdrawal symptoms in someone who is receiving opioids\n",
      "264 600\n",
      "Original :  a negative udt for the prescribed opioid\n",
      "Extracted:  a negative udt for the prescribed opioid\n",
      "265 815\n",
      "Original :  routine udt\n",
      "Extracted:  routine udt\n",
      "266 886\n",
      "Original :  methadone, fentanyl, tramadol\n",
      "Extracted:  methadone, fentanyl, tramadol\n",
      "267 950\n",
      "Original :  oxycodone, hydrocodone, hydromorphone\n",
      "Extracted:  oxycodone, hydrocodone, hydromorphone\n",
      "268 1052\n",
      "Original :  discontinue opioids according to recommendations 14 and 15 and assess for underlying oud and/or psychiatric comorbidities\n",
      "Extracted:  discontinue opioids according to recommendations 14 and 15 and assess for underlying oud and/or psychiatric comorbidities\n",
      "269 990\n",
      "Original :  when there is evidence that the patient is diverting opioids\n",
      "Extracted:  when there is evidence that the patient is diverting opioids\n",
      "270 990\n",
      "Original :  when there is evidence that the patient is diverting opioids\n",
      "Extracted:  when there is evidence that the patient is diverting opioids\n",
      "271 1373\n",
      "Original :  sudden discontinuation of opioids due to suspected diversion may place them at high risk for illicit opioid use and resulting opioid overdose (see recommendation 17)\n",
      "Extracted:  sudden discontinuation of opioids due to suspected diversion may place them at high risk for illicit opioid use and resulting opioid overdose (see recommendation 17)\n",
      "272 41\n",
      "Original :  the recommendation to use non-opioid modalities in lieu of  lot to treat their pain\n",
      "Extracted:  the recommendation to use non-opioid modalities in lieu of  lot to treat their pain\n",
      "273 41\n",
      "Original :  oend, udt, pdmp, face-to-face follow-up with frequency determined by risk\n",
      "Extracted:  oend, udt, pdmp, face-to-face follow-up with frequency determined by risk\n",
      "274 177\n",
      "Original :  risks of ot outweigh benefits, patient preference, diversion\n",
      "Extracted:  risks of ot outweigh benefits, patient preference, diversion\n",
      "275 316\n",
      "Original :  lack of clinically meaningful improvement in function, concomitant use of medications that increase risk of overdose, co-occurring medical or mental health conditions that increase risk, concerns about oud or other sud, patient non-compliance with opioid safety measures and opioid risk mitigation strategies, patient non-participation in a comprehensive pain care plan, prescribed dose higher than the maximal recommended dose, pain condition not effectively treated with opioids (e.g., back pain with normal mri; fibromyalgia), medical or mental health comorbidities that increase risk, improvement in the underlying pain condition being treated, unmanageable side effects\n",
      "Extracted:  lack of clinically meaningful improvement in function, concomitant use of medications that increase risk of overdose, co-occurring medical or mental health conditions that increase risk, concerns about oud or other sud, patient non-compliance with opioid safety measures and opioid risk mitigation strategies, patient non-participation in a comprehensive pain care plan, prescribed dose higher than the maximal recommended dose, pain condition not effectively treated with opioids (e.g., back pain with normal mri; fibromyalgia), medical or mental health comorbidities that increase risk, improvement in the underlying pain condition being treated, unmanageable side effects\n",
      "276 1055\n",
      "Original :  non-adherence to comprehensive pain care plan (e.g., attendance at appointment), unexpected udt and pdmp results, non-adherence to opioid prescription (e.g., using more than prescribed and/or running out early), higher risk medication characteristics (e.g., high-dose opioids, combination of opioids and benzodiazepines), patients with mental health, medical, or sud comorbidities that increase risk for adverse outcomes\n",
      "Extracted:  non-adherence to comprehensive pain care plan (e.g., attendance at appointment), unexpected udt and pdmp results, non-adherence to opioid prescription (e.g., using more than prescribed and/or running out early), higher risk medication characteristics (e.g., high-dose opioids, combination of opioids and benzodiazepines), patients with mental health, medical, or sud comorbidities that increase risk for adverse outcomes\n",
      "277 1108\n",
      "Original :  attendance at appointment\n",
      "Extracted:  attendance at appointment\n",
      "278 1213\n",
      "Original :  using more than prescribed and/or running out early\n",
      "Extracted:  using more than prescribed and/or running out early\n",
      "279 1313\n",
      "Original :  high-dose opioids, combination of opioids and benzodiazepines\n",
      "Extracted:  high-dose opioids, combination of opioids and benzodiazepines\n",
      "280 1492\n",
      "Original :  morphine equivalent daily dose\n",
      "Extracted:  morphine equivalent daily dose\n",
      "281 1581\n",
      "Original :  overdose education and naloxone distribution\n",
      "Extracted:  overdose education and naloxone distribution\n",
      "282 139\n",
      "Original :  self-management strategies and other non-pharmacological treatments\n",
      "Extracted:  self-management strategies and other non-pharmacological treatments\n",
      "283 54\n",
      "Original :  opioid therapy\n",
      "Extracted:  opioid therapy\n",
      "284 208\n",
      "Original :  when pharmacologic therapies are used\n",
      "Extracted:  when pharmacologic therapies are used\n",
      "285 260\n",
      "Original :  non-opioids over opioids\n",
      "Extracted:  non-opioids over opioids\n",
      "286 3\n",
      "Original :  strongly recommend against\n",
      "Extracted:  strongly recommend against\n",
      "287 361\n",
      "Original :  a short duration\n",
      "Extracted:  a short duration\n",
      "288 286\n",
      "Original :  if prescribing opioid therapy for patients with chronic pain\n",
      "Extracted:  if prescribing opioid therapy for patients with chronic pain\n",
      "289 385\n",
      "Original :  consideration of opioid therapy beyond 90 days\n",
      "Extracted:  consideration of opioid therapy beyond 90 days\n",
      "290 441\n",
      "Original :  reevaluation and discussion with patient of risks and benefits\n",
      "Extracted:  reevaluation and discussion with patient of risks and benefits\n",
      "291 0\n",
      "Original :  individuals with conditions that result in or co-occur with chronic pain\n",
      "Extracted:  individuals with conditions that result in or co-occur with chronic pain\n",
      "292 176\n",
      "Original :  many different physical and psychological conditions have a pain component\n",
      "Extracted:  many different physical and psychological conditions have a pain component\n",
      "293 95\n",
      "Original :  multiple instances in which confidence in the quality of the evidence was low or very low, while there was marked imbalance of benefits and harms, as well as certain other important considerations arising from the domains of values and preferences and/or other implications\n",
      "Extracted:  multiple instances in which confidence in the quality of the evidence was low or very low, while there was marked imbalance of benefits and harms, as well as certain other important considerations arising from the domains of values and preferences and/or other implications\n",
      "294 385\n",
      "Original :  the harms due to the potential for severe adverse events associated with opioids, particularly overdose and oud\n",
      "Extracted:  the harms due to the potential for severe adverse events associated with opioids, particularly overdose and oud\n",
      "295 586\n",
      "Original :  these factors\n",
      "Extracted:  these factors\n",
      "296 21\n",
      "Original :  offered treatments (e.g., ot) and may also decline risk mitigation strategies (e.g.,  udt, pill counts) that are recommended in the course of clinical care\n",
      "Extracted:  offered treatments (e.g., ot) and may also decline risk mitigation strategies (e.g.,  udt, pill counts) that are recommended in the course of clinical care\n",
      "297 7\n",
      "Original :  screening and treatment is offered for conditions that can complicate pain management\n",
      "Extracted:  screening and treatment is offered for conditions that can complicate pain management\n",
      "298 179\n",
      "Original :  mental health disorders, oud and other sud, moral injury, central sensitization, medical complications, sleep disorders\n",
      "Extracted:  mental health disorders, oud and other sud, moral injury, central sensitization, medical complications, sleep disorders\n",
      "299 332\n",
      "Original :  ptsd, anxiety disorders, depressive disorders\n",
      "Extracted:  ptsd, anxiety disorders, depressive disorders\n",
      "300 379\n",
      "Original :  if suicidal, then activate suicide prevention plan. if high suicide risk or actively suicidal, consult with mental health provider before beginning taper.\n",
      "Extracted:  if suicidal, then activate suicide prevention plan. if high suicide risk or actively suicidal, consult with mental health provider before beginning taper.\n",
      "301 397\n",
      "Original :  activate suicide prevention plan\n",
      "Extracted:  activate suicide prevention plan\n",
      "302 474\n",
      "Original :  consult with mental health provider before beginning taper\n",
      "Extracted:  consult with mental health provider before beginning taper\n",
      "303 474\n",
      "Original :  consult with mental health provider before beginning taper\n",
      "Extracted:  consult with mental health provider before beginning taper\n",
      "304 635\n",
      "Original :  about 41%: approximately 28% for mild symptoms, 10% for moderate symptoms and 3.5% for severe symptoms of oud\n",
      "Extracted:  about 41%: approximately 28% for mild symptoms, 10% for moderate symptoms and 3.5% for severe symptoms of oud\n",
      "305 646\n",
      "Original :  approximately 28%\n",
      "Extracted:  approximately 28%\n",
      "306 683\n",
      "Original :  10%\n",
      "Extracted:  10%\n",
      "307 713\n",
      "Original :  3.5%\n",
      "Extracted:  3.5%\n",
      "308 746\n",
      "Original :  patients with chronic pain who develop oud from opioid analgesic therapy\n",
      "Extracted:  patients with chronic pain who develop oud from opioid analgesic therapy\n",
      "309 832\n",
      "Original :  both pain and oud\n",
      "Extracted:  both pain and oud\n",
      "310 861\n",
      "Original :  either tapering the opioid analgesic or continuing to prescribe the opioid without providing oud treatment\n",
      "Extracted:  either tapering the opioid analgesic or continuing to prescribe the opioid without providing oud treatment\n",
      "311 993\n",
      "Original :  overdose and other adverse events\n",
      "Extracted:  overdose and other adverse events\n",
      "312 993\n",
      "Original :  overdose and other adverse events\n",
      "Extracted:  overdose and other adverse events\n",
      "313 13\n",
      "Original :  interdisciplinary\n",
      "Extracted:  interdisciplinary\n",
      "314 41\n",
      "Original :  addresses pain, substance use disorders, and/or mental health problems for patients presenting with high risk and/or aberrant behavior\n",
      "Extracted:  addresses pain, substance use disorders, and/or mental health problems for patients presenting with high risk and/or aberrant behavior\n",
      "315 199\n",
      "Original :  medication assisted treatment\n",
      "Extracted:  medication assisted treatment\n",
      "316 256\n",
      "Original :  patients with chronic pain and opioid use disorder\n",
      "Extracted:  patients with chronic pain and opioid use disorder\n",
      "317 233\n",
      "Original :  opioid use disorder\n",
      "Extracted:  opioid use disorder\n",
      "318 322\n",
      "Original :  va/dod clinical practice guideline\n",
      "Extracted:  va/dod clinical practice guideline\n",
      "319 126\n",
      "Original :  along with a clinical evidence review, during which the evidence was evaluated using grade, the cdc guideline developers also considered the findings of a contextual evidence review. further, the cdc core expert group, which consisted of subject matter experts,  representatives of primary care professional societies and state agencies, and an expert in guideline methodology, reviewed recommendations drafted by the cdc and evaluated how the evidence was used in the development of the recommendations, rather than developing the recommendations themselves  (as was the va/dod ot work group’s role in the development of the va/dod ot cpg). while experts provided feedback on the cdc recommendations and their development, the cdc determined the final recommendations. cdc also used a review process considering and incorporating feedback from federal partners (e.g., samhsa, va, dod), stakeholders (e.g., professional organizations, delivery systems,  community organizations), and other constituents (e.g., clinicians, prospective patients).\n",
      "Extracted:  along with a clinical evidence review, during which the evidence was evaluated using grade, the cdc guideline developers also considered the findings of a contextual evidence review. further, the cdc core expert group, which consisted of subject matter experts,  representatives of primary care professional societies and state agencies, and an expert in guideline methodology, reviewed recommendations drafted by the cdc and evaluated how the evidence was used in the development of the recommendations, rather than developing the recommendations themselves  (as was the va/dod ot work group’s role in the development of the va/dod ot cpg). while experts provided feedback on the cdc recommendations and their development, the cdc determined the final recommendations. cdc also used a review process considering and incorporating feedback from federal partners (e.g., samhsa, va, dod), stakeholders (e.g., professional organizations, delivery systems,  community organizations), and other constituents (e.g., clinicians, prospective patients).\n",
      "320 1218\n",
      "Original :  notice in the federal register for a public review and comment period as well as peer review\n",
      "Extracted:  notice in the federal register for a public review and comment period as well as peer review\n",
      "321 1421\n",
      "Original :  based on a slightly different evidence base and revised based on the feedback of individuals who were considering a larger group of potential patients relative to the va/dod\n",
      "Extracted:  based on a slightly different evidence base and revised based on the feedback of individuals who were considering a larger group of potential patients relative to the va/dod\n",
      "322 1896\n",
      "Original :  a document that details the process by which va/dod guidelines will be developed, including the use of the  grade methodology\n",
      "Extracted:  a document that details the process by which va/dod guidelines will be developed, including the use of the  grade methodology\n",
      "323 30\n",
      "Original :  patients with a history of tbi who use chronic short-acting and  long-acting opioids\n",
      "Extracted:  patients with a history of tbi who use chronic short-acting and  long-acting opioids\n",
      "324 124\n",
      "Original :  potential drug interactions prior to initiating lot\n",
      "Extracted:  potential drug interactions prior to initiating lot\n",
      "325 236\n",
      "Original :  i)opioids with benzodiazepines (compared to patients with no prescription, the odds ratio [or] and 95% confidence interval [ci] for drug-related death was or: 14.92, 95% ci: 7.00- 31.77 for patients who filled a prescription for opioids and benzodiazepines; or: 3.40, 95%  ci: 1.60-7.21 for patients who filled only an opioid prescription, and 7.21, 95% ci: 3.33-15.60 for patients who filled only a benzodiazepine prescription) (see recommendation 5) [66,67], ii)fentanyl with cyp3a4 inhibitors, iii) methadone with drugs that can prolong the qt interval (the heart rate’s corrected time  interval from the start of the q wave to the end of the t wave) (e.g., cyp450 2b6 inhibitors)\n",
      "Extracted:  i)opioids with benzodiazepines (compared to patients with no prescription, the odds ratio [or] and 95% confidence interval [ci] for drug-related death was or: 14.92, 95% ci: 7.00- 31.77 for patients who filled a prescription for opioids and benzodiazepines; or: 3.40, 95%  ci: 1.60-7.21 for patients who filled only an opioid prescription, and 7.21, 95% ci: 3.33-15.60 for patients who filled only a benzodiazepine prescription) (see recommendation 5) [66,67], ii)fentanyl with cyp3a4 inhibitors, iii) methadone with drugs that can prolong the qt interval (the heart rate’s corrected time  interval from the start of the q wave to the end of the t wave) (e.g., cyp450 2b6 inhibitors)\n",
      "326 155\n",
      "Original :  good neurophysiologic rationale\n",
      "Extracted:  good neurophysiologic rationale\n",
      "327 250\n",
      "Original :  studies in other areas (e.g., use of different  substances)\n",
      "Extracted:  studies in other areas (e.g., use of different  substances)\n",
      "328 324\n",
      "Original :  developing brains (age <30 years)\n",
      "Extracted:  developing brains (age <30 years)\n",
      "329 365\n",
      "Original :  increased risk of abnormalities and  addiction\n",
      "Extracted:  increased risk of abnormalities and  addiction\n",
      "330 198\n",
      "Original :  prior  practice of using opioid treatment (or pain care) agreements\n",
      "Extracted:  prior  practice of using opioid treatment (or pain care) agreements\n",
      "331 292\n",
      "Original :  as coercive rather  than therapeutic, lack respect for individual autonomy, can be a barrier to pain care, and may be harmful  to the patient-provider relationship\n",
      "Extracted:  as coercive rather  than therapeutic, lack respect for individual autonomy, can be a barrier to pain care, and may be harmful  to the patient-provider relationship\n",
      "332 6\n",
      "Original :  shared decision-making\n",
      "Extracted:  shared decision-making\n",
      "333 76\n",
      "Original :  medication-assisted therapy (mat)\n",
      "Extracted:  medication-assisted therapy (mat)\n",
      "334 178\n",
      "Original :  opioid agonist therapy (oat)\n",
      "Extracted:  opioid agonist therapy (oat)\n",
      "335 242\n",
      "Original :  taking opioid agonist medications such as buprenorphine/naloxone (suboxone) or methadone\n",
      "Extracted:  taking opioid agonist medications such as buprenorphine/naloxone (suboxone) or methadone\n",
      "336 284\n",
      "Original :  buprenorphine/naloxone (suboxone) or methadone\n",
      "Extracted:  buprenorphine/naloxone (suboxone) or methadone\n",
      "337 359\n",
      "Original :  through a federally regulated opioid treatment program for oud therapy\n",
      "Extracted:  through a federally regulated opioid treatment program for oud therapy\n",
      "338 464\n",
      "Original :  extended-release (er) injectable naltrexone (vivitrol)\n",
      "Extracted:  extended-release (er) injectable naltrexone (vivitrol)\n",
      "339 585\n",
      "Original :  residential sud treatment, intensive outpatient sud treatment, regular sud specialty care clinic, primary care or general mental health clinic, or federally regulated opioid treatment program\n",
      "Extracted:  residential sud treatment, intensive outpatient sud treatment, regular sud specialty care clinic, primary care or general mental health clinic, or federally regulated opioid treatment program\n",
      "340 794\n",
      "Original :  an act of transgression that leads to serious inner conflict typically brought on by betrayal, disproportionate violence, incidents involving civilians, within-rank violence\n",
      "Extracted:  an act of transgression that leads to serious inner conflict typically brought on by betrayal, disproportionate violence, incidents involving civilians, within-rank violence\n",
      "341 879\n",
      "Original :  betrayal, disproportionate violence, incidents involving civilians, within-rank violence\n",
      "Extracted:  betrayal, disproportionate violence, incidents involving civilians, within-rank violence\n",
      "342 997\n",
      "Original :  via psychologists or chaplains\n",
      "Extracted:  via psychologists or chaplains\n",
      "343 1262\n",
      "Original :  sleep apnea\n",
      "Extracted:  sleep apnea\n",
      "344 21\n",
      "Original :  over months or years\n",
      "Extracted:  over months or years\n",
      "345 81\n",
      "Original :  5 to 20% every 4 weeks with pauses in taper as needed\n",
      "Extracted:  5 to 20% every 4 weeks with pauses in taper as needed\n",
      "346 0\n",
      "Original :  slower taper\n",
      "Extracted:  slower taper\n",
      "347 336\n",
      "Original :  75 mg (60 mg+15 mg)sr q8h\n",
      "Extracted:  75 mg (60 mg+15 mg)sr q8h\n",
      "348 417\n",
      "Original :  60 mg sr q8h\n",
      "Extracted:  60 mg sr q8h\n",
      "349 443\n",
      "Original :  45 mg sr q8h\n",
      "Extracted:  45 mg sr q8h\n",
      "350 469\n",
      "Original :  30 mg sr q8h\n",
      "Extracted:  30 mg sr q8h\n",
      "351 495\n",
      "Original :  15 mg sr q8h\n",
      "Extracted:  15 mg sr q8h\n",
      "352 521\n",
      "Original :  15 mg sr q12h\n",
      "Extracted:  15 mg sr q12h\n",
      "353 548\n",
      "Original :  15mg sr qhs\n",
      "Extracted:  15mg sr qhs\n",
      "354 594\n",
      "Original :  after month 7\n",
      "Extracted:  after month 7\n",
      "355 625\n",
      "Original :  morphine ir 15 mg ½ tablet (7.5 mg) twice daily\n",
      "Extracted:  morphine ir 15 mg ½ tablet (7.5 mg) twice daily\n",
      "356 0\n",
      "Original :  some patients with sud\n",
      "Extracted:  some patients with sud\n",
      "357 0\n",
      "Original :  harms may outweigh benefits\n",
      "Extracted:  harms may outweigh benefits\n",
      "358 119\n",
      "Original :  concurrent use of benzodiazepines with prescription opioids\n",
      "Extracted:  concurrent use of benzodiazepines with prescription opioids\n",
      "359 179\n",
      "Original :  increases the risk of  overdose and overdose death\n",
      "Extracted:  increases the risk of  overdose and overdose death\n",
      "360 268\n",
      "Original :  the adjusted odds ratio (aor) for drug  overdose\n",
      "Extracted:  the adjusted odds ratio (aor) for drug  overdose\n",
      "361 333\n",
      "Original :  individuals on lot for chronic pain (without anxiety or ptsd) who also received  concurrent long-term benzodiazepine therapy\n",
      "Extracted:  individuals on lot for chronic pain (without anxiety or ptsd) who also received  concurrent long-term benzodiazepine therapy\n",
      "362 574\n",
      "Original :  veterans receiving both opioids and  benzodiazepines\n",
      "Extracted:  veterans receiving both opioids and  benzodiazepines\n",
      "363 656\n",
      "Original :  death from drug overdose\n",
      "Extracted:  death from drug overdose\n",
      "364 0\n",
      "Original :  offer risk mitigation strategies, including naloxone\n",
      "Extracted:  offer risk mitigation strategies, including naloxone\n",
      "365 145\n",
      "Original :  at least every 3 months\n",
      "Extracted:  at least every 3 months\n",
      "366 206\n",
      "Original :  at least annually\n",
      "Extracted:  at least annually\n",
      "367 145\n",
      "Original :  at least every 3 months\n",
      "Extracted:  at least every 3 months\n",
      "368 206\n",
      "Original :  at least annually\n",
      "Extracted:  at least annually\n",
      "369 0\n",
      "Original :  offer risk mitigation strategies, including naloxone\n",
      "Extracted:  offer risk mitigation strategies, including naloxone\n",
      "370 243\n",
      "Original :  opioid and benzodiazepines\n",
      "Extracted:  opioid and benzodiazepines\n",
      "371 333\n",
      "Original :  mat (medication-assisted treatment)\n",
      "Extracted:  mat (medication-assisted treatment)\n",
      "372 333\n",
      "Original :  mat (medication-assisted treatment)\n",
      "Extracted:  mat (medication-assisted treatment)\n",
      "373 333\n",
      "Original :  mat (medication-assisted treatment)\n",
      "Extracted:  mat (medication-assisted treatment)\n",
      "374 373\n",
      "Original :  patients with oud (opioid use disorder)\n",
      "Extracted:  patients with oud (opioid use disorder)\n",
      "375 373\n",
      "Original :  patients with oud (opioid use disorder)\n",
      "Extracted:  patients with oud (opioid use disorder)\n",
      "376 113\n",
      "Original :  continue the strategy of reducing to morphine sr 30 mg every 8 hours, follow up in 1 to 4 weeks to determine the next step in the taper\n",
      "Extracted:  continue the strategy of reducing to morphine sr 30 mg every 8 hours, follow up in 1 to 4 weeks to determine the next step in the taper\n",
      "377 294\n",
      "Original :  request mental health support and consider the possibility of oud\n",
      "Extracted:  request mental health support and consider the possibility of oud\n",
      "378 414\n",
      "Original :  explore the reason for the reluctance\n",
      "Extracted:  explore the reason for the reluctance\n",
      "379 491\n",
      "Original :  medical (increased pain), mental health (worsening depression, anxiety, etc.), and substance use disorder (sud)/opioid use disorder (oud)\n",
      "Extracted:  medical (increased pain), mental health (worsening depression, anxiety, etc.), and substance use disorder (sud)/opioid use disorder (oud)\n",
      "380 797\n",
      "Original :  remain at morphine sr 45 mg every 8 hours for 1 to 2 months then reassess\n",
      "Extracted:  remain at morphine sr 45 mg every 8 hours for 1 to 2 months then reassess\n",
      "381 928\n",
      "Original :  skills training and/or have a comprehensive pain care plan\n",
      "Extracted:  skills training and/or have a comprehensive pain care plan\n",
      "382 1015\n",
      "Original :  review the risk of the taper vs. the benefit of remaining at the current dose\n",
      "Extracted:  review the risk of the taper vs. the benefit of remaining at the current dose\n",
      "383 1015\n",
      "Original :  review the risk of the taper vs. the benefit of remaining at the current dose, and if necessary, adjust the speed of the taper according to the response of the veteran\n",
      "Extracted:  review the risk of the taper vs. the benefit of remaining at the current dose, and if necessary, adjust the speed of the taper according to the response of the veteran\n",
      "384 13\n",
      "Original :  implementing risk mitigation strategies\n",
      "Extracted:  implementing risk mitigation strategies\n",
      "385 98\n",
      "Original :  starting with an informed consent conversation covering the risks and benefits of opioid therapy as well as alternative therapies\n",
      "Extracted:  starting with an informed consent conversation covering the risks and benefits of opioid therapy as well as alternative therapies\n",
      "386 229\n",
      "Original :  the strategies and their frequency\n",
      "Extracted:  the strategies and their frequency\n",
      "387 317\n",
      "Original :  ongoing, random urine drug testing (including appropriate confirmatory testing), checking state prescription drug monitoring programs, monitoring for overdose potential and suicidality, providing overdose education, prescribing of naloxone rescue and accompanying education\n",
      "Extracted:  ongoing, random urine drug testing (including appropriate confirmatory testing), checking state prescription drug monitoring programs, monitoring for overdose potential and suicidality, providing overdose education, prescribing of naloxone rescue and accompanying education\n",
      "388 27\n",
      "Original :  pain lasting three months or more. it is often associated with changes in the  central nervous system (cns) known as central sensitization.\n",
      "Extracted:  pain lasting three months or more. it is often associated with changes in the  central nervous system (cns) known as central sensitization.\n",
      "389 223\n",
      "Original :  primarily nociceptive processing areas\n",
      "Extracted:  primarily nociceptive processing areas\n",
      "390 106\n",
      "Original :  central nervous system\n",
      "Extracted:  central nervous system\n",
      "391 274\n",
      "Original :  chronic pain is thought to be  associated with alterations in brain centers involved with emotions, reward, and executive function as well  as central sensitization of nociceptive pathways across several cns areas.\n",
      "Extracted:  chronic pain is thought to be  associated with alterations in brain centers involved with emotions, reward, and executive function as well  as central sensitization of nociceptive pathways across several cns areas.\n",
      "392 20\n",
      "Original :  younger patients using opioids\n",
      "Extracted:  younger patients using opioids\n",
      "393 157\n",
      "Original :  patients 18-30 years old\n",
      "Extracted:  patients 18-30 years old\n",
      "394 133\n",
      "Original :  patients ≥65 years old\n",
      "Extracted:  patients ≥65 years old\n",
      "395 190\n",
      "Original :  11\n",
      "Extracted:  11\n",
      "396 230\n",
      "Original :  patients 31-40 years\n",
      "Extracted:  patients 31-40 years\n",
      "397 312\n",
      "Original :  those  ≥65 years old\n",
      "Extracted:  those  ≥65 years old\n",
      "398 144\n",
      "Original :  5\n",
      "Extracted:  5\n",
      "399 410\n",
      "Original :  patients 30-39  years old\n",
      "Extracted:  patients 30-39  years old\n",
      "400 384\n",
      "Original :  subjects 18-29 years old\n",
      "Extracted:  subjects 18-29 years old\n",
      "401 440\n",
      "Original :  roughly half\n",
      "Extracted:  roughly half\n",
      "402 566\n",
      "Original :  patients ≥70 years old\n",
      "Extracted:  patients ≥70 years old\n",
      "403 384\n",
      "Original :  subjects 18-29 years old\n",
      "Extracted:  subjects 18-29 years old\n",
      "404 595\n",
      "Original :  far less risk (nearly 1/17)\n",
      "Extracted:  far less risk (nearly 1/17)\n",
      "405 46\n",
      "Original :  conditions that may warrant evaluation\n",
      "Extracted:  conditions that may warrant evaluation\n",
      "406 271\n",
      "Original :  before deciding to change therapy, look for “red flags”. the red flags are progressive numbness or weakness, progressive changes in bowel or bladder function, unexplained weight loss, history of internal malignancy that has not been re-staged, signs of/risk factors for infection.\n",
      "Extracted:  before deciding to change therapy, look for “red flags”. the red flags are progressive numbness or weakness, progressive changes in bowel or bladder function, unexplained weight loss, history of internal malignancy that has not been re-staged, signs of/risk factors for infection.\n",
      "407 271\n",
      "Original :  before deciding to change therapy, look for “red flags”. the red flags are progressive numbness or weakness, progressive changes in bowel or bladder function, unexplained weight loss, history of internal malignancy that has not been re-staged, signs of/risk factors for infection.\n",
      "Extracted:  before deciding to change therapy, look for “red flags”. the red flags are progressive numbness or weakness, progressive changes in bowel or bladder function, unexplained weight loss, history of internal malignancy that has not been re-staged, signs of/risk factors for infection.\n",
      "408 346\n",
      "Original :  progressive numbness or weakness, progressive changes in bowel or bladder function, unexplained weight loss, history of internal malignancy that has not been re-staged, signs of/risk factors for infection\n",
      "Extracted:  progressive numbness or weakness, progressive changes in bowel or bladder function, unexplained weight loss, history of internal malignancy that has not been re-staged, signs of/risk factors for infection\n",
      "409 587\n",
      "Original :  when there is progressive numbness or weakness, progressive changes in bowel or bladder function, unexplained weight loss, a history of internal malignancy that has not been re-staged, signs of/risk factors for infection such as fever, recent skin or urinary infection, immunosuppression, iv drug use\n",
      "Extracted:  when there is progressive numbness or weakness, progressive changes in bowel or bladder function, unexplained weight loss, a history of internal malignancy that has not been re-staged, signs of/risk factors for infection such as fever, recent skin or urinary infection, immunosuppression, iv drug use\n",
      "410 552\n",
      "Original :  an urgent evaluation\n",
      "Extracted:  an urgent evaluation\n",
      "411 552\n",
      "Original :  an urgent evaluation\n",
      "Extracted:  an urgent evaluation\n",
      "412 552\n",
      "Original :  an urgent evaluation\n",
      "Extracted:  an urgent evaluation\n",
      "413 552\n",
      "Original :  an urgent evaluation\n",
      "Extracted:  an urgent evaluation\n",
      "414 552\n",
      "Original :  an urgent evaluation\n",
      "Extracted:  an urgent evaluation\n",
      "415 816\n",
      "Original :  fever, recent skin or urinary infection, immunosuppression, iv drug use\n",
      "Extracted:  fever, recent skin or urinary infection, immunosuppression, iv drug use\n",
      "416 31\n",
      "Original :  continuing ot beyond 90 days’ duration\n",
      "Extracted:  continuing ot beyond 90 days’ duration\n",
      "417 134\n",
      "Original :  continuing ot for longer than 90 days\n",
      "Extracted:  continuing ot for longer than 90 days\n",
      "418 217\n",
      "Original :  there may be some situations where the benefits of lot clearly outweigh the risks.\n",
      "Extracted:  there may be some situations where the benefits of lot clearly outweigh the risks.\n",
      "419 325\n",
      "Original :  through individual clinical assessment\n",
      "Extracted:  through individual clinical assessment\n",
      "420 4\n",
      "Original :  immediate-release\n",
      "Extracted:  immediate-release\n",
      "421 72\n",
      "Original :  lowest\n",
      "Extracted:  lowest\n",
      "422 198\n",
      "Original :  benefits and risks\n",
      "Extracted:  benefits and risks\n",
      "423 198\n",
      "Original :  benefits and risks\n",
      "Extracted:  benefits and risks\n",
      "424 253\n",
      "Original :  if benefits do not outweigh harms\n",
      "Extracted:  if benefits do not outweigh harms\n",
      "425 253\n",
      "Original :  if benefits do not outweigh harms\n",
      "Extracted:  if benefits do not outweigh harms\n",
      "426 0\n",
      "Original :  an age of 30 years was chosen based on how age was categorized in the six studies that showed an inverse  relationship between age and oud or overdose.\n",
      "Extracted:  an age of 30 years was chosen based on how age was categorized in the six studies that showed an inverse  relationship between age and oud or overdose.\n",
      "427 0\n",
      "Original :  chronic pain\n",
      "Extracted:  chronic pain\n",
      "428 127\n",
      "Original :  the institute of medicine [iom]\n",
      "Extracted:  the institute of medicine [iom]\n",
      "429 161\n",
      "Original :  at least 100 million\n",
      "Extracted:  at least 100 million\n",
      "430 247\n",
      "Original :  the treatment of chronic pain with opioids\n",
      "Extracted:  the treatment of chronic pain with opioids\n",
      "431 401\n",
      "Original :  an epidemic of opioid-related adverse events\n",
      "Extracted:  an epidemic of opioid-related adverse events\n",
      "432 15\n",
      "Original :  tapering or discontinuation of opioid therapy\n",
      "Extracted:  tapering or discontinuation of opioid therapy\n",
      "433 139\n",
      "Original :  repeat comprehensive biopsychosocial assessment. then see if the patient demonstrates signs or symptoms of sud.\n",
      "Extracted:  repeat comprehensive biopsychosocial assessment. then see if the patient demonstrates signs or symptoms of sud.\n",
      "434 310\n",
      "Original :  see whether the patient is willing to engage in sud therapy\n",
      "Extracted:  see whether the patient is willing to engage in sud therapy\n",
      "435 428\n",
      "Original :  access specialized sud care with monitoring and follow-up appropriate for the patient’s needs (e.g., mat, treatment for comorbidities), see va/dod sud cpg, exit algorithms and manage with non-opioid modalities\n",
      "Extracted:  access specialized sud care with monitoring and follow-up appropriate for the patient’s needs (e.g., mat, treatment for comorbidities), see va/dod sud cpg, exit algorithms and manage with non-opioid modalities\n",
      "436 706\n",
      "Original :  look for evidence of diversion\n",
      "Extracted:  look for evidence of diversion\n",
      "437 778\n",
      "Original :  immediately discontinue opioid therapy\n",
      "Extracted:  immediately discontinue opioid therapy\n",
      "438 861\n",
      "Original :  look for high-risk or dangerous behavior (e.g., overdose event, accidents, and threatening provider)\n",
      "Extracted:  look for high-risk or dangerous behavior (e.g., overdose event, accidents, and threatening provider)\n",
      "439 909\n",
      "Original :  overdose event, accidents, and threatening provider\n",
      "Extracted:  overdose event, accidents, and threatening provider\n",
      "440 1106\n",
      "Original :  address safety and misuse, assess for withdrawal symptoms and offer expedited taper, immediate discontinuation or detox as indicated, continue to monitor for sud and mental health comorbidities and offer treatment as indicated (see va/dod sud cpg and academic detailing tapering document), exit algorithm and manage with non-opioid modalities\n",
      "Extracted:  address safety and misuse, assess for withdrawal symptoms and offer expedited taper, immediate discontinuation or detox as indicated, continue to monitor for sud and mental health comorbidities and offer treatment as indicated (see va/dod sud cpg and academic detailing tapering document), exit algorithm and manage with non-opioid modalities\n",
      "441 1106\n",
      "Original :  address safety and misuse, assess for withdrawal symptoms and offer expedited taper, immediate discontinuation or detox as indicated, continue to monitor for sud and mental health comorbidities and offer treatment as indicated (see va/dod sud cpg and academic detailing tapering document), exit algorithm and manage with non-opioid modalities\n",
      "Extracted:  address safety and misuse, assess for withdrawal symptoms and offer expedited taper, immediate discontinuation or detox as indicated, continue to monitor for sud and mental health comorbidities and offer treatment as indicated (see va/dod sud cpg and academic detailing tapering document), exit algorithm and manage with non-opioid modalities\n",
      "442 1106\n",
      "Original :  address safety and misuse, assess for withdrawal symptoms and offer expedited taper, immediate discontinuation or detox as indicated, continue to monitor for sud and mental health comorbidities and offer treatment as indicated (see va/dod sud cpg and academic detailing tapering document), exit algorithm and manage with non-opioid modalities\n",
      "Extracted:  address safety and misuse, assess for withdrawal symptoms and offer expedited taper, immediate discontinuation or detox as indicated, continue to monitor for sud and mental health comorbidities and offer treatment as indicated (see va/dod sud cpg and academic detailing tapering document), exit algorithm and manage with non-opioid modalities\n",
      "443 1503\n",
      "Original :  develop an individualized tapering treatment plan (including pace of tapering, setting of care) based on patient and treatment characteristics\n",
      "Extracted:  develop an individualized tapering treatment plan (including pace of tapering, setting of care) based on patient and treatment characteristics\n",
      "444 1657\n",
      "Original :  1 week to 1 month\n",
      "Extracted:  1 week to 1 month\n",
      "445 1657\n",
      "Original :  1 week to 1 month\n",
      "Extracted:  1 week to 1 month\n",
      "446 1608\n",
      "Original :  patient and treatment characteristics\n",
      "Extracted:  patient and treatment characteristics\n",
      "447 1839\n",
      "Original :  educate on self-management and risks of ot, optimize whole person approach to pain care, optimize treatment of co-occurring mental health conditions, optimize non-opioid pain treatment modalities, reassess for oud and readiness for oud treatment as indicated\n",
      "Extracted:  educate on self-management and risks of ot, optimize whole person approach to pain care, optimize treatment of co-occurring mental health conditions, optimize non-opioid pain treatment modalities, reassess for oud and readiness for oud treatment as indicated\n",
      "448 2231\n",
      "Original :  repeat comprehensive biopsychosocial assessment and see if an sud is identified\n",
      "Extracted:  repeat comprehensive biopsychosocial assessment and see if an sud is identified\n",
      "449 2231\n",
      "Original :  repeat comprehensive biopsychosocial assessment and see if an sud is identified\n",
      "Extracted:  repeat comprehensive biopsychosocial assessment and see if an sud is identified\n",
      "450 2231\n",
      "Original :  repeat comprehensive biopsychosocial assessment and see if an sud is identified\n",
      "Extracted:  repeat comprehensive biopsychosocial assessment and see if an sud is identified\n",
      "451 2342\n",
      "Original :  find out if the patient is willing to engage in sud therapy\n",
      "Extracted:  find out if the patient is willing to engage in sud therapy\n",
      "452 2437\n",
      "Original :  identify the followings: use of opioids to modulate emotions (i.e., “chemical coping”), untreated or undertreated psychiatric disorder\n",
      "Extracted:  identify the followings: use of opioids to modulate emotions (i.e., “chemical coping”), untreated or undertreated psychiatric disorder\n",
      "453 2709\n",
      "Original :  engage the patient in appropriate behavioral and/or psychiatric treatment, ideally in an interdisciplinary setting, consider reduced rate of taper or pause in taper for patients actively engaged in skills training\n",
      "Extracted:  engage the patient in appropriate behavioral and/or psychiatric treatment, ideally in an interdisciplinary setting, consider reduced rate of taper or pause in taper for patients actively engaged in skills training\n",
      "454 2709\n",
      "Original :  engage the patient in appropriate behavioral and/or psychiatric treatment, ideally in an interdisciplinary setting, consider reduced rate of taper or pause in taper for patients actively engaged in skills training\n",
      "Extracted:  engage the patient in appropriate behavioral and/or psychiatric treatment, ideally in an interdisciplinary setting, consider reduced rate of taper or pause in taper for patients actively engaged in skills training\n",
      "455 2462\n",
      "Original :  use of opioids to modulate emotions\n",
      "Extracted:  use of opioids to modulate emotions\n",
      "456 2834\n",
      "Original :  reduced rate of taper or pause in taper\n",
      "Extracted:  reduced rate of taper or pause in taper\n",
      "457 3040\n",
      "Original :  provide additional education about whole person pain care and lot and reassurance that the patient will not be abandoned, consider more frequent follow-up using the expanded care team (registered nurse, clinical pharmacist, health coach, mental health provider), consider reduced rate of taper or pause in taper for patients actively engaged in skills training, reassess for oud throughout the taper\n",
      "Extracted:  provide additional education about whole person pain care and lot and reassurance that the patient will not be abandoned, consider more frequent follow-up using the expanded care team (registered nurse, clinical pharmacist, health coach, mental health provider), consider reduced rate of taper or pause in taper for patients actively engaged in skills training, reassess for oud throughout the taper\n",
      "458 3201\n",
      "Original :  the expanded care team\n",
      "Extracted:  the expanded care team\n",
      "459 3225\n",
      "Original :  registered nurse, clinical pharmacist, health coach, mental health provider\n",
      "Extracted:  registered nurse, clinical pharmacist, health coach, mental health provider\n",
      "460 778\n",
      "Original :  immediately discontinue opioid therapy\n",
      "Extracted:  immediately discontinue opioid therapy\n",
      "461 1647\n",
      "Original :  follow-up 1 week to 1 month after each change in dosage and after discontinuation considering patient and treatment characteristics\n",
      "Extracted:  follow-up 1 week to 1 month after each change in dosage and after discontinuation considering patient and treatment characteristics\n",
      "462 33\n",
      "Original :  progression from acute to long-term ot is associated with little evidence  for sustained analgesic efficacy but a substantial increase in risk for oud\n",
      "Extracted:  progression from acute to long-term ot is associated with little evidence  for sustained analgesic efficacy but a substantial increase in risk for oud\n",
      "463 33\n",
      "Original :  progression from acute to long-term ot\n",
      "Extracted:  progression from acute to long-term ot\n",
      "464 33\n",
      "Original :  progression from acute to long-term ot is associated with little evidence  for sustained analgesic efficacy but a substantial increase in risk for oud\n",
      "Extracted:  progression from acute to long-term ot is associated with little evidence  for sustained analgesic efficacy but a substantial increase in risk for oud\n",
      "465 241\n",
      "Original :  at initiation of ot and continuously thereafter\n",
      "Extracted:  at initiation of ot and continuously thereafter\n",
      "466 289\n",
      "Original :  to ensure that the patient  understands the associated risks and benefits of lot\n",
      "Extracted:  to ensure that the patient  understands the associated risks and benefits of lot\n",
      "467 482\n",
      "Original :  research\n",
      "Extracted:  research\n",
      "468 482\n",
      "Original :  research\n",
      "Extracted:  research\n",
      "469 533\n",
      "Original :  how long it takes for oud to occur and whether the  nature of the pain is one of the factors that can influence either of this phenomena\n",
      "Extracted:  how long it takes for oud to occur and whether the  nature of the pain is one of the factors that can influence either of this phenomena\n",
      "470 18\n",
      "Original :  determination of appropriateness for opioid therapy\n",
      "Extracted:  determination of appropriateness for opioid therapy\n",
      "471 77\n",
      "Original :  non-pharmacologic and non-opioid pharmacologic\n",
      "Extracted:  non-pharmacologic and non-opioid pharmacologic\n",
      "472 263\n",
      "Original :  proceed to module d\n",
      "Extracted:  proceed to module d\n",
      "473 385\n",
      "Original :  obtain biopsychosocial assessment. then educate or re-educate on non-opioid management, self-management to improve function and quality of life, realistic expectations and limitations of medical treatment. then implement and optimize non-opioid treatments for chronic pain (e.g., physical, psychological, and complementary and integrative treatments).\n",
      "Extracted:  obtain biopsychosocial assessment. then educate or re-educate on non-opioid management, self-management to improve function and quality of life, realistic expectations and limitations of medical treatment. then implement and optimize non-opioid treatments for chronic pain (e.g., physical, psychological, and complementary and integrative treatments).\n",
      "474 450\n",
      "Original :  non-opioid management, self-management to improve function and quality of life, realistic expectations and limitations of medical treatment\n",
      "Extracted:  non-opioid management, self-management to improve function and quality of life, realistic expectations and limitations of medical treatment\n",
      "475 619\n",
      "Original :  non-opioid treatments for chronic pain\n",
      "Extracted:  non-opioid treatments for chronic pain\n",
      "476 816\n",
      "Original :  exit algorithm; manage with non-opioid modalities\n",
      "Extracted:  exit algorithm; manage with non-opioid modalities\n",
      "477 950\n",
      "Original :  complete opioid risk assessment and see if patient risks outweigh benefits by considering strength and number of risk factors and patient preference\n",
      "Extracted:  complete opioid risk assessment and see if patient risks outweigh benefits by considering strength and number of risk factors and patient preference\n",
      "478 1025\n",
      "Original :  by considering strength and number of risk factors and patient preference\n",
      "Extracted:  by considering strength and number of risk factors and patient preference\n",
      "479 1141\n",
      "Original :  see whether referral/consultation for evaluation and treatment is indicated (e.g., mental health, sud, more intensive interdisciplinary care)\n",
      "Extracted:  see whether referral/consultation for evaluation and treatment is indicated (e.g., mental health, sud, more intensive interdisciplinary care)\n",
      "480 1357\n",
      "Original :  refer/consult with appropriate interdisciplinary treatments. then after referral/consultation with appropriate interdisciplinary treatments, see if the patient is willing to engage in a comprehensive pain care plan.\n",
      "Extracted:  refer/consult with appropriate interdisciplinary treatments. then after referral/consultation with appropriate interdisciplinary treatments, see if the patient is willing to engage in a comprehensive pain care plan.\n",
      "481 1498\n",
      "Original :  see if the patient is willing to engage in a comprehensive pain care plan\n",
      "Extracted:  see if the patient is willing to engage in a comprehensive pain care plan\n",
      "482 816\n",
      "Original :  exit algorithm; manage with non-opioid modalities\n",
      "Extracted:  exit algorithm; manage with non-opioid modalities\n",
      "483 1932\n",
      "Original :  educate the patient and family about treatment options, including education on known risks and unknown long-term benefits of ot, risks of sud and overdose, need for risk mitigation strategies, naloxone rescue. then see if adding ot to comprehensive pain therapy is indicated at this time.\n",
      "Extracted:  educate the patient and family about treatment options, including education on known risks and unknown long-term benefits of ot, risks of sud and overdose, need for risk mitigation strategies, naloxone rescue. then see if adding ot to comprehensive pain therapy is indicated at this time.\n",
      "484 1969\n",
      "Original :  treatment options, including education on known risks and unknown long-term benefits of ot, risks of sud and overdose, need for risk mitigation strategies, naloxone rescue\n",
      "Extracted:  treatment options, including education on known risks and unknown long-term benefits of ot, risks of sud and overdose, need for risk mitigation strategies, naloxone rescue\n",
      "485 2296\n",
      "Original :  see if the patient is prepared to accept responsibilities and the provider is prepared to implement risk mitigation strategies\n",
      "Extracted:  see if the patient is prepared to accept responsibilities and the provider is prepared to implement risk mitigation strategies\n",
      "486 816\n",
      "Original :  exit algorithm; manage with non-opioid modalities\n",
      "Extracted:  exit algorithm; manage with non-opioid modalities\n",
      "487 2683\n",
      "Original :  discuss and complete written informed consent with patient and family, determine and document treatment plan, and proceed to module b\n",
      "Extracted:  discuss and complete written informed consent with patient and family, determine and document treatment plan, and proceed to module b\n",
      "488 816\n",
      "Original :  exit algorithm; manage with non-opioid modalities\n",
      "Extracted:  exit algorithm; manage with non-opioid modalities\n",
      "489 3\n",
      "Original :  recommend against\n",
      "Extracted:  recommend against\n",
      "490 127\n",
      "Original :  patients currently on long-term opioid therapy with evidence of untreated substance use  disorder\n",
      "Extracted:  patients currently on long-term opioid therapy with evidence of untreated substance use  disorder\n",
      "491 239\n",
      "Original :  close monitoring, including engagement in substance use disorder treatment, and discontinuation of opioid therapy for pain with appropriate tapering\n",
      "Extracted:  close monitoring, including engagement in substance use disorder treatment, and discontinuation of opioid therapy for pain with appropriate tapering\n",
      "492 0\n",
      "Original :  the accumulation of evidence of harms and the absence of evidence of long-term benefits\n",
      "Extracted:  the accumulation of evidence of harms and the absence of evidence of long-term benefits\n",
      "493 188\n",
      "Original :  the evidence of both the safety and efficacy for non-pharmacologic and non-opioid pharmacologic pain therapies\n",
      "Extracted:  the evidence of both the safety and efficacy for non-pharmacologic and non-opioid pharmacologic pain therapies\n",
      "494 436\n",
      "Original :  as a complex multidimensional experience that requires multimodal and integrated care approaches\n",
      "Extracted:  as a complex multidimensional experience that requires multimodal and integrated care approaches\n",
      "495 555\n",
      "Original :  non-pharmacologic treatments and non-opioid medications\n",
      "Extracted:  non-pharmacologic treatments and non-opioid medications\n",
      "496 694\n",
      "Original :  primarily in the treatment of severe acute pain, post-operative pain, and end-of-life pain\n",
      "Extracted:  primarily in the treatment of severe acute pain, post-operative pain, and end-of-life pain\n",
      "497 680\n",
      "Original :  limited\n",
      "Extracted:  limited\n",
      "498 0\n",
      "Original :  a number of studies suggest\n",
      "Extracted:  a number of studies suggest\n",
      "499 28\n",
      "Original :  certain chronic pain conditions\n",
      "Extracted:  certain chronic pain conditions\n",
      "500 70\n",
      "Original :  an independent risk factor for suicide\n",
      "Extracted:  an independent risk factor for suicide\n",
      "501 119\n",
      "Original :  a recent large retrospective cohort study\n",
      "Extracted:  a recent large retrospective cohort study\n",
      "502 222\n",
      "Original :  suicide risk among veterans receiving ot for cncp\n",
      "Extracted:  suicide risk among veterans receiving ot for cncp\n",
      "503 195\n",
      "Original :  prescribed opioid dose\n",
      "Extracted:  prescribed opioid dose\n",
      "504 222\n",
      "Original :  suicide risk\n",
      "Extracted:  suicide risk\n",
      "505 333\n",
      "Original :  an individual’s risk of suicide at any given point in time\n",
      "Extracted:  an individual’s risk of suicide at any given point in time\n",
      "506 310\n",
      "Original :  many factors\n",
      "Extracted:  many factors\n",
      "507 278\n",
      "Original :  suicide risk is not static, and many factors influence an individual’s risk of suicide at any given point in time, as noted in the va/dod  suicide cpg.\n",
      "Extracted:  suicide risk is not static, and many factors influence an individual’s risk of suicide at any given point in time, as noted in the va/dod  suicide cpg.\n",
      "508 484\n",
      "Original :  whether one is initiating, maintaining,  or terminating lot\n",
      "Extracted:  whether one is initiating, maintaining,  or terminating lot\n",
      "509 81\n",
      "Original :  duration and dose of ot, severe respiratory instability or sleep disordered breathing, acute psychiatric instability or intermediate to high acute suicide risk, mental health disorders, history of drug overdose, under 30 years of age, co-administration of a drug capable of inducing fatal drug-drug interactions, qtc interval >450 ms for using methadone, evidence for or history of diversion of controlled substances, intolerance, serious adverse effects, or a history of inadequate beneficial response to opioids, impaired bowel motility unresponsive to therapy, headache not responsive to other pain treatment modalities, traumatic brain injury (tbi), true allergy to opioid agents\n",
      "Extracted:  duration and dose of ot, severe respiratory instability or sleep disordered breathing, acute psychiatric instability or intermediate to high acute suicide risk, mental health disorders, history of drug overdose, under 30 years of age, co-administration of a drug capable of inducing fatal drug-drug interactions, qtc interval >450 ms for using methadone, evidence for or history of diversion of controlled substances, intolerance, serious adverse effects, or a history of inadequate beneficial response to opioids, impaired bowel motility unresponsive to therapy, headache not responsive to other pain treatment modalities, traumatic brain injury (tbi), true allergy to opioid agents\n",
      "510 0\n",
      "Original :  those patients receiving opioid analgesics who do not meet dsm-5 criteria for oud\n",
      "Extracted:  those patients receiving opioid analgesics who do not meet dsm-5 criteria for oud\n",
      "511 99\n",
      "Original :  an  alternative management strategy: close follow-up and cbt\n",
      "Extracted:  an  alternative management strategy: close follow-up and cbt\n",
      "512 136\n",
      "Original :  close follow-up and cbt\n",
      "Extracted:  close follow-up and cbt\n",
      "513 6\n",
      "Original :  recommend against\n",
      "Extracted:  recommend against\n",
      "514 6\n",
      "Original :  recommend\n",
      "Extracted:  recommend\n",
      "515 238\n",
      "Original :  when pharmacologic therapies are used\n",
      "Extracted:  when pharmacologic therapies are used\n",
      "516 153\n",
      "Original :  self-management strategies and other non-pharmacological treatments\n",
      "Extracted:  self-management strategies and other non-pharmacological treatments\n",
      "517 3\n",
      "Original :  recommend against\n",
      "Extracted:  recommend against\n",
      "518 200\n",
      "Original :  evaluate for tapering to reduced dose or to discontinuation\n",
      "Extracted:  evaluate for tapering to reduced dose or to discontinuation\n",
      "519 113\n",
      "Original :  patients who are currently prescribed doses over 90 mg morphine equivalent daily dose\n",
      "Extracted:  patients who are currently prescribed doses over 90 mg morphine equivalent daily dose\n",
      "520 3\n",
      "Original :  recommend against\n",
      "Extracted:  recommend against\n",
      "521 3\n",
      "Original :  recommend against\n",
      "Extracted:  recommend against\n",
      "522 57\n",
      "Original :  the rate of heroin overdose deaths\n",
      "Extracted:  the rate of heroin overdose deaths\n",
      "523 103\n",
      "Original :  nearly four-fold\n",
      "Extracted:  nearly four-fold\n",
      "524 333\n",
      "Original :  80%\n",
      "Extracted:  80%\n",
      "525 445\n",
      "Original :  75%\n",
      "Extracted:  75%\n",
      "526 69\n",
      "Original :  heroin\n",
      "Extracted:  heroin\n",
      "527 507\n",
      "Original :  prescription opioids\n",
      "Extracted:  prescription opioids\n",
      "528 556\n",
      "Original :  increase in the use of opioids, as well as associated morbidity, mortality, and other adverse outcomes\n",
      "Extracted:  increase in the use of opioids, as well as associated morbidity, mortality, and other adverse outcomes\n",
      "529 760\n",
      "Original :  the va/dod clinical practice guideline for the management of substance use disorders (va/dod sud cpg)\n",
      "Extracted:  the va/dod clinical practice guideline for the management of substance use disorders (va/dod sud cpg)\n",
      "530 764\n",
      "Original :  va/dod clinical practice guideline for the management of substance use disorders\n",
      "Extracted:  va/dod clinical practice guideline for the management of substance use disorders\n",
      "531 31\n",
      "Original :  morphine causes a release of histamine\n",
      "Extracted:  morphine causes a release of histamine\n",
      "532 196\n",
      "Original :  anaphylaxis\n",
      "Extracted:  anaphylaxis\n",
      "533 392\n",
      "Original :  when an opioid allergy is present and ot is being considered\n",
      "Extracted:  when an opioid allergy is present and ot is being considered\n",
      "534 454\n",
      "Original :  consultation with an allergist may be helpful\n",
      "Extracted:  consultation with an allergist may be helpful\n",
      "535 18\n",
      "Original :  treatment with opioid therapy\n",
      "Extracted:  treatment with opioid therapy\n",
      "536 96\n",
      "Original :  the candidate for trial of ot with consent (in conjunction with a comprehensive pain care plan)\n",
      "Extracted:  the candidate for trial of ot with consent (in conjunction with a comprehensive pain care plan)\n",
      "537 235\n",
      "Original :  short duration (e.g., 1 week initial prescription; no more than 3 months total), use the lowest effective dose recognizing that no dose is completely safe, long-acting opioids should not be prescribed for opioid-naive individuals, consider alternatives to methadone and transdermal fentanyl, assessment of improvement in pain and functional status and adverse effects, offer overdose education and naloxone distribution (oend)\n",
      "Extracted:  short duration (e.g., 1 week initial prescription; no more than 3 months total), use the lowest effective dose recognizing that no dose is completely safe, long-acting opioids should not be prescribed for opioid-naive individuals, consider alternatives to methadone and transdermal fentanyl, assessment of improvement in pain and functional status and adverse effects, offer overdose education and naloxone distribution (oend)\n",
      "538 235\n",
      "Original :  short duration (e.g., 1 week initial prescription; no more than 3 months total), use the lowest effective dose recognizing that no dose is completely safe\n",
      "Extracted:  short duration (e.g., 1 week initial prescription; no more than 3 months total), use the lowest effective dose recognizing that no dose is completely safe\n",
      "539 663\n",
      "Original :  a strategy of escalating dose to achieve benefit increases risk and has not been shown to improve function.\n",
      "Extracted:  a strategy of escalating dose to achieve benefit increases risk and has not been shown to improve function.\n",
      "540 787\n",
      "Original :  above 20-50 mg medd\n",
      "Extracted:  above 20-50 mg medd\n",
      "541 440\n",
      "Original :  opioid-naive individuals\n",
      "Extracted:  opioid-naive individuals\n",
      "542 391\n",
      "Original :  long-acting opioids should not be prescribed for opioid-naive individuals\n",
      "Extracted:  long-acting opioids should not be prescribed for opioid-naive individuals\n",
      "543 491\n",
      "Original :  methadone and transdermal fentanyl\n",
      "Extracted:  methadone and transdermal fentanyl\n",
      "544 925\n",
      "Original :  admit/provide medical and psychiatric treatment to stabilize as indicated\n",
      "Extracted:  admit/provide medical and psychiatric treatment to stabilize as indicated\n",
      "545 1064\n",
      "Original :  see if there is a clinically meaningful improvement in function in the absence of significant risk factors\n",
      "Extracted:  see if there is a clinically meaningful improvement in function in the absence of significant risk factors\n",
      "546 1281\n",
      "Original :  review and optimize comprehensive pain care plan (e.g., non-opioid treatments, self-management strategies)\n",
      "Extracted:  review and optimize comprehensive pain care plan (e.g., non-opioid treatments, self-management strategies)\n",
      "547 1337\n",
      "Original :  non-opioid treatments, self-management strategies\n",
      "Extracted:  non-opioid treatments, self-management strategies\n",
      "548 1499\n",
      "Original :  taper to discontinuation (consult module c if needed), exit algorithm and manage with non-opioid modalities\n",
      "Extracted:  taper to discontinuation (consult module c if needed), exit algorithm and manage with non-opioid modalities\n",
      "549 1638\n",
      "Original :  patient risk factors (e.g., 1-4 weeks with any dose change; up to every 3 months without dose change if clinically and functionally stable)\n",
      "Extracted:  patient risk factors (e.g., 1-4 weeks with any dose change; up to every 3 months without dose change if clinically and functionally stable)\n",
      "550 1799\n",
      "Original :  assess function, risks, and benefits of ot, progress toward functional treatment goals, adverse effects, adherence to treatment plan, complications or co-occurring conditions (e.g., medical, mental health, and/or sud); complete risk mitigation strategies; review and optimize comprehensive pain care plan\n",
      "Extracted:  assess function, risks, and benefits of ot, progress toward functional treatment goals, adverse effects, adherence to treatment plan, complications or co-occurring conditions (e.g., medical, mental health, and/or sud); complete risk mitigation strategies; review and optimize comprehensive pain care plan\n",
      "551 1806\n",
      "Original :  function, risks, and benefits of ot, progress toward functional treatment goals, adverse effects, adherence to treatment plan, complications or co-occurring conditions (e.g., medical, mental health, and/or sud)\n",
      "Extracted:  function, risks, and benefits of ot, progress toward functional treatment goals, adverse effects, adherence to treatment plan, complications or co-occurring conditions (e.g., medical, mental health, and/or sud)\n",
      "552 162\n",
      "Original :  comprehensive pain care plan\n",
      "Extracted:  comprehensive pain care plan\n",
      "553 2147\n",
      "Original :  non-adherence, co-occurring conditions, behaviors suggesting oud, indications for referral\n",
      "Extracted:  non-adherence, co-occurring conditions, behaviors suggesting oud, indications for referral\n",
      "554 2274\n",
      "Original :  consider one or more of the following: shortening prescribing interval, intensifying risk mitigation strategies, increasing intensity of monitoring, referring to interdisciplinary care and consulting with or referring to specialty care\n",
      "Extracted:  consider one or more of the following: shortening prescribing interval, intensifying risk mitigation strategies, increasing intensity of monitoring, referring to interdisciplinary care and consulting with or referring to specialty care\n",
      "555 2574\n",
      "Original :  see if there are indications to discontinue or taper\n",
      "Extracted:  see if there are indications to discontinue or taper\n",
      "556 2683\n",
      "Original :  taper to reduced dose or taper to discontinuation\n",
      "Extracted:  taper to reduced dose or taper to discontinuation\n",
      "557 2792\n",
      "Original :  reassess in 1-3 months or more frequently as determined by patient risk factors\n",
      "Extracted:  reassess in 1-3 months or more frequently as determined by patient risk factors\n",
      "558 60\n",
      "Original :  lot\n",
      "Extracted:  lot\n",
      "559 60\n",
      "Original :  lot\n",
      "Extracted:  lot\n",
      "560 60\n",
      "Original :  lot\n",
      "Extracted:  lot\n",
      "561 60\n",
      "Original :  lot\n",
      "Extracted:  lot\n",
      "562 60\n",
      "Original :  lot\n",
      "Extracted:  lot\n",
      "563 120\n",
      "Original :  migraine headaches (with or without aura), tension-type headaches,  occipital neuralgia, or myofascial pain\n",
      "Extracted:  migraine headaches (with or without aura), tension-type headaches,  occipital neuralgia, or myofascial pain\n",
      "564 232\n",
      "Original :  may result in worsening of the underlying headache  condition through factors such as central sensitization and withdrawal\n",
      "Extracted:  may result in worsening of the underlying headache  condition through factors such as central sensitization and withdrawal\n",
      "565 60\n",
      "Original :  lot\n",
      "Extracted:  lot\n",
      "566 37\n",
      "Original :  before the opioids are prescribed\n",
      "Extracted:  before the opioids are prescribed\n",
      "567 0\n",
      "Original :  risk mitigation for lot should begin\n",
      "Extracted:  risk mitigation for lot should begin\n",
      "568 72\n",
      "Original :  through an informed consent  discussion, reviewing the patient’s history, checking state pdmps, or instructing patients about using drug  take back programs to dispose of unused medication\n",
      "Extracted:  through an informed consent  discussion, reviewing the patient’s history, checking state pdmps, or instructing patients about using drug  take back programs to dispose of unused medication\n",
      "569 283\n",
      "Original :  concurrently with the therapy  (e.g., ongoing udt, oend) and in response to adverse events (e.g., needle exchange programs for those  who develop an intravenous drug use disorder)\n",
      "Extracted:  concurrently with the therapy  (e.g., ongoing udt, oend) and in response to adverse events (e.g., needle exchange programs for those  who develop an intravenous drug use disorder)\n",
      "570 492\n",
      "Original :  use of an opioid pain  care agreement, monitoring for appropriate opioid use, and, with patients’ consent, obtaining a udt\n",
      "Extracted:  use of an opioid pain  care agreement, monitoring for appropriate opioid use, and, with patients’ consent, obtaining a udt\n",
      "571 834\n",
      "Original :  one identified study was a systematic review of 11 studies\n",
      "Extracted:  one identified study was a systematic review of 11 studies\n",
      "572 1051\n",
      "Original :  weak\n",
      "Extracted:  weak\n",
      "573 904\n",
      "Original :  opioid treatment agreements\n",
      "Extracted:  opioid treatment agreements\n",
      "574 78\n",
      "Original :  hydroxyzine 25 to 50 mg three times a day as needed, diphenhydramine 25 mg every 6 hours as needed\n",
      "Extracted:  hydroxyzine 25 to 50 mg three times a day as needed, diphenhydramine 25 mg every 6 hours as needed\n",
      "575 200\n",
      "Original :  for veterans older than 65 years\n",
      "Extracted:  for veterans older than 65 years\n",
      "576 273\n",
      "Original :  nsaids (e.g., naproxen 375 to 500 mg twice daily or ibuprofen 400 to 600 mg four times daily), acetaminophen 650 mg every 6 hours as needed, topical medications like menthol/methylsalicylate cream, lidocaine cream/ointment\n",
      "Extracted:  nsaids (e.g., naproxen 375 to 500 mg twice daily or ibuprofen 400 to 600 mg four times daily), acetaminophen 650 mg every 6 hours as needed, topical medications like menthol/methylsalicylate cream, lidocaine cream/ointment\n",
      "577 525\n",
      "Original :  patients with risk of gi bleed, renal compromise, cardiac disease\n",
      "Extracted:  patients with risk of gi bleed, renal compromise, cardiac disease\n",
      "578 638\n",
      "Original :  trazodone 25 to 300 mg orally at bedtime\n",
      "Extracted:  trazodone 25 to 300 mg orally at bedtime\n",
      "579 72\n",
      "Original :  morbidity, mortality, opioid-related  overdose death rates, and substance use disorders (sud) treatment admissions\n",
      "Extracted:  morbidity, mortality, opioid-related  overdose death rates, and substance use disorders (sud) treatment admissions\n",
      "580 216\n",
      "Original :  drug overdose\n",
      "Extracted:  drug overdose\n",
      "581 343\n",
      "Original :  1.9 million americans were affected by an oud related to non-medical  use of prescription pain relievers, and in the same year, 18,893 individuals died as a result of a  prescription drug overdose\n",
      "Extracted:  1.9 million americans were affected by an oud related to non-medical  use of prescription pain relievers, and in the same year, 18,893 individuals died as a result of a  prescription drug overdose\n",
      "582 343\n",
      "Original :  1.9 million\n",
      "Extracted:  1.9 million\n",
      "583 471\n",
      "Original :  18,893\n",
      "Extracted:  18,893\n",
      "584 556\n",
      "Original :  a four-fold increase\n",
      "Extracted:  a four-fold increase\n",
      "585 660\n",
      "Original :  14% increase\n",
      "Extracted:  14% increase\n",
      "586 806\n",
      "Original :  34%\n",
      "Extracted:  34%\n",
      "587 806\n",
      "Original :  34%\n",
      "Extracted:  34%\n",
      "588 985\n",
      "Original :  22%\n",
      "Extracted:  22%\n",
      "589 806\n",
      "Original :  34% of patients reported that they thought they were “addicted” or “dependent” on opioid pain medication, 34% said that they used the medication for “fun” or to “get high,” while 22% used the medication to relieve day-to-day stress\n",
      "Extracted:  34% of patients reported that they thought they were “addicted” or “dependent” on opioid pain medication, 34% said that they used the medication for “fun” or to “get high,” while 22% used the medication to relieve day-to-day stress\n",
      "590 749\n",
      "Original :  chronic non-cancer pain\n",
      "Extracted:  chronic non-cancer pain\n",
      "591 0\n",
      "Original :  chronic pain\n",
      "Extracted:  chronic pain\n",
      "592 0\n",
      "Original :  chronic pain\n",
      "Extracted:  chronic pain\n",
      "593 0\n",
      "Original :  chronic pain\n",
      "Extracted:  chronic pain\n",
      "594 113\n",
      "Original :  approximately 100 million\n",
      "Extracted:  approximately 100 million\n",
      "595 273\n",
      "Original :  the late 1990s and early 2000s\n",
      "Extracted:  the late 1990s and early 2000s\n",
      "596 273\n",
      "Original :  the late 1990s and early 2000s\n",
      "Extracted:  the late 1990s and early 2000s\n",
      "597 496\n",
      "Original :  approximately one in five\n",
      "Extracted:  approximately one in five\n",
      "598 684\n",
      "Original :  quadrupled\n",
      "Extracted:  quadrupled\n",
      "599 791\n",
      "Original :  four-fold\n",
      "Extracted:  four-fold\n",
      "600 826\n",
      "Original :  14%\n",
      "Extracted:  14%\n",
      "601 879\n",
      "Original :  more than 183,000\n",
      "Extracted:  more than 183,000\n",
      "602 118\n",
      "Original :  on the basis of all clinical data available for an individual case and are subject to change as scientific knowledge and technology advances and patterns evolve\n",
      "Extracted:  on the basis of all clinical data available for an individual case and are subject to change as scientific knowledge and technology advances and patterns evolve\n",
      "603 364\n",
      "Original :  the variety of ever-changing state regulations that may be pertinent\n",
      "Extracted:  the variety of ever-changing state regulations that may be pertinent\n",
      "604 535\n",
      "Original :  the individual clinician\n",
      "Extracted:  the individual clinician\n",
      "605 573\n",
      "Original :  the patient’s clinical presentation, patient preferences, and the available diagnostic and treatment options\n",
      "Extracted:  the patient’s clinical presentation, patient preferences, and the available diagnostic and treatment options\n",
      "606 795\n",
      "Original :  a recommendation, within the context of a provider’s clinical judgment and patient values and preferences, in the care for an individual patient.\n",
      "Extracted:  a recommendation, within the context of a provider’s clinical judgment and patient values and preferences, in the care for an individual patient.\n",
      "607 77\n",
      "Original :  80%\n",
      "Extracted:  80%\n",
      "608 187\n",
      "Original :  illicit use of injectable opioids\n",
      "Extracted:  illicit use of injectable opioids\n",
      "609 239\n",
      "Original :  an increased rate of human immunodeficiency virus (hiv) and hepatitis infection\n",
      "Extracted:  an increased rate of human immunodeficiency virus (hiv) and hepatitis infection\n",
      "610 0\n",
      "Original :  community-based needle exchange programs\n",
      "Extracted:  community-based needle exchange programs\n",
      "611 461\n",
      "Original :  sharing needles\n",
      "Extracted:  sharing needles\n",
      "612 380\n",
      "Original :  be an effective risk mitigation strategy for reducing high-risk behaviors (e.g., sharing needles) and infectious disease transmission among injection drug users\n",
      "Extracted:  be an effective risk mitigation strategy for reducing high-risk behaviors (e.g., sharing needles) and infectious disease transmission among injection drug users\n",
      "613 557\n",
      "Original :  patients who develop oud and progress to intravenous drug use\n",
      "Extracted:  patients who develop oud and progress to intravenous drug use\n",
      "614 659\n",
      "Original :  medication assisted treatment (mat) for oud\n",
      "Extracted:  medication assisted treatment (mat) for oud\n",
      "615 732\n",
      "Original :  patients who decline mat for oud\n",
      "Extracted:  patients who decline mat for oud\n",
      "616 794\n",
      "Original :  educating the patient regarding sterile injection techniques and community based needle exchange programs, if programs are available\n",
      "Extracted:  educating the patient regarding sterile injection techniques and community based needle exchange programs, if programs are available\n",
      "617 928\n",
      "Original :  the 2015 outbreak of hiv/hepatitis in rural  indiana and subsequent successful implementation of a needle exchange program\n",
      "Extracted:  the 2015 outbreak of hiv/hepatitis in rural  indiana and subsequent successful implementation of a needle exchange program\n",
      "618 1068\n",
      "Original :  the threat to rural communities from non-prescription opioid use and the potential benefits of needle exchange programs for use as a risk mitigation strategy\n",
      "Extracted:  the threat to rural communities from non-prescription opioid use and the potential benefits of needle exchange programs for use as a risk mitigation strategy\n",
      "619 54\n",
      "Original :  in the way pain is viewed and treated\n",
      "Extracted:  in the way pain is viewed and treated\n",
      "620 0\n",
      "Original :  the u.s. is in the midst of a cultural transformation in the way pain is viewed and treated\n",
      "Extracted:  the u.s. is in the midst of a cultural transformation in the way pain is viewed and treated\n",
      "621 137\n",
      "Original :  the pain experience is reduced to a pain generator and pain treatment is aimed at fixing or numbing pain with medications, interventions, or surgery\n",
      "Extracted:  the pain experience is reduced to a pain generator and pain treatment is aimed at fixing or numbing pain with medications, interventions, or surgery\n",
      "622 219\n",
      "Original :  fixing or numbing pain with medications, interventions, or surgery\n",
      "Extracted:  fixing or numbing pain with medications, interventions, or surgery\n",
      "623 297\n",
      "Original :  the 1990s and the first decade of the 2000s\n",
      "Extracted:  the 1990s and the first decade of the 2000s\n",
      "624 342\n",
      "Original :  as the cost, potential harm, and limited effectiveness of the approach in the biomedical model of pain care to chronic pain was becoming apparent\n",
      "Extracted:  as the cost, potential harm, and limited effectiveness of the approach in the biomedical model of pain care to chronic pain was becoming apparent\n",
      "625 575\n",
      "Original :  a biopsychosocial, multimodal, interdisciplinary model\n",
      "Extracted:  a biopsychosocial, multimodal, interdisciplinary model\n",
      "626 0\n",
      "Original :  with the passage of the patient protection and affordable care act (ppaca) in march 2010\n",
      "Extracted:  with the passage of the patient protection and affordable care act (ppaca) in march 2010\n",
      "627 159\n",
      "Original :  coordinate pain research efforts  throughout federal government agencies\n",
      "Extracted:  coordinate pain research efforts  throughout federal government agencies\n",
      "628 78\n",
      "Original :  march 2010\n",
      "Extracted:  march 2010\n",
      "629 263\n",
      "Original :  summarizing advances in pain  care research, identifying gaps in research, and developing recommendations regarding ways to minimize  duplicative efforts, disseminate pain care information, and expand public/private research partnerships  and collaborations\n",
      "Extracted:  summarizing advances in pain  care research, identifying gaps in research, and developing recommendations regarding ways to minimize  duplicative efforts, disseminate pain care information, and expand public/private research partnerships  and collaborations\n",
      "630 233\n",
      "Original :  the committee\n",
      "Extracted:  the committee\n",
      "631 576\n",
      "Original :  march 2016\n",
      "Extracted:  march 2016\n",
      "632 587\n",
      "Original :  in response to the  call from the national academy of medicine to increase awareness of pain as a significant public health  issue in the u.s.\n",
      "Extracted:  in response to the  call from the national academy of medicine to increase awareness of pain as a significant public health  issue in the u.s.\n",
      "633 795\n",
      "Original :  prevention and  care, professional education and training, and population research\n",
      "Extracted:  prevention and  care, professional education and training, and population research\n",
      "634 900\n",
      "Original :  decreasing the  prevalence of all types of pain (acute and chronic) in the u.s., as well as the disability and morbidity  associated with pain\n",
      "Extracted:  decreasing the  prevalence of all types of pain (acute and chronic) in the u.s., as well as the disability and morbidity  associated with pain\n",
      "635 63\n",
      "Original :  an investment of resources\n",
      "Extracted:  an investment of resources\n",
      "636 151\n",
      "Original :  to allow for shared decision making and treatment planning\n",
      "Extracted:  to allow for shared decision making and treatment planning\n",
      "637 254\n",
      "Original :  can affect access to care for all empaneled patients\n",
      "Extracted:  can affect access to care for all empaneled patients\n",
      "638 340\n",
      "Original :  vha policy regarding education and signature informed consent\n",
      "Extracted:  vha policy regarding education and signature informed consent\n",
      "639 402\n",
      "Original :  when  providing lot for patients with non-cancer pain\n",
      "Extracted:  when  providing lot for patients with non-cancer pain\n",
      "640 309\n",
      "Original :  vha providers\n",
      "Extracted:  vha providers\n",
      "641 3\n",
      "Original :  recommend against\n",
      "Extracted:  recommend against\n",
      "642 150\n",
      "Original :  consider tapering one or both when risks exceed benefits and obtaining specialty consultation as appropriate\n",
      "Extracted:  consider tapering one or both when risks exceed benefits and obtaining specialty consultation as appropriate\n",
      "643 3\n",
      "Original :  recommend against\n",
      "Extracted:  recommend against\n",
      "644 498\n",
      "Original :  close monitoring and consideration for tapering when risks exceed benefits\n",
      "Extracted:  close monitoring and consideration for tapering when risks exceed benefits\n",
      "645 71\n",
      "Original :  in 2015\n",
      "Extracted:  in 2015\n",
      "646 187\n",
      "Original :  objective, evidence-based information on the management of chronic pain\n",
      "Extracted:  objective, evidence-based information on the management of chronic pain\n",
      "647 275\n",
      "Original :  to assist healthcare providers in all aspects of patient care, including, but not limited to, diagnosis, treatment, and follow-up\n",
      "Extracted:  to assist healthcare providers in all aspects of patient care, including, but not limited to, diagnosis, treatment, and follow-up\n",
      "648 115\n",
      "Original :  those diagnosed with cncp and an alcohol use or non-opioid drug use disorder\n",
      "Extracted:  those diagnosed with cncp and an alcohol use or non-opioid drug use disorder\n",
      "649 516\n",
      "Original :  the presence of a lifetime history of sud for patients with cncp\n",
      "Extracted:  the presence of a lifetime history of sud for patients with cncp\n",
      "650 601\n",
      "Original :  28 times increased  odds of therapeutic opioid addiction compared to patients with cncp without a lifetime history of sud\n",
      "Extracted:  28 times increased  odds of therapeutic opioid addiction compared to patients with cncp without a lifetime history of sud\n",
      "651 0\n",
      "Original :  naloxone administration\n",
      "Extracted:  naloxone administration\n",
      "652 44\n",
      "Original :  as a life saving measure following opioid overdose\n",
      "Extracted:  as a life saving measure following opioid overdose\n",
      "653 96\n",
      "Original :  a  systematic review of 22 observational studies provided moderate quality evidence\n",
      "Extracted:  a  systematic review of 22 observational studies provided moderate quality evidence\n",
      "654 742\n",
      "Original :  prescription of naloxone rescue and accompanying education\n",
      "Extracted:  prescription of naloxone rescue and accompanying education\n",
      "655 936\n",
      "Original :  samhsa, the american medical association (ama), and other medical societies\n",
      "Extracted:  samhsa, the american medical association (ama), and other medical societies\n",
      "656 1041\n",
      "Original :  the va via pharmacy benefits management\n",
      "Extracted:  the va via pharmacy benefits management\n",
      "657 1137\n",
      "Original :  short-acting opioids\n",
      "Extracted:  short-acting opioids\n",
      "658 1182\n",
      "Original :  long-acting opioids such as methadone or  exceptionally potent opioids\n",
      "Extracted:  long-acting opioids such as methadone or  exceptionally potent opioids\n",
      "659 64\n",
      "Original :  establish treatment goals\n",
      "Extracted:  establish treatment goals\n",
      "660 127\n",
      "Original :  plan\n",
      "Extracted:  plan\n",
      "661 181\n",
      "Original :  if there is clinically meaningful improvement in pain and function\n",
      "Extracted:  if there is clinically meaningful improvement in pain and function\n",
      "662 257\n",
      "Original :  risks, benefits and responsibilities for managing therapy\n",
      "Extracted:  risks, benefits and responsibilities for managing therapy\n",
      "663 257\n",
      "Original :  risks, benefits and responsibilities for managing therapy\n",
      "Extracted:  risks, benefits and responsibilities for managing therapy\n",
      "664 0\n",
      "Original :  opioids\n",
      "Extracted:  opioids\n",
      "665 16\n",
      "Original :  patients currently on opioid therapy\n",
      "Extracted:  patients currently on opioid therapy\n",
      "666 84\n",
      "Original :  look for factors that would require immediate attention and possible discontinuation of ot due to unacceptable risk\n",
      "Extracted:  look for factors that would require immediate attention and possible discontinuation of ot due to unacceptable risk\n",
      "667 267\n",
      "Original :  admit/provide treatment to stabilize, including opioid tapering or sud treatment as indicated\n",
      "Extracted:  admit/provide treatment to stabilize, including opioid tapering or sud treatment as indicated\n",
      "668 431\n",
      "Original :  obtain a biopsychosocial assessment\n",
      "Extracted:  obtain a biopsychosocial assessment\n",
      "669 582\n",
      "Original :  review data and re-assess risks and benefits of continuing ot and consider strength and number of risk factors\n",
      "Extracted:  review data and re-assess risks and benefits of continuing ot and consider strength and number of risk factors\n",
      "670 503\n",
      "Original :  current prescriber, prior and current udt, pdmp\n",
      "Extracted:  current prescriber, prior and current udt, pdmp\n",
      "671 715\n",
      "Original :  address factors related to incomplete data prior to prescribing. then review data and re-assess risks and benefits of continuing ot and consider strength and number of risk factors.\n",
      "Extracted:  address factors related to incomplete data prior to prescribing. then review data and re-assess risks and benefits of continuing ot and consider strength and number of risk factors.\n",
      "672 947\n",
      "Original :  proceed to module c\n",
      "Extracted:  proceed to module c\n",
      "673 1025\n",
      "Original :  educate/re-educate on the following: non-opioid management, self-management to improve function and quality of life, realistic expectations and limitations of medical treatment options, preferred treatment methods being non-pharmacotherapy and non-opioid pharmacotherapy, new information on risks and lack of benefits of long-term ot\n",
      "Extracted:  educate/re-educate on the following: non-opioid management, self-management to improve function and quality of life, realistic expectations and limitations of medical treatment options, preferred treatment methods being non-pharmacotherapy and non-opioid pharmacotherapy, new information on risks and lack of benefits of long-term ot\n",
      "674 1402\n",
      "Original :  identify if there is presence of prescribed opioid dose>90 mg medd or combined sedating medication that increases risk of adverse events (e.g., benzodiazepine) or patient non-participation in a comprehensive pain care plan or other indications for tapering\n",
      "Extracted:  identify if there is presence of prescribed opioid dose>90 mg medd or combined sedating medication that increases risk of adverse events (e.g., benzodiazepine) or patient non-participation in a comprehensive pain care plan or other indications for tapering\n",
      "675 1726\n",
      "Original :  reassess and optimize preferred non-opioid treatments for chronic pain (e.g., physical and psychological treatments) recognizing that the patient is willing to continue to engage in a comprehensive treatment plan including non-opioid treatments\n",
      "Extracted:  reassess and optimize preferred non-opioid treatments for chronic pain (e.g., physical and psychological treatments) recognizing that the patient is willing to continue to engage in a comprehensive treatment plan including non-opioid treatments\n",
      "676 1804\n",
      "Original :  physical and psychological treatments\n",
      "Extracted:  physical and psychological treatments\n",
      "677 2056\n",
      "Original :  continue ot using the following approach: shortest duration, using lowest effective dose (recognizing that no dose is completely safe and overdose risk increases at doses > 20-50 mg medd), continual assessment of improvement in pain and functional status and adverse effects\n",
      "Extracted:  continue ot using the following approach: shortest duration, using lowest effective dose (recognizing that no dose is completely safe and overdose risk increases at doses > 20-50 mg medd), continual assessment of improvement in pain and functional status and adverse effects\n",
      "678 2378\n",
      "Original :  patient risk factors\n",
      "Extracted:  patient risk factors\n",
      "679 947\n",
      "Original :  proceed to module c\n",
      "Extracted:  proceed to module c\n",
      "680 947\n",
      "Original :  proceed to module c\n",
      "Extracted:  proceed to module c\n",
      "681 947\n",
      "Original :  proceed to module c\n",
      "Extracted:  proceed to module c\n",
      "682 0\n",
      "Original :  given the recognized risks of opioid therapy\n",
      "Extracted:  given the recognized risks of opioid therapy\n",
      "683 89\n",
      "Original :  a robust,  signature informed consent process that is patient-centered and provides patients with information about  known benefits and harms of ot and treatment alternatives\n",
      "Extracted:  a robust,  signature informed consent process that is patient-centered and provides patients with information about  known benefits and harms of ot and treatment alternatives\n",
      "684 46\n",
      "Original :  an optimal approach to care\n",
      "Extracted:  an optimal approach to care\n",
      "685 289\n",
      "Original :  a requirement for  signature informed consent, consistent with va policy for other treatments or procedures with a  significant risk of complications or morbidity\n",
      "Extracted:  a requirement for  signature informed consent, consistent with va policy for other treatments or procedures with a  significant risk of complications or morbidity\n",
      "686 66\n",
      "Original :  when patients have a history of  previous opioid or non-opioid sud\n",
      "Extracted:  when patients have a history of  previous opioid or non-opioid sud\n",
      "687 75\n",
      "Original :  a short duration\n",
      "Extracted:  a short duration\n",
      "688 136\n",
      "Original :  consideration of opioid therapy beyond 90 days\n",
      "Extracted:  consideration of opioid therapy beyond 90 days\n",
      "689 192\n",
      "Original :  re-evaluation and discussion with patient of risks and benefits\n",
      "Extracted:  re-evaluation and discussion with patient of risks and benefits\n",
      "690 322\n",
      "Original :  ongoing risk mitigation strategies (see recommendations 7-9), assessment for opioid use disorder, and consideration for tapering when risks exceed benefits (see recommendation 14)\n",
      "Extracted:  ongoing risk mitigation strategies (see recommendations 7-9), assessment for opioid use disorder, and consideration for tapering when risks exceed benefits (see recommendation 14)\n",
      "691 261\n",
      "Original :  patients currently on long-term opioid therapy\n",
      "Extracted:  patients currently on long-term opioid therapy\n",
      "692 261\n",
      "Original :  patients currently on long-term opioid therapy\n",
      "Extracted:  patients currently on long-term opioid therapy\n",
      "693 261\n",
      "Original :  patients currently on long-term opioid therapy\n",
      "Extracted:  patients currently on long-term opioid therapy\n",
      "694 261\n",
      "Original :  patients currently on long-term opioid therapy\n",
      "Extracted:  patients currently on long-term opioid therapy\n",
      "695 32\n",
      "Original :  the addition of other psychoactive medications to lot\n",
      "Extracted:  the addition of other psychoactive medications to lot\n",
      "696 120\n",
      "Original :  the evidence for harm associated with the combination of opioids and z-drugs (e.g.,  zolpidem, eszopiclone)\n",
      "Extracted:  the evidence for harm associated with the combination of opioids and z-drugs (e.g.,  zolpidem, eszopiclone)\n",
      "697 446\n",
      "Original :  the combination of zolpidem and opioids\n",
      "Extracted:  the combination of zolpidem and opioids\n",
      "698 496\n",
      "Original :  the aor of  overdose\n",
      "Extracted:  the aor of  overdose\n",
      "699 560\n",
      "Original :  potential adverse outcomes (e.g., risk of overdose)\n",
      "Extracted:  potential adverse outcomes (e.g., risk of overdose)\n",
      "700 618\n",
      "Original :  the combined use of antidepressants and opioids\n",
      "Extracted:  the combined use of antidepressants and opioids\n",
      "701 669\n",
      "Original :  patients who do not have depression\n",
      "Extracted:  patients who do not have depression\n",
      "702 57\n",
      "Original :  inhibit bowel peristalsis\n",
      "Extracted:  inhibit bowel peristalsis\n",
      "703 137\n",
      "Original :  can increase the risk of severe constipation/impaction or possible obstruction\n",
      "Extracted:  can increase the risk of severe constipation/impaction or possible obstruction\n",
      "704 41\n",
      "Original :  a biopsychosocial interview and focused physical exam\n",
      "Extracted:  a biopsychosocial interview and focused physical exam\n",
      "705 151\n",
      "Original :  a pain-related history, assessment of pertinent  medical and psychiatric comorbidities including personal and family history of sud, functional status and  functional goals, coping strategies, and a variety of psychosocial factors such as the patient’s beliefs and  expectations about chronic pain and its treatment\n",
      "Extracted:  a pain-related history, assessment of pertinent  medical and psychiatric comorbidities including personal and family history of sud, functional status and  functional goals, coping strategies, and a variety of psychosocial factors such as the patient’s beliefs and  expectations about chronic pain and its treatment\n",
      "706 516\n",
      "Original :  worsened quality of life, mental health, immune system function, physical function, sleep, employment  status, and impaired personal relationships\n",
      "Extracted:  worsened quality of life, mental health, immune system function, physical function, sleep, employment  status, and impaired personal relationships\n",
      "707 664\n",
      "Original :  worsening of some of these factors (e.g., quality of  life, change in employment status)\n",
      "Extracted:  worsening of some of these factors (e.g., quality of  life, change in employment status)\n",
      "708 468\n",
      "Original :  patients with chronic pain\n",
      "Extracted: "
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 765/765 [00:00<00:00, 48536.37it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " patients with chronic pain\n",
      "709 882\n",
      "Original :  psychological complaints (e.g.,  depression, anxiety, poor self-efficacy, poor general emotional functioning)\n",
      "Extracted:  psychological complaints (e.g.,  depression, anxiety, poor self-efficacy, poor general emotional functioning)\n",
      "710 915\n",
      "Original :  depression, anxiety, poor self-efficacy, poor general emotional functioning\n",
      "Extracted:  depression, anxiety, poor self-efficacy, poor general emotional functioning\n",
      "711 1108\n",
      "Original :  decreased  ability to successfully maintain relationship and career roles and increased depression, fear, and anxiety as  a result of pain\n",
      "Extracted:  decreased  ability to successfully maintain relationship and career roles and increased depression, fear, and anxiety as  a result of pain\n",
      "712 0\n",
      "Original :  younger patients\n",
      "Extracted:  younger patients\n",
      "713 46\n",
      "Original :  opioid misuse (as suggested by a udt indicating high-risk  medication-related behavior)\n",
      "Extracted:  opioid misuse (as suggested by a udt indicating high-risk  medication-related behavior)\n",
      "714 168\n",
      "Original :  patients in the 45-64 year age group\n",
      "Extracted:  patients in the 45-64 year age group\n",
      "715 245\n",
      "Original :  an aberrant udt (detection of a non-prescribed opioid, non-prescribed  benzodiazepine, illicit drug, or tetrahydrocannabinol [thc])\n",
      "Extracted:  an aberrant udt (detection of a non-prescribed opioid, non-prescribed  benzodiazepine, illicit drug, or tetrahydrocannabinol [thc])\n",
      "716 394\n",
      "Original :  patients in the 20-44 age  group\n",
      "Extracted:  patients in the 20-44 age  group\n",
      "717 432\n",
      "Original :  patients in the 45-64 and ≥65 age groups\n",
      "Extracted:  patients in the 45-64 and ≥65 age groups\n",
      "718 509\n",
      "Original :  20-44 year olds\n",
      "Extracted:  20-44 year olds\n",
      "719 525\n",
      "Original :  to  have non-detection of a prescribed opioid as well (indicating possible diversion)\n",
      "Extracted:  to  have non-detection of a prescribed opioid as well (indicating possible diversion)\n",
      "720 0\n",
      "Original :  some patients on lot who suffer from chronic pain and co-occurring oud, depression, and/or personality disorders\n",
      "Extracted:  some patients on lot who suffer from chronic pain and co-occurring oud, depression, and/or personality disorders\n",
      "721 117\n",
      "Original :  threaten suicide when providers recommend discontinuation of opioid\n",
      "Extracted:  threaten suicide when providers recommend discontinuation of opioid\n",
      "722 197\n",
      "Original :  continuing lot to “prevent suicide” in someone with chronic pain\n",
      "Extracted:  continuing lot to “prevent suicide” in someone with chronic pain\n",
      "723 212\n",
      "Original :  to “prevent suicide” in someone with chronic pain\n",
      "Extracted:  to “prevent suicide” in someone with chronic pain\n",
      "724 284\n",
      "Original :  an appropriate response if suicide risk is high or increases\n",
      "Extracted:  an appropriate response if suicide risk is high or increases\n",
      "725 187\n",
      "Original :  however,  continuing lot to “prevent suicide” in someone with chronic pain is not recommended as an appropriate response if suicide risk is high or increases.\n",
      "Extracted:  however,  continuing lot to “prevent suicide” in someone with chronic pain is not recommended as an appropriate response if suicide risk is high or increases.\n",
      "726 380\n",
      "Original :  involve behavioral health to assess, monitor, and treat\n",
      "Extracted:  involve behavioral health to assess, monitor, and treat\n",
      "727 542\n",
      "Original :  further research\n",
      "Extracted:  further research\n",
      "728 569\n",
      "Original :  to identify strategies for safely managing patients at elevated risk of suicide who demand opioid medications or become further destabilized during tapering\n",
      "Extracted:  to identify strategies for safely managing patients at elevated risk of suicide who demand opioid medications or become further destabilized during tapering\n",
      "729 9\n",
      "Original :  use of adjuvant medications\n",
      "Extracted:  use of adjuvant medications\n",
      "730 184\n",
      "Original :  clonidine 0.1 to 0.2 mg oral every 6 to 8 hours\n",
      "Extracted:  clonidine 0.1 to 0.2 mg oral every 6 to 8 hours\n",
      "731 243\n",
      "Original :  if blood pressure <90/60 mmhg (0.1 to 0.2 mg 2 to 4 times daily is commonly used in the outpatient setting)\n",
      "Extracted:  if blood pressure <90/60 mmhg (0.1 to 0.2 mg 2 to 4 times daily is commonly used in the outpatient setting)\n",
      "732 373\n",
      "Original :  0.1 mg oral\n",
      "Extracted:  0.1 mg oral\n",
      "733 148\n",
      "Original :  sweating, tachycardia, myoclonus\n",
      "Extracted:  sweating, tachycardia, myoclonus\n",
      "734 661\n",
      "Original :  baclofen, gabapentin, tizanidine\n",
      "Extracted:  baclofen, gabapentin, tizanidine\n",
      "735 781\n",
      "Original :  5 mg 3 times daily; may increase to 40 mg total daily dose; re-evaluate in 3 to 7 days; average duration 15 days; may continue after acute withdrawal to help decrease cravings; should be tapered when it is discontinued\n",
      "Extracted:  5 mg 3 times daily; may increase to 40 mg total daily dose; re-evaluate in 3 to 7 days; average duration 15 days; may continue after acute withdrawal to help decrease cravings; should be tapered when it is discontinued\n",
      "736 1089\n",
      "Original :  start at 100 to 300 mg and titrate to 1800 to 2100 mg divided in 2 to 3 daily doses; adjust dose if renal impairment\n",
      "Extracted:  start at 100 to 300 mg and titrate to 1800 to 2100 mg divided in 2 to 3 daily doses; adjust dose if renal impairment\n",
      "737 671\n",
      "Original :  gabapentin\n",
      "Extracted:  gabapentin\n",
      "738 671\n",
      "Original :  gabapentin\n",
      "Extracted:  gabapentin\n",
      "739 671\n",
      "Original :  gabapentin\n",
      "Extracted:  gabapentin\n",
      "740 1234\n",
      "Original :  withdrawal symptoms and help with pain, anxiety, and sleep\n",
      "Extracted:  withdrawal symptoms and help with pain, anxiety, and sleep\n",
      "741 1382\n",
      "Original :  4 mg three times daily, can increase to 8 mg three times daily\n",
      "Extracted:  4 mg three times daily, can increase to 8 mg three times daily\n",
      "742 20\n",
      "Original :  an unpleasant sensory and emotional experience associated with actual or potential  tissue damage, or described in terms of such damage…pain is always subjective…it is unquestionably a  sensation in a part or parts of the body, but it is also always unpleasant and therefore also an emotional  experience.\n",
      "Extracted:  an unpleasant sensory and emotional experience associated with actual or potential  tissue damage, or described in terms of such damage…pain is always subjective…it is unquestionably a  sensation in a part or parts of the body, but it is also always unpleasant and therefore also an emotional  experience.\n",
      "743 476\n",
      "Original :  multifaceted\n",
      "Extracted:  multifaceted\n",
      "744 553\n",
      "Original :  quality (e.g., sharp versus dull), intensity, timing, location, and  whether it is associated with position or movement\n",
      "Extracted:  quality (e.g., sharp versus dull), intensity, timing, location, and  whether it is associated with position or movement\n",
      "745 37\n",
      "Original :  oud, overdose, and death, especially among patients with untreated  sud\n",
      "Extracted:  oud, overdose, and death, especially among patients with untreated  sud\n",
      "746 0\n",
      "Original :  opioids\n",
      "Extracted:  opioids\n",
      "747 498\n",
      "Original :  patients whose sole  sud relates to tobacco misuse\n",
      "Extracted:  patients whose sole  sud relates to tobacco misuse\n",
      "748 21\n",
      "Original :  over weeks\n",
      "Extracted:  over weeks\n",
      "749 67\n",
      "Original :  10 to 20% every week\n",
      "Extracted:  10 to 20% every week\n",
      "750 242\n",
      "Original :  75 mg sr q8h\n",
      "Extracted:  75 mg sr q8h\n",
      "751 309\n",
      "Original :  60 mg sr (15 mg x 4) q8h\n",
      "Extracted:  60 mg sr (15 mg x 4) q8h\n",
      "752 346\n",
      "Original :  45 mg sr (15 mg x 3) q8h\n",
      "Extracted:  45 mg sr (15 mg x 3) q8h\n",
      "753 383\n",
      "Original :  30 mg sr (15 mg x 2) q8h\n",
      "Extracted:  30 mg sr (15 mg x 2) q8h\n",
      "754 420\n",
      "Original :  15 mg sr q8h\n",
      "Extracted:  15 mg sr q8h\n",
      "755 445\n",
      "Original :  15 mg sr q12h\n",
      "Extracted:  15 mg sr q12h\n",
      "756 471\n",
      "Original :  15 mg sr qhs x 7 days\n",
      "Extracted:  15 mg sr qhs x 7 days\n",
      "757 526\n",
      "Original :  after week 7\n",
      "Extracted:  after week 7\n",
      "758 556\n",
      "Original :  morphine ir 15 mg ½ tablet (7.5 mg) twice daily\n",
      "Extracted:  morphine ir 15 mg ½ tablet (7.5 mg) twice daily\n",
      "759 486\n",
      "Original :  given the lack of evidence  showing sustained functional benefit of lot and moderate evidence outlining harms\n",
      "Extracted:  given the lack of evidence  showing sustained functional benefit of lot and moderate evidence outlining harms\n",
      "760 188\n",
      "Original :  no\n",
      "Extracted:  no\n",
      "761 652\n",
      "Original :  patient values, goals, concerns, and preferences\n",
      "Extracted:  patient values, goals, concerns, and preferences\n",
      "762 850\n",
      "Original :  consider whether lot will result in clinically meaningful  improvements in function such as readiness to return to work/duty and/or measurable improvement in  other areas of function, such that the benefits outweigh the potential harms\n",
      "Extracted:  consider whether lot will result in clinically meaningful  improvements in function such as readiness to return to work/duty and/or measurable improvement in  other areas of function, such that the benefits outweigh the potential harms\n",
      "763 102\n",
      "Original :  duration of opioid use as well as dose\n",
      "Extracted:  duration of opioid use as well as dose\n",
      "764 1097\n",
      "Original :  duration of ot\n",
      "Extracted:  duration of ot\n",
      "Unique Contexts: 115\n",
      " Ratio of QA Pair-to-Contexts: 6.6521739130434785\n",
      "0 6\n",
      "Original :  recommend against\n",
      "Extracted:  recommend against\n",
      "1 263\n",
      "Original :  close monitoring and consideration for tapering when risks exceed benefits\n",
      "Extracted:  close monitoring and consideration for tapering when risks exceed benefits\n",
      "2 0\n",
      "Original :  short-term oral medications\n",
      "Extracted:  short-term oral medications\n",
      "3 172\n",
      "Original :  an opioid or benzodiazepine\n",
      "Extracted:  an opioid or benzodiazepine\n",
      "4 266\n",
      "Original :  with a gradual taper\n",
      "Extracted:  with a gradual taper\n",
      "5 308\n",
      "Original :  hours to days\n",
      "Extracted:  hours to days\n",
      "6 498\n",
      "Original :  days to weeks\n",
      "Extracted:  days to weeks\n",
      "7 785\n",
      "Original :  weeks to months\n",
      "Extracted:  weeks to months\n",
      "8 356\n",
      "Original :  anxiety/restlessness, rapid short respirations, runny nose, tearing eyes, sweating, insomnia, and dilated reactive pupils\n",
      "Extracted:  anxiety/restlessness, rapid short respirations, runny nose, tearing eyes, sweating, insomnia, and dilated reactive pupils\n",
      "9 545\n",
      "Original :  runny nose, tearing eyes, rapid breathing, yawning, tremor, diffuse muscle spasms/aches, piloerection, nausea, vomiting, and diarrhea, abdominal pain, fever, chills, increased white blood cells if sudden withdrawal\n",
      "Extracted:  runny nose, tearing eyes, rapid breathing, yawning, tremor, diffuse muscle spasms/aches, piloerection, nausea, vomiting, and diarrhea, abdominal pain, fever, chills, increased white blood cells if sudden withdrawal\n",
      "10 839\n",
      "Original :  irritability, fatigue, bradycardia, decreased body temperature, craving, insomnia\n",
      "Extracted:  irritability, fatigue, bradycardia, decreased body temperature, craving, insomnia\n",
      "11 955\n",
      "Original :  5 to 10 days following opioid dose reduction/cessation but may take longer depending on the half-life of the opioid (e.g., methadone)\n",
      "Extracted:  5 to 10 days following opioid dose reduction/cessation but may take longer depending on the half-life of the opioid (e.g., methadone)\n",
      "12 1126\n",
      "Original :  dysphoria, insomnia\n",
      "Extracted:  dysphoria, insomnia\n",
      "13 1244\n",
      "Original :  fatigue, mental functioning, pain, and well-being\n",
      "Extracted:  fatigue, mental functioning, pain, and well-being\n",
      "14 139\n",
      "Original :  frequent requests for early refills or atypically large quantities required to control pain\n",
      "Extracted:  frequent requests for early refills or atypically large quantities required to control pain\n",
      "15 242\n",
      "Original :  an emerging sud as well as  diversion\n",
      "Extracted:  an emerging sud as well as  diversion\n",
      "16 242\n",
      "Original :  an emerging sud as well as  diversion\n",
      "Extracted:  an emerging sud as well as  diversion\n",
      "17 518\n",
      "Original :  a history of depression\n",
      "Extracted:  a history of depression\n",
      "18 577\n",
      "Original :  opioid-related toxicity/overdose\n",
      "Extracted:  opioid-related toxicity/overdose\n",
      "19 653\n",
      "Original :  lot\n",
      "Extracted:  lot\n",
      "20 682\n",
      "Original :  worsening depressive symptoms\n",
      "Extracted:  worsening depressive symptoms\n",
      "21 883\n",
      "Original :  patients with a history of ptsd (with or  without other mental health diagnoses) as compared to patients with other (or no) mental  health diagnoses\n",
      "Extracted:  patients with a history of ptsd (with or  without other mental health diagnoses) as compared to patients with other (or no) mental  health diagnoses\n",
      "22 812\n",
      "Original :  a prevalence of self inflicted injuries\n",
      "Extracted:  a prevalence of self inflicted injuries\n",
      "23 1067\n",
      "Original :  va/dod ptsd cpg\n",
      "Extracted:  va/dod ptsd cpg\n",
      "24 1111\n",
      "Original :  a history of overdose\n",
      "Extracted:  a history of overdose\n",
      "25 18\n",
      "Original :  physical, psychological, and pain rehabilitation modalities\n",
      "Extracted:  physical, psychological, and pain rehabilitation modalities\n",
      "26 233\n",
      "Original :  all avenues for obtaining these treatments (e.g. internet based cbt) and all appropriate non opioid medications\n",
      "Extracted:  all avenues for obtaining these treatments (e.g. internet based cbt) and all appropriate non opioid medications\n",
      "27 15\n",
      "Original :  limited\n",
      "Extracted:  limited\n",
      "28 168\n",
      "Original :  increased mortality, oud, overdose, sexual dysfunction, fractures, myocardial infarction, constipation, and sleep-disordered breathing\n",
      "Extracted:  increased mortality, oud, overdose, sexual dysfunction, fractures, myocardial infarction, constipation, and sleep-disordered breathing\n",
      "29 364\n",
      "Original :  259 million\n",
      "Extracted:  259 million\n",
      "30 22\n",
      "Original :  over years\n",
      "Extracted:  over years\n",
      "31 73\n",
      "Original :  2 to 10% every 4 to 8 weeks with pauses in taper as needed\n",
      "Extracted:  2 to 10% every 4 to 8 weeks with pauses in taper as needed\n",
      "32 164\n",
      "Original :  patients taking high doses of long-acting opioids for many years\n",
      "Extracted:  patients taking high doses of long-acting opioids for many years\n",
      "33 384\n",
      "Original :  90 mg sr qam, 75 mg for noon, 90 mg qpm\n",
      "Extracted:  90 mg sr qam, 75 mg for noon, 90 mg qpm\n",
      "34 453\n",
      "Original :  veteran response\n",
      "Extracted:  veteran response\n",
      "35 471\n",
      "Original :  pauses in the taper\n",
      "Extracted:  pauses in the taper\n",
      "36 495\n",
      "Original :  allow the patient time to acquire new skills for management of pain and emotional distress while allowing for neurobiological equilibration\n",
      "Extracted:  allow the patient time to acquire new skills for management of pain and emotional distress while allowing for neurobiological equilibration\n",
      "37 691\n",
      "Original :  75 mg sr qam, 75 mg noon, 90 mg qpm\n",
      "Extracted:  75 mg sr qam, 75 mg noon, 90 mg qpm\n",
      "38 740\n",
      "Original :  75 mg sr (60 mg+15 mg) q8h\n",
      "Extracted:  75 mg sr (60 mg+15 mg) q8h\n",
      "39 780\n",
      "Original :  75 mg sr qam, 60 mg noon, 75 mg qpm\n",
      "Extracted:  75 mg sr qam, 60 mg noon, 75 mg qpm\n",
      "40 829\n",
      "Original :  60 mg sr qam, 60 mg noon, 75 mg qpm\n",
      "Extracted:  60 mg sr qam, 60 mg noon, 75 mg qpm\n",
      "41 878\n",
      "Original :  60 mg sr q8h\n",
      "Extracted:  60 mg sr q8h\n",
      "42 904\n",
      "Original :  60 mg sr qam, 45 mg noon, 60 mg qpm\n",
      "Extracted:  60 mg sr qam, 45 mg noon, 60 mg qpm\n",
      "43 953\n",
      "Original :  45 mg sr qam, 45 mg noon, 60 mg qpm\n",
      "Extracted:  45 mg sr qam, 45 mg noon, 60 mg qpm\n",
      "44 1002\n",
      "Original :  45 mg sr q8h\n",
      "Extracted:  45 mg sr q8h\n",
      "45 1066\n",
      "Original :  until off the morphine or the desired dose of opioid is reached\n",
      "Extracted:  until off the morphine or the desired dose of opioid is reached\n",
      "46 0\n",
      "Original :  state database queries\n",
      "Extracted:  state database queries\n",
      "47 27\n",
      "Original :  detection of multi-sourcing of controlled substances\n",
      "Extracted:  detection of multi-sourcing of controlled substances\n",
      "48 281\n",
      "Original :  at least quarterly\n",
      "Extracted:  at least quarterly\n",
      "49 252\n",
      "Original :  the cdc\n",
      "Extracted:  the cdc\n",
      "50 311\n",
      "Original :  the state database system\n",
      "Extracted:  the state database system\n",
      "51 80\n",
      "Original :  osi toolkit and the patient  guide “taking opioids responsibly for your safety and the safety of others: patient information guide on  long-term opioid therapy for chronic pain”\n",
      "Extracted:  osi toolkit and the patient  guide “taking opioids responsibly for your safety and the safety of others: patient information guide on  long-term opioid therapy for chronic pain”\n",
      "52 292\n",
      "Original :  provide clinicians with  materials to inform clinical decision-making regarding opioid therapy and safe opioid prescribing\n",
      "Extracted:  provide clinicians with  materials to inform clinical decision-making regarding opioid therapy and safe opioid prescribing\n",
      "53 475\n",
      "Original :  https://www.va.gov/painmanagement/opioid_safety_initiative_toolkit.asp\n",
      "Extracted:  https://www.va.gov/painmanagement/opioid_safety_initiative_toolkit.asp\n",
      "54 703\n",
      "Original :  providing information to patients as well as their providers regarding the safe use  of opioids\n",
      "Extracted:  providing information to patients as well as their providers regarding the safe use  of opioids\n",
      "55 853\n",
      "Original :  http://www.healthquality.va.gov/guidelines/pain/cot/opiodtheraphyforchronicpainpatienttool20may20 13print.pdf\n",
      "Extracted:  http://www.healthquality.va.gov/guidelines/pain/cot/opiodtheraphyforchronicpainpatienttool20may20 13print.pdf\n",
      "56 1017\n",
      "Original :  the vha\n",
      "Extracted:  the vha\n",
      "57 964\n",
      "Original :  to further promote safety and patient centered care\n",
      "Extracted:  to further promote safety and patient centered care\n",
      "58 1041\n",
      "Original :  in 2014\n",
      "Extracted:  in 2014\n",
      "59 1060\n",
      "Original :  standardized education and signature informed consent for all patients receiving lot for non-cancer  pain\n",
      "Extracted:  standardized education and signature informed consent for all patients receiving lot for non-cancer  pain\n",
      "60 58\n",
      "Original :  executive departments and agencies shall, to the extent permitted by law, provide training on the appropriate and effective prescribing of opioid medications to all employees who are health care professionals and who prescribe controlled substances as part of their federal responsibilities and duties\n",
      "Extracted:  executive departments and agencies shall, to the extent permitted by law, provide training on the appropriate and effective prescribing of opioid medications to all employees who are health care professionals and who prescribe controlled substances as part of their federal responsibilities and duties\n",
      "61 0\n",
      "Original :  the presidential memorandum of october 2015\n",
      "Extracted:  the presidential memorandum of october 2015\n",
      "62 0\n",
      "Original :  the presidential memorandum of october 2015\n",
      "Extracted:  the presidential memorandum of october 2015\n",
      "63 444\n",
      "Original :  modules on pain management and opioid prescribing safety, the recent centers for disease control and prevention (cdc) guideline, and the identification of substance misuse and referral to specialized services\n",
      "Extracted:  modules on pain management and opioid prescribing safety, the recent centers for disease control and prevention (cdc) guideline, and the identification of substance misuse and referral to specialized services\n",
      "64 365\n",
      "Original :  dod opioid prescriber safety  training program\n",
      "Extracted:  dod opioid prescriber safety  training program\n",
      "65 654\n",
      "Original :  defense centers of  excellence for psychological health and traumatic brain injury\n",
      "Extracted:  defense centers of  excellence for psychological health and traumatic brain injury\n",
      "66 828\n",
      "Original :  http://opstp.cds.pesgce.com/hub.php\n",
      "Extracted:  http://opstp.cds.pesgce.com/hub.php\n",
      "67 43\n",
      "Original :  pact team\n",
      "Extracted:  pact team\n",
      "68 98\n",
      "Original :  a team function with various team members taking on roles in which they have demonstrated specific competencies\n",
      "Extracted:  a team function with various team members taking on roles in which they have demonstrated specific competencies\n",
      "69 0\n",
      "Original :  follow-up for tapering\n",
      "Extracted:  follow-up for tapering\n",
      "70 211\n",
      "Original :  mental health practitioners\n",
      "Extracted:  mental health practitioners\n",
      "71 339\n",
      "Original :  1 to 4 weeks after starting taper then monthly before each reduction\n",
      "Extracted:  1 to 4 weeks after starting taper then monthly before each reduction\n",
      "72 339\n",
      "Original :  1 to 4 weeks after starting taper then monthly before each reduction\n",
      "Extracted:  1 to 4 weeks after starting taper then monthly before each reduction\n",
      "73 583\n",
      "Original :  weekly before each dose reduction\n",
      "Extracted:  weekly before each dose reduction\n",
      "74 669\n",
      "Original :  daily before each dose reduction or if available offer inpatient admission\n",
      "Extracted:  daily before each dose reduction or if available offer inpatient admission\n",
      "75 819\n",
      "Original :  in the clinic and/or over telephone\n",
      "Extracted:  in the clinic and/or over telephone\n",
      "76 819\n",
      "Original :  in the clinic and/or over telephone\n",
      "Extracted:  in the clinic and/or over telephone\n",
      "77 819\n",
      "Original :  in the clinic and/or over telephone\n",
      "Extracted:  in the clinic and/or over telephone\n",
      "78 908\n",
      "Original :  in the hospital, clinic or over telephone\n",
      "Extracted:  in the hospital, clinic or over telephone\n",
      "79 1053\n",
      "Original :  the risk category of the veteran\n",
      "Extracted:  the risk category of the veteran\n",
      "80 951\n",
      "Original :  providers\n",
      "Extracted:  providers\n",
      "81 1087\n",
      "Original :  a veteran with high risk due to a medical condition\n",
      "Extracted:  a veteran with high risk due to a medical condition\n",
      "82 1087\n",
      "Original :  a veteran with high risk due to a medical condition\n",
      "Extracted:  a veteran with high risk due to a medical condition\n",
      "83 1372\n",
      "Original :  providing follow-up in a clinic visit may be more optimal than a telephone visit\n",
      "Extracted:  providing follow-up in a clinic visit may be more optimal than a telephone visit\n",
      "84 1372\n",
      "Original :  providing follow-up in a clinic visit may be more optimal than a telephone visit\n",
      "Extracted:  providing follow-up in a clinic visit may be more optimal than a telephone visit\n",
      "85 1467\n",
      "Original :  patient function, pain intensity, sleep, physical activity, personal goals, and stress level\n",
      "Extracted:  patient function, pain intensity, sleep, physical activity, personal goals, and stress level\n",
      "86 20\n",
      "Original :  a gradual taper rate (5-10% reduction every 4 weeks) allows time for neurobiological, psychological, and behavioral adaptations\n",
      "Extracted:  a gradual taper rate (5-10% reduction every 4 weeks) allows time for neurobiological, psychological, and behavioral adaptations\n",
      "87 42\n",
      "Original :  5-10% reduction every 4 weeks\n",
      "Extracted:  5-10% reduction every 4 weeks\n",
      "88 80\n",
      "Original :  time for neurobiological, psychological, and behavioral adaptations\n",
      "Extracted:  time for neurobiological, psychological, and behavioral adaptations\n",
      "89 276\n",
      "Original :  consider interdisciplinary services that may include mental health, sud, primary care, and specialty pain care\n",
      "Extracted:  consider interdisciplinary services that may include mental health, sud, primary care, and specialty pain care\n",
      "90 208\n",
      "Original :  unmasked oud, exacerbation of underlying mental health conditions\n",
      "Extracted:  unmasked oud, exacerbation of underlying mental health conditions\n",
      "91 329\n",
      "Original :  mental health, sud, primary care, and specialty pain care\n",
      "Extracted:  mental health, sud, primary care, and specialty pain care\n",
      "92 396\n",
      "Original :  concerns that may negatively impact taper (e.g., inability for adequate follow-up, inability to provide adequate treatment for co-occurring medical and mental health conditions and sud)\n",
      "Extracted:  concerns that may negatively impact taper (e.g., inability for adequate follow-up, inability to provide adequate treatment for co-occurring medical and mental health conditions and sud)\n",
      "93 445\n",
      "Original :  inability for adequate follow-up, inability to provide adequate treatment for co-occurring medical and mental health conditions and sud\n",
      "Extracted:  inability for adequate follow-up, inability to provide adequate treatment for co-occurring medical and mental health conditions and sud\n",
      "94 684\n",
      "Original :  opioid dose, duration of therapy, type of opioid formulation, psychiatric, medical and sud comorbidities and other patient risk factors (e.g., non-adherence, high-risk medication-related behavior, strength of social support, and coping)\n",
      "Extracted:  opioid dose, duration of therapy, type of opioid formulation, psychiatric, medical and sud comorbidities and other patient risk factors (e.g., non-adherence, high-risk medication-related behavior, strength of social support, and coping)\n",
      "95 98\n",
      "Original :  the duration and dose of opioid analgesic use\n",
      "Extracted:  the duration and dose of opioid analgesic use\n",
      "96 297\n",
      "Original :  given the insufficient evidence of benefit for lot\n",
      "Extracted:  given the insufficient evidence of benefit for lot\n",
      "97 505\n",
      "Original :  as patient values and preferences may be impacted by other clinical considerations, some patients with one or more risk factors for adverse outcomes may differ with the clinician’s assessment that the risks of ot  outweigh the potential for modest short-term benefits.\n",
      "Extracted:  as patient values and preferences may be impacted by other clinical considerations, some patients with one or more risk factors for adverse outcomes may differ with the clinician’s assessment that the risks of ot  outweigh the potential for modest short-term benefits.\n",
      "98 1148\n",
      "Original :  should be carefully monitored, and ongoing assessment of risk should be performed with vigilance for the development of additional risk factors and adverse outcomes\n",
      "Extracted:  should be carefully monitored, and ongoing assessment of risk should be performed with vigilance for the development of additional risk factors and adverse outcomes\n",
      "99 1341\n",
      "Original :  consider consultation with appropriate specialty care providers\n",
      "Extracted:  consider consultation with appropriate specialty care providers\n",
      "100 9\n",
      "Original :  in response to the recognition of pain and its management as a public health problem\n",
      "Extracted:  in response to the recognition of pain and its management as a public health problem\n",
      "101 95\n",
      "Original :  the  national academy of medicine\n",
      "Extracted:  the  national academy of medicine\n",
      "102 -1\n",
      "Original :  the state of pain research, treatment, and education in the u.s.\n",
      "Extracted:  \n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    },
    {
     "ename": "AssertionError",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mAssertionError\u001b[0m                            Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-18-06ed409024d9>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[1;32m      2\u001b[0m \u001b[0;31m# data_path = Path('../data/')\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      3\u001b[0m \u001b[0mdf_to_json\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mtrain\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mdata_path\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m'train_otquad.json'\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m----> 4\u001b[0;31m \u001b[0mdf_to_json\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mtest\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mdata_path\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m'test_otquad.json'\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[0;32m<ipython-input-16-2939411817f4>\u001b[0m in \u001b[0;36mdf_to_json\u001b[0;34m(df, data_path, json_filename)\u001b[0m\n\u001b[1;32m      9\u001b[0m       \u001b[0mprint\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m'Extracted: '\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mdf\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'context'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mvalues\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mi\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mlower\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mstart_index\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mi\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0mstart_index\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mi\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m+\u001b[0m\u001b[0mlen\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mdf\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'answer_y'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mvalues\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mi\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     10\u001b[0m       assert df['answer_y'].values[i].lower() == df['context'].values[i].lower()[\n\u001b[0;32m---> 11\u001b[0;31m         start_index[i]:start_index[i]+len(df['answer_y'].values[i])]\n\u001b[0m\u001b[1;32m     12\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     13\u001b[0m   \u001b[0mprint\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34mf'Unique Contexts: {len(np.unique(df.context.values))}\\n Ratio of QA Pair-to-Contexts: {len(df)/len(np.unique(df.context.values))}'\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mAssertionError\u001b[0m: "
     ]
    }
   ],
   "source": [
    "data_path = Path('../')\n",
    "# data_path = Path('../data/')\n",
    "df_to_json(train, data_path, 'train_otquad.json')\n",
    "df_to_json(test, data_path, 'test_otquad.json')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Plot q-type frequency"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_qtype_freq():\n",
    "  q_list = df['question'].values.tolist()\n",
    "  q_type = ['what', 'when', 'where', 'who', 'whom', \n",
    "            'which', 'why', 'how'] #, 'name', 'whose', \n",
    "  \n",
    "  q_freq = {}\n",
    "  for ques in q_list:\n",
    "    q_tokens = ques.lower().split()\n",
    "    for typ in q_type:\n",
    "      if typ in q_tokens[0]:\n",
    "        q_freq.setdefault(typ, []).append(ques)\n",
    "\n",
    "  freq_qtype = [len(x) for x in list(q_freq.values())]\n",
    "  print(freq_qtype, sum(freq_qtype))\n",
    "  \n",
    "  df_sorted = pd.DataFrame()\n",
    "  df_sorted['QTYPE'] = q_type\n",
    "  df_sorted['QFREQ'] = freq_qtype\n",
    "  df_sorted['n'] = freq_qtype\n",
    "  df_sorted = df_sorted.sort_values(\"QFREQ\", ascending=False)\n",
    "\n",
    "  return df_sorted\n",
    "  "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "def plot_qtype_frequency(df_sorted):\n",
    "  \n",
    "  # Values for the x axis\n",
    "  ANGLES = np.linspace(0.05, 2 * np.pi - 0.05, len(df_sorted), endpoint=False)\n",
    "\n",
    "  # Cumulative length\n",
    "  QFREQ = df_sorted[\"QFREQ\"].values\n",
    "\n",
    "  # # Mean gain length\n",
    "  # MEAN_GAIN = df_sorted[\"mean_gain\"].values\n",
    "\n",
    "  # Region label\n",
    "  QTYPE = df_sorted[\"QTYPE\"].values\n",
    "\n",
    "  # Number of tracks per region\n",
    "  N = df_sorted[\"n\"].values\n",
    "\n",
    "  GREY12 = \"#1f1f1f\"\n",
    "\n",
    "  # Set default font color to GREY12\n",
    "  plt.rcParams[\"text.color\"] = GREY12\n",
    "\n",
    "  # The minus glyph is not available in Bell MT\n",
    "  # This disables it, and uses a hyphen\n",
    "  plt.rc(\"axes\", unicode_minus=False)\n",
    "\n",
    "  # Colors\n",
    "  COLORS = [\"#6C5B7B\",\"#C06C84\",\"#F67280\",\"#F8B195\"]\n",
    "\n",
    "  # Colormap\n",
    "  cmap = mpl.colors.LinearSegmentedColormap.from_list(\"my color\", COLORS, N=256)\n",
    "\n",
    "  # Normalizer\n",
    "  norm = mpl.colors.Normalize(vmin=N.min(), vmax=N.max())\n",
    "\n",
    "  # Normalized colors. Each number of tracks is mapped to a color in the \n",
    "  # color scale 'cmap'\n",
    "  COLORS = cmap(norm(N))\n",
    "\n",
    "  # Some layout stuff ----------------------------------------------\n",
    "  # Initialize layout in polar coordinates\n",
    "  fig, ax = plt.subplots(figsize=(6, 6), subplot_kw={\"projection\": \"polar\"})\n",
    "\n",
    "  # Set background color to white, both axis and figure.\n",
    "  # fig.patch.set_facecolor(\"white\")\n",
    "  # ax.set_facecolor(\"white\")\n",
    "\n",
    "  ax.set_theta_offset(100 * np.pi / 3)\n",
    "  ax.set_ylim(-100, 350)\n",
    "\n",
    "  # Add geometries to the plot -------------------------------------\n",
    "  # See the zorder to manipulate which geometries are on top\n",
    "\n",
    "  # Add bars to represent the cumulative track lengths\n",
    "  ax.bar(ANGLES, QFREQ, color=COLORS, alpha=1, width=0.6, zorder=11) #, ls=(0, (4, 4))\n",
    "\n",
    "  # Add dashed vertical lines. These are just references\n",
    "  ax.vlines(ANGLES, 0, 350, alpha=0.5, color=GREY12, zorder=11)\n",
    "\n",
    "  # # Add dots to represent the mean gain\n",
    "  # ax.scatter(ANGLES, MEAN_GAIN, s=60, color=GREY12, zorder=11)\n",
    "\n",
    "  # Add labels for the regions -------------------------------------\n",
    "  # Note the 'wrap()' function.\n",
    "  # The '5' means we want at most 5 consecutive letters in a word, \n",
    "  # but the 'break_long_words' means we don't want to break words \n",
    "  # longer than 5 characters.\n",
    "  QTYPE = [\"\\n\".join(wrap(r, 5, break_long_words=False)) for r in QTYPE]\n",
    "\n",
    "  # Set the labels\n",
    "  ax.set_xticks(ANGLES)\n",
    "  ax.set_xticklabels(QTYPE, size=15);\n",
    "\n",
    "  plt.show()\n",
    "  \n",
    "  sns.set(style=\"whitegrid\")\n",
    "  colors = sns.color_palette('pastel')[0:len(df_sorted)]\n",
    "\n",
    "  plt.subplots(figsize=(8, 15))\n",
    "  explode = (0, 0.02, 0.03, 0.05, 0.1, 0.15, 0.4, 0.6)\n",
    "  plt.pie(df_sorted['QFREQ'].values, labels=df_sorted['QTYPE'].values,\n",
    "          explode=explode, colors = colors, autopct='%1.1f%%', shadow=False,\n",
    "          textprops={'fontsize': 14})\n",
    "  plt.xticks(size=25)\n",
    "  plt.title(\"Distribution of 'type of questions'\\nin OTQuAD\", size=15)\n",
    "  plt.show()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "def density_plot_data(col_name_list, which_attr, figsize=(6,4)):\n",
    "  plt.figure(figsize=figsize)\n",
    "  for col_name in col_name_list:\n",
    "    fig = sns.kdeplot(df[col_name], shade=True, label = col_name)\n",
    "  plt.xticks(size=14)\n",
    "  plt.yticks(size=14)\n",
    "  plt.xlabel('Length', size=15)\n",
    "  plt.ylabel('Density\\n', size=15)\n",
    "  plt.legend(loc='best', fontsize=14)\n",
    "  plt.title(f\"Distribution of '{which_attr}'\\nin OTQuAD\", size=15)\n",
    "  plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[361, 75, 56, 29, 46, 2, 13, 5] 587\n"
     ]
    },
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAZcAAAF3CAYAAABpIgaPAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjMuMiwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy8vihELAAAACXBIWXMAAAsTAAALEwEAmpwYAAC9T0lEQVR4nOy9d5xcZ30u/pxeps92rXq3itVWyMYyGLkg3DDGQCBxMCH3crlcbrgO5BquU0hISEiBG8wNBOcXk4BJjLGxwbiCLWxZtrSrYhWr2JKstkW7O33m9PP7451zdlfbZnfe2Z1dzfP5+GNpNfvOmZkz7/N+2/Mwruu6qKGGGmqooQaKYKf7AmqooYYaaph9qJFLDTXUUEMN1FEjlxpqqKGGGqijRi411FBDDTVQR41caqihhhpqoI4audRQQw011EAdNXKpYcrx2GOPYcWKFcjlctN9KTXUUEOFUCOXGmqooYYaqKNGLjXUUEMNNVBHjVxqKBu7du3CihUr0N3d7f/sYx/7GK644gqk02n/Z7fddhu++c1v+n8/d+4cPvWpT2H9+vXYvn07nnvuOf/ffvSjH2HDhg3DUmevvfYaVqxYgaNHj1bwFdVQQw3lokYuNZSNDRs2QBAEdHR0AAAKhQIOHz4MQRCwd+9eAEAymcSJEyewadMm//e++MUvYtu2bXjggQewcOFC3Hvvvejq6gJAiMi2bTz77LNDnuvxxx/H6tWrsXLlyil6dTXUUMNkUCOXGsqGLMtYvXo12tvbAQD79+9HIBDA9ddf7/+so6MDDMNg48aN/u998pOfxN13342tW7fi61//OhzHwYsvvggACIfDuOmmm/DYY4/5j8/lcnjuuedw5513TuGrq6GGGiaDGrnUQAWbNm3yiaS9vR1tbW3YvHnzkJ+tXLkSwWDQ/52tW7f6f47FYojH437kAgB33XUX2tvbcfbsWQDA008/DcuycOutt07FS6qhhhrKQI1caqCCzZs348SJE0in0z65tLW14dChQ9B1He3t7UNSYgAQCoWG/F0URRiG4f99y5YtmDdvnh+9PPbYY7j++usRjUYr/npqqKGG8lAjlxqoYOPGjXBdF7t378aBAwfQ1taGZcuWIRAIYNeuXThy5Aja2tomtCbDMPjwhz+MJ554AqdPn0ZHR0ctJVZDDTMENXKpgQoikQiWLVuGhx56CCzLYtWqVX6N5cEHH4RlWcMil1LwoQ99CF1dXfjKV76CpqYmXHPNNRW4+hpqqIE2auRSAzVs3rwZe/bswYYNG8BxHACgra0Ne/bswcKFC9HQ0DDhNZuamnDttdeio6MDd9xxh79uDTXUUN2okUsN1OClvTZv3jzsZ4O7xCaKG264AQBqKbEaaphBYGo2xzVUO/7gD/4AFy9exMMPPzzdl1JDDTWUCH66L6CGGkbDsWPHcOjQITz//PP4h3/4h+m+nBpqqGECqJFLDVWLz372s0gkEvjEJz6B7du3T/fl1FBDDRNALS1WQw011FADddQK+jXUUEMNNVBHjVxqqKGGGmqgjlrNpYbLHhPJDDMMU/LveI+toYbLETVyqWHW4lICGEwMrjvw767rwnHcYf8fWAdDfg9wwTBM8T9c8v+BP7MsM+Rnl17DSNd2OeOxxx7Dl7/8ZezduxeBQGC6L6eGMlEjlxpmNAZv0gzDDCEOx3Fh2w5s24FlObAsewhpTAcYBmBZBjzPgedZcBwHjhtKRMDA66qRTg0zFTVyqWHGYPCG65GI4xDyME0bpmnDspxpvsqx4bqAbbuwbQu6PvzfGQbgeQ6iyIHnOXAc6xNPjXBqmEmoFfRrqFoQAhlIU1mWg0LBRCKRQ29vFn19WSQSeaTTGgoFs+qJpRS4LmCaNnI5A6lUAf39A681m9Wh6xYsyx6S0qvWaYJK2F97+OEPf4ibbroJa9aswY033oiHHnqooq+lhomjRi41VA1M00R/fz9clxCJrltIpzX09ZHNNZnMI5fTZwWJTBSO40LTTGQyGhKJvE84+bwBy3L8dF81kU0l7K8B4JFHHsFf/MVfYNu2bfjud7+L7du346//+q/xz//8z1P7AmsYEzVyqWHaMDgysW0HO3fuwkMP/RsuXOhHIpFDJqPBMCxUyV5ZdXAcF/m8gWQyj76+LHp7M8hmdZimXRVkUwn7a8dx8O1vfxt33nkn7rvvPmzduhV/+Id/iN/6rd/C9773Pegj5RprmBbUyKWGKYW30TmOC9O0kclo6O3Nor8/h0ikHgzjoru7c5qvcmbCdQFNM5FKFfxoT9NMvwNuOoiGtv11V1cXenp6hskB3Xzzzchmszh27FilX1INJaJGLjVUFIM3NNt2oGmWv/GlUgXouuU/trm5GQBTIxdKcBwX2azu120yGQ2maU8p0dC2v7548SIAoK6ubshjvL+nUqlKvZQaJogaudRQEQwuxGuaib4+Ep1ks9qo7cA8L6ChobFGLhWCrltIpQro7c0inS5MCdHQtr/2DOf6+vqG/Nz7eyQSoXfxNZSFGrnUQA2DI5RCwURfX65IKHrJ8yVNTXPQ399Xy51XGIZhTwnR0La/bm5uRmNjI5555pkhP3/66acRDAaxYsUKatdeQ3mozbnUUBYGb0SGYSOf12BZk9+cGhubAQBdXRewYMGisq+vhvFhGDYMowAAkGUeiiKC48i5k8ZMzebNm/GjH/0IW7duHWJ//Y1vfGPC9tcsy+Lzn/88/uRP/gTRaBTXXHMN9uzZgx//+Me49957IUlS2ddbAx3UyKWGSWFolGJA06xxfqM0NDY2gWVZ9PR01shlGqBpFjTNAsMwCAQkSBI/TLpmomhra8OPfvQjavbXH/3oR2EYBn7wgx/g3//939HU1IT77rsP99xzz6Sur4bKoObnUkPJGHyraJqFXE6rSJvw88//EppWwG23fZj+4jVMGKLIIxCgG83UMPtRq7nUMC4Gtw/ncjp6e7PIZitDLABJjSUS/dC0QmWeoIYJwTAsJBJklkbXrWlra65hZqFGLjWMCm8DsSwHiUQe/f05FApmxZ+3qWkOGIZBZ+eFij9XDaXDdeHPJRUKhi8QWiOZGkZCjVxqGAZvwzAMC319OSSTeViWPWXP39DQAI7j0NPTNf6Da5gW5HKGr3c2WA2ghho81Ar6NfjwNgfDsJDJVC7tNR44jkNjYzO6umqRS7VD00xomglB4BAMSuB5Dq7r1uoyNdTIpYYBUtF1q6K1lImgqakZ+/a1I5/PQ1VV6usPNvca8FKB/+fB/iosO9RkDLjUbGyo8dhQczEXtu3CcZyqeF8rBdO0kUjkIQgcQiEZHMfUSOYyR41cLmNUI6l4GFx3WbJk6aTW4Di2aMg18H+PNAAMc58k/jADQpoD/w4MuE8CwIDbJIAhf2ZZdshjWJYp/scWn9PxTcw8GwHP0Gw2wDRt9PfnIIocgkEZxZddI5nLEDVyuQzhkYpp2kinC1VFKh7q6xvA8zx6ejrHJZfhJELcHQe7UBIflAHCmA4QsmGLzpPk/7LMg+PItY/knDlT7QUMwyMZHsGgVCOZyxA1crmM4KUpbNtBOl2AbVchqxTBsiyamprR3T207iIIHASBWATzPAeWZfzN2BPGtG2jKiMB4kLpwLYBYHiDBMsyPtHwPAtFEcCyLCzL9p02TXPqGitowDAs9PdbkGUBgYAELwKsYfajRi6XAQbPqWSzBRjGzNigGhvn4Pz5s3AcA/F4FDxPNlrDsKuaRCYLx3HhOEMJhGEGCDUQEMHzHCxrsK2zXbJu23TCK/wDJt5++zja2trA87XtZzaj9unOcnjEksvpUzKjUi54noUo8hBFDqtWLcX+/btx4cJ5SJIy407tNOC6nvbXwGvneUI2sixAEGS4ruuTjWFYVU02L7/8Ms6cOY1ly5YjHo8BqKXKZitq5DJLMbitOJ3WpvlqRgfDoEgmhFAch1xzLmeAYRTwvIAzZ85g7tyazpgHUouxUSgKGHAcOyS6sW0Xum5C16uLaLq6unD69NtYvXo9HEdAKlVAKESK/jWCmX2okcssw+AUWDqtTenw40QgSTxkWQDPc/6JO5cbKs3PMAyam+fUJvXHgdcEQNJOJI0mSTxiMbVqiMZ1XXR0vAZZVrF27XoAA51lgYAIRREB1EhmNqFGLrMIHrEUCgZyOWOar2Y4vE1PkgSYpo1CwfSl3kdDY2MLzp49jUwmjVAoPEVXOrPhpciyWd1Pn6mqBNsmtSpPH2wq8dZbx9Hf34urr74WgiAM+bdczkChYCISUWrimLMINXKZJfBmM5LJQlXJcLAsA1kWIMsCXJe4UiYSuZJP0c3NLQCAzs4LNXKZBAZ3mIkiB0kiXVuWZUPXp4ZoDMPAvn17UFfXgCVLlo/4GMdxkUjkoSjk+moDmDMfNXKZ4fA2hmxW99Mi1YDBaS9dN5FOFyY1sxGLxSFJMnp6OrF8+coKXOnlg8GNAaLIQ5J4n2gKBaNiXYQHD+6Drhfw3vfeMC5hFAqkqywSUcDzxFisRjIzEzVymcGotmiF51nIsgBJEmBZNjTNhK6XJ5vPMAyamuagq6uzdpqlCMOwYBjE4E2SeKiqhEBgYHOnhVQqhTffPIRFi5aiqam5pN9xXSCZLECSeIRCcu1zn6GokcsMRLXVVsjmRAqymmZNKO1VCpqbm3HmzEmkUilEo1Fq69ZA4KXHBIGDoogIBEQUCqYvq18O9u3bDY5jsWHDuyZ1XYaRRTSqguPYGsHMMNTIZYbB08JKpfLTPmHvpVVs20E2q1dsDqWpaQ4AoLv7Qo1cKghSnymA44g6QDwehK6byOeNSR0Wzp8/i7NnT2PdujYEAoFJXZPrAolEvtZRNgNR83OZIfAUdnXdQn9/blqJRZYFxOMByLKATEZDKlWo6IBjJBKFLKvo7u6s2HPUMADvsOBFoLGYinBYBs+Xvl04joOOjtehqkGsWrW27GvK5Qwkk/khCtQ1VDdqkcsMgPdlSqenV7qFtLSKRW2yqZuhIfMuLejsvFDLv08hHMdFPm8gnzcgywLCYQWO4yCfN/16zWg4fvwIUqkErr32emoyL5bloK8vi0hEgSDUiv3VjlrkUuXw0mB9fblpIxYvUhFFHul0AalUYcqHMxsbW6DrBSSTiSl93hoINM1Ef38O+bwJVRURi5H7YeTHati/fy+amlqwYAF9ZYVUqoBsVgdQi2KqGbXIpUpRDfItiiJAUURYlj3pVmJaaG726i6diMXi03Ydlzu8LjMiNSNBVUVks9qQe+ONNzpgmgY2bbqqYpGFppmwLAuRSAA1peXqRI1cqhDTPbvipb+qgVQ8hMNhqGoQXV2dWLlyNdW1h7pOYlQnSmAkN8rBfx7qRklUjmenA6Vp2kgm85AkHuGwAssiigB9fX04fvwoli5dgbq6+opeg2W56O+vdZNVK2rkUmXwNqZkcuqL9jzPIhgkcwWpVKGq5Oy9usu5c2cmXHcZ7JHi/X8kR8rBTpReOtJxHFjWUL2zoU6TAMBe4kw54ELJcWxxXce3O7btAVOwanqPJwOvjVlVRUSjKn71q6fB8zzWr980Jc/vdZOFQjIkiWxnNZKpDtTIpYrgbWiJRG5KT7sMAwQCEkSRRy6nQ9fHLtZOFxobW3Dy5An09/eNeCoeTCCD/0w2cxu27cAwLBQKTpE4puZNHu5AyUIQhOJ1Mr4D5WBTsJkW7eTzBo4ePYHz58/hPe95D6LR8JTeR5mMBtMUEAzWpGOqBTVyqRJ4nhypVHkT7ROFZ0NrGNaUk9pE0dJC6i5dXZ1oaGjwZeYFgRtCIpZFSCSfr47IYDwHSo5jimRIhhhDIQ6O4wxxn6wm6fyRYFkWOjpeQzAYxoIFy6AoZC7l0npMJaFpJkzTQiwWqBFMFaBGLtMML0+vaabfATMVYFkGwaAMjmOqWprfA8MwqKuLIRwOI5W6iFgsANO0YJp2sbg7/SQyWXikONQQjJCNKPJFe2AMiWyq7fUePXoY2Wwa73vf++G6DJLJPGRZQCSiQNeJncJUHFxsm3RWxuMqgFqKbDpRI5dpxHQV7hVFhKoKyOdNpNPTLx8zGgZcKXlwHAvTtDFnTivefvttXLyYBsvO3k56y3JgWQMeLSzL+FGaLAtgWfJ+6DqZOZnOiDOfz+PgwX2YM2ce5s6d7/+caMuZCAQkxOMBZLNTk3J1XUIwsVit0D+dqJHLNMEjlkpPtw8Gz7MIhWRf3rwaUy3e5klcKV0Yho1cbkBaJh5vwtGjR9HX14uGhsZpvtqpg+O4fvEcGHDwlCQewaA8rUSzf387bNvGpk1XDfs31x04PIVCCkSRRzarTck1JhJ5f+CyRjBTjxq5TAM8YkkkpqYjrNoL9hzH+GrKjkM8Xy51pfTQ3DwHruuiu7vzsiKXS+G6A51aA0QjFInGGkJElcTFiz04efI4VqxYM6bum2U5SCRyCAYlxGKBKWtxT6UKCAYlyLJQI5gpRo1cphheyytt5eDRIAgcQiG56gr2DANIEjER4zgGmmaV1P4cCAQQiUTQ3d2JNWvWTdHVVjcuJRrPSycYJJ87URemTzSedbEoSrjyyg0l/U42q0MUbUQiCvJ5orxcaWSzOhzHgaqS2lWNZKYGNXKZQnjE0t+fmxLZClUVfXHJqUq9jYeBtBcP07SQz+sTlrVpbGzB6dNvw3GcWV13mQxcl9geaJoFhmEgSTwURUAoJEPXyWZOK1o+deptXLzYg3e96xpIklTy75GDjo1QSIYoKshktIoftPJ5E66LmsvlFKL2zZwieDMs/f3ZihMLyzJ+rjmZzE87sbAsA1UVEY8HEAhIME0b/f05pNPapPTSmprmwLIsXLzYU4GrnT3wbKVTqYIfKUejnsIxV9balmVi3749iEZjWLZsxYR/n9hGkHpjLKaOqlNGE4WCWdMkm0LUIpcpwACx5Cr+XF4aTNOID8d0guMYqKoEUeRKTnuVgpaWFriui56ezpLdDS93DFc4lv2fTSZldujQAeTzWVxzzS1lRY/e84fDCgyDq3g7vtd9Vxu2rDxqkUuFMZXEoqoiQiEZmYw2rcTCcaQrLRpVYdsO+vtzyOV0agONiqIiGo2hq6vm7zIZDCgcG35EKctCyb+fzWZw5MhBzJ+/yBcULQdesZ9hGMRigQn5xkwGmmYikyFisLUIpnKoRS4VxFQRC8MA4bACgLRfTtcXhuNYqKoIUeSQz5sVbTltbp6Dt946Btu2wXHlpXguV3gKxzxPPrcBe2NzzHuoo2M3XNfFxo0Tty4eDa5LJFwkiS8W+w0UCpWb/dJ1C65bQDis1CKYCqEWuVQIU0UsHMciFgvAshykUoVpIRaOYxEOy4hGiTpuX1+Oiv/6WGhsbIZt27W6CwVYFjF/SybzYFkG8XgAwaA0RA3aQ1dXJ86cOYlVq9YiFApTvxZdt5BI5P226krCMIjqN1CLYCqBGrlUAJ6qbiJRWWKRJB7RqIJcTkcuN3XSMR54npBKJKLAND1SmRqlAS8dU0uN0YNtu8hm9WI3IxCLBaCqov/vruuivX0XFCWANWvWV+w6HMf1iS4SUVDJoMIw7FqRv0KokQtlDG03rtzzBAISAgEJyWRhyociWZZBOCwjHFb8zq+pIhUPsiwjGo2jp6dGLrThui5yOR2JRA4cx/o1mRMnjiGR6MOGDZshCKXXaCaLdJo0gESj6ohRFC14Q7s10EWNXChiqoglFJLB82xxwn9qBQwVRUQspsI0nWkhlcFobm7BxYvdsKzqUhyYLXAcF5mMhnS6AIaxcfBgBxoamrB48dIpuwYiHWP5hmCVQim1phomhlpBnxK8mzKZrOyAJCncu1Muzc/zHEIhCbZdPbpkTU0tOHbsMLq7u9DaOrfs9QYcKC91pyQ/8z7WATfKkZwpPdOx2eNAaVkOXnvtdeTzedx++wcRDiujyvNUAoWCAcdxEI0qSKcrNxCcy+lgGAayzNcK/BRQIxcKGCxCWSmtMK8jzDtNThUG65Jls3pFZEQmi6amFrgucPFiaeTCskzRQIzzjcRYdsDGmDRhDNTMhrpSws/9syw7xI1yJBfKkR0oB/83c5gnmUzi2LFDWLx4OQQhCNt2EIupFe/oGgxdt+A4LsJhuaLqytmsBpaVIYo1gikXNXKhhGxWr9iJimFIYdPzKZ8qEMVdqdjBUz26ZB4kSUJdXT26ui4M+Tkx3+KGuVI6jgvLIpu7aVbekdIjGc/umGVZ3z6AZRnYtjvEo6UajM1Gwt69r4NhWGzYsBkAGXzUdRPBoFyUF9KnxA/ING0kkwVEIgo4jq3YLFc6rdXk+imgRi5lwnVdFApGxfxYvI4ZXbembDCS44iRGMMwSKWmRr12smhsbMHRo4fAcUAgIEMQOLguiiRiwzAsP1qYanL0roNgJAdKFoLAgud5KIoIlmWKRmADhDPdOH/+LM6fP4N169qgqqr/c9smqVlR5BEOT50ihG07SCbzCIcVsCxTscNWIpFHXV0AQE3ocrKokUsZcF0XhmEhl6vMl4rjGEQiKgqFqUs/qKoIRRGmNOUxUTAMA1EkLo0rVizG0aMHcfFiN3i+taiAW2Uh1ijwSA/wPFoGDMECAQk8z8KyPLtja1I6bOVdn432dmJdvGrV2hEf44lQkjknFel0oeLvP9ElIwQTDiv+rApt9PcTgqkNWU4ONXKZJFzXhW2T4bNKgONYf1J5KlwqOY5BOKzAtp2qKdgPxnBXSrLZqmoMrgucOnUa8XjTdF9mWfAOK4PrWh7ZqKqEUIiFrpvQdWtKoppjx95EOp3Ee95zA3h+9K3CdUkUoygCYjF1ShwnXXfAqyUaVZFM5ivwHC6SyQKi0doU/2RQI5dJYGBIkv4NDZCNNBJRpswW1qut5HJTQ2Slwuvc8YyePC/2wRsrx/Gor29AT0/XNF5p5eClx/J5AyxLJPQDAQkcx/geLpUgGk0r4ODBvWhqmoP58xeW9DuFggnDIFHMVDlOZrM6gkEJkYhSkQ5Kr84ZDJZuKVADQY1cJogBF8nKEIsgcAiHifjkVKRBgkEJgsAjmaSjWEwDoshDlnkIAg/DsMZtlmhunoNDh96AYRgQRXHUx810OI7rz2MQohEqRjQHDnTAMAy0tV01oRO7F/kOOE5qFS/2Z7M6QiEZ4bBckUyCppngOBaKUnOznAhqQ5STQKXMjUSR878glSYWokmmgmGYaRnGHOl6AgEJdXUBKIoAw7DQ358tyeisoaEZDEOsjy8XEKIxkEzmkUySNGYwKCEeDxQ3wcmv3dfXi+PHj2L58pWIx+smtUY2qyOb1RCJyEMkZCqFTEYDwzAIhSqjR5bL6bAspzZkOQFUJbncd999uPPOO6f7MobBM1+qRKqK54lMvWegVEmIItEkKxSMKZ2ZGQmyLCAaVRGJKH6qMZUqQNOsklMqzc3NAJjLilwGw7aJL0sikUc6XQDPc0VjNnHCsinEuvh1CIKIdes2lXVdhmEjkchDELiKS7gApAbDcQwCgcqksJLJvD8oW8P4qEpyqUZ4BfxKtD4SrS5i91rptt9AQEQwKPkb+HRBlgXE4wFIEo9cTvf9RSYTEfK8gIaGxsuWXAbDshxkMloxbUv8UUIhuWTplDNnTqO7+wLWrdsIWVbKvh7PcVLXTUSjasW9WlKpQrEBojLRUjJZeV+m2YIauZQAT9KjEnUWhoHfFVbJVJj3PDzPIZHIT9vsikcqosgjnS5Qi9Samuagv78Pmja9kVi1wHHcImlnYdsOIhHFt74eDZZloaPjdUQiMaxYsYrq9RCLYQ2RiFJRS2Ovi0ySeCgKfXFN2ybvay16GR9VTS47d+7EbbfdhvXr1+PjH/84Tpw44f9boVDA1772NVxzzTVYu3YtPvzhD+OVV17x//3RRx/F+vXrYZoD3U9bt27Fli1b/BvDcRy0tbXhkUceGfdaUqnKFPAjEQWGYVe0S6saPF8UZSippNN0hzObmloAAN3dF8Z55OUF1yUT9f39ueJUvTSqZ/2bbx5ELpfBpk1byrIuHg2GYfvtwxNxvpwoBlqjRcgyfSIrFEyYpl0jmHFQteTS2dmJb3zjG/jsZz+Lv//7v0d/fz++8IUv+B/o/fffj5/+9Kf4b//tv+GBBx5AS0sLPvOZz6C9vR0AsHnzZhQKBRw5cgQAcPr0afT39yOXy+Gtt94CABw9ehSZTAabNo2eWyYT+GZFTvqhkOyfhCoFnmen1fPFIxVB4CpCKh4aGhrBsuysbUmmAU0jRly5nI5AQBySpsrlcjh4cD9aW+ejtXVexa7BssiEvaIIFauNAAODlqoqVSRS8g5pNYIZHVXbipxKpfDjH/8YCxcuBEA2+c997nM4efIkAOCpp57C17/+dXzoQx8CAFx77bW4/fbb8U//9E/4l3/5FyxYsAANDQ1ob2/HunXr0N7ejpUrV0IQBLS3t2PZsmVob29HPB7HkiVLRrwGr85SiU05ECBOf5VUN57qtubB8OYxLMsuCnpWNg3H8zwaG5tr5mElwDBsGEYeksT7njw7d+6A6zrYtOmqij+/ZwZGJuwr0z4MDEjUEDVll3qjTDKZRywWoLrmbELVRi6tra0+sQDwCaC7uxsHDx6E67rYvn27/+8sy2L79u3o6Ojwf7Zp0yY/kmlvb0dbWxva2tqG/Gy0qGVAQp9+OkyWBYgiVzHZCgC+5tNUtDUPBpGsUaAoYjFS0aaszbmxsRmJRD80bWrtCGYqdN1Cf38OFy504tSpE1i7dh0ikciUPLdXG3FdIBqtnNukbZNUcDgsU28msG23aOddi15GQtWSSygUGvJ3z/lO13X09PRAVVUoytBulrq6OhQKBRgG0fravHkz9u7dW7RnHSAXj4A6OjrQ1tY26jVkMvQnjEWRh6qK/herEpAkHqGQNCVtzYOhqiTVYhgWksmpbxpoapoDhmHQ2Vmru5QK13Xxyiu/gSTJ2Lx5s18Xmyp4c0zRaKBircpeB50ndkkTuZxRFEWtEcylqFpyGQuNjY3I5/MoFIaeUPv6+qAoij+l3dbWhmQyiZ07d+LcuXNoa2vDpk2b0N3djVdeeQW9vb0jRi6exhPteRYyyyJVVNxPlgXf/niqNndB4BCLBYrumPlpE7xsaGgAx3G1luQJ4OTJt9DbexHr1rVB14lXUCAgFmXtp2YaPZczUCgYFW1V9ppmwmH6Q5bJJNmHagQzFDOSXNauXQuGYfDss8/6P3NdF88+++wQsli+fDnC4TC++93vYvHixYjH4wiHw1i2bBm++93vQlVVXHHFFUPW9tqOaeeBp2KWRVVFqKqIZDI/JakobyI6FJKRy2lIpyujXFAqOI5DY2Nz2eTCMAw4jhiLCQIHSSL6ZrIsQJJ4SBIPUeR8UcnBxmMzCaZpYt++PYjF6rBs2Yriz8jgo2EQa+FKdnUNhqYNtCrz/Ojt0uWAzFGBuk6Y67pT6rM0U1C1Bf2xsGTJEtxyyy348z//c2SzWcyfPx8/+clPcPLkSfzpn/6p/ziWZbFx40a89NJL+NjHPub/vK2tDT/60Y9wzTXXjKj2WolaSKVnWYhbJOdLgVQaJEISoWkkb18taG5uwd69e5DP54f4jwyGZ97lkQLPc4NsjeFPYXtOlN7/geGOk0MdKYmr5WAHyqHuk05VqU0fOrQfhUIOW7e+b5hmFhGhtBAKKRBFDplM5Wc7DMNGOk0kYyrlI5TJFBCNBiBJNtXMhKaZkGUePM/V9MeKmJHkAgBf+9rX8Hd/93f4f//v/yGdTmP58uX47ne/O6yGsmnTJrz00kvYvHmz/zOPXDZu3Djksa7rVsSkKRiUYFlOxWZZgkEJPM/58hSVBMMAoRDJXVeT2KWHxsYWv+6yZMlSP7Lgec53pfS6AC2L/Kfrlp83p/H+eZEPy7J+BCRJAw6U3j3mmYJNRzYlk0njyJGDWLBgCZqbW0Z8jG2Trq5AgMzGlKLzVi5M00YmoyMcVpBK5anbQZOsBOkg8+4BWkilCqirC9bk+Ytg3FqiEMBAvrS3N0t1XVEkcvaVsgkOBiVwHIt0unINAh54nrQ2e9L31QiOY/CjHz2E5cuX46abbvTNtshGYk+LI+VgMAx5HwdSahwcx/EJxzTtKYludux4AefPn8Xtt9+FYDA07uMFgUMoNHWfvdfKXqlIvFLfS1kWEAxKNXLBDI5cKoFK1Fm8rq1KbGiqKvoRS6WhKCJUVZiWmZmxwLKMXxcRBB627WDOnDk4c+YM+vqy00okI8F1MSw6HlzbCQYluC58U7BKpIa6ui7gzJlTWLt2Q0nEAgzUYkIhYs6VyRSoRxWDoetW0eJbLUbkdJ+LNOwQwqT5vdc0E4oigOPYy55gZmRBnzZc14Vl2UMcAGkgFJIrNt3vFZkrOSsDkJN2OKxAkrhiobc6iEWSeEQiCmIx0jrrzWwkk3nE401Ip9PIZOhGoZWCZTkoFEyk0xr6+nL+ZxoOk9enqmLJwpPjwXEc7NmzC6oaxJo16yb0u67rIp3WoGnmlBT7CwWzKHhZmTmYXE4Hy7LUX0clB6NnEmqRC4BXX30VgIBly1ZSO20oCmmHzucNKusNhiBwCAZJu3ElUyie1bKuW0inpz8NxvNssWNLgGXZRfuD4V/k5uY5YBigq+s8li5dMQ1XWh5ILchALmcU6zWCb0lATMHMSUcNJ04cRTLZj2uueR94fnKbqqYRba1wWIYgcBW1bcjnDTDMQARDG+l0AbGYCsuyqR0CHcctFvgvb3Oxyz5yMU0T77xzFq+/vhPPPPMk+vp6y16T51k/hUQbHMf6k/eVLKZLEj+tmmQeWJaBooiIxVSEQgps20UikSvKuI8cadbV1UEQxFmhM2ZZjm9JkMnoYBjG978ZS+F4JOi6jgMHOlBf34RFi0aWPCoVnuMk2fgrN2EPDBh1RSLlWwBcCsdxi06WdF9DNqtf9t4vlzW5uK4LluVwww0346qrrkU6ncbTTz+BPXt2+VP+E4WXRspkdOpRBclBK+Pa/pYLVRX9QcxKGKOVAo4j5mmxWAAcxxQ9SnIoFMb3fGEYBs3Nc2bdpL5l2cjldPT15aBpAwrHklRaAuKNN/bBMHRs3nw1tRN1Ok06BittBpbNanBdtyJDkMQe2kIwSHftSqesqx2XNbkApIjPMAyWLVuBD37wI1iyZDmOHTuMJ598FKdPn5zwySMYlGEYFvX6jefHQvLQldvwg0GiIptITM0g5qXwIrNoVIFlOejvzyKb1SecsmhsbEE+n0U6narQlU4vdJ0oHGezuu+RoyjiqKfvZDKBY8cOY/Hi5aivb6B6LdmsDk0jQ5e0akMjwfuu0h6CBMhr4HmWqvSN125+uUYvly25eDMtljUQAciyjKuvvhY33ngrZFnGyy//Ci+88AxSqdI2KEkiQ1SVmNb11GsLBfo1HA+eY2EqRb87ZzzwPCGVSIS8zr6+XFEUcHLrebMbs10l2TSJ6nQqVQDPs4jHgwgEhrfCdnS8Do7jsH796Fp65aBQMJDL6YhGJ56umwjSaeI0WQmflmxWL7YR01szlbp8zesuW3IBRm89bmpqxs0334FNm65Gb283fvGLn2L//nZY1ugRA8uSE1UmQz8UDoVkuC4qKjERDitgGKaigpojgZCK4pNnf3+OijZZLBaHJMmXjXmYbTt+6hAA4nHVt/o9d+4MLlw4i7VrN4yqWkADpPFDQzgsl5yqmyg8aaZAQKKuQ+a1iKsqvcjIa8K4HKOXy5JcXJd0c4z1gbMsi1Wr1uD22z+CuXMX4ODBffj5z3+K8+fPjvj4cFhGPm9Qbzv22lArlb/10m2kzXTqcsSeLlk4rMAwLGqkMnj9pqY56O7uuqy+2J69cSKRL3b7ydi793WEQmFcccWaij+/adpIJgsIBKSK+dgTItX9AxFNkDQjT5W4vMaey+k+BC5bcik9CggEAnjve6/Htm3bwTDAr3/9DHbseAHZ7MAMhSwLcF1QVwPmeQ6KUrlZFq/F0zv1ThVIjUCF4zjo789VTBanubkZhUKu5LTmbILjEIXj119vRzqdwnvfex0kaWpEKG2buE2KIl8xt0nDsCqicuyJUNIu7ldiJKHacdmRi+u6yOcnnl5qbZ2HW2/9MK68chPOnTuDJ5/8CQ4degOu6yIQEKmnrEjXGXGRrMQsC8syiEYVmKY1ZYquHMf6w3fJZAG5XGW/cE1NcwDgskmNXYpCIY/9+zvQ3NyKpqY5iEQU6jWF0eDZDIsiV7EIJp8nNTnaBOalsWgOV5JrvbxskS8rcvGECScbYfA8j3XrNuK22z6MxsYW7Nv3Op5++mc4deos9c6qga4z+i3HhFhUaJpV8Q3eA/FsV6Bp5pRZAkQiUciyetn6u+zf3wHLsrBp0xYYhu2rVxNVg8oV3T24LvE6kSQBilKZqCmT0XwLBJrIZnUEAiLV9upMZvoHkacSlxW5AKAyEBgOR3D99e/HddfdCMPQ8cQTP8Wrr/6Gmr0u6TpjKxJRkBqLinzeqGjnmQdR5BCPB8CyLPr78xVLgY0EhmHQ0tKCrq7Oy+rECAB9fb14661jWLZsJWKxOICBdHA6rSEYlCvS0nspXJdEMIoiVqTI77ok/RcKyVSJwLaJJA/N98gwrCH2DbMdlw25eCEprc2NYRisXbsKd975UVxxxZU4efIEnnjiURw/frSsm8frOqMtoukhElFhGOaUbPKBgIRgkKT2iGX01H+pGhpaoOsFJJOJKX/u6YLruujoeA2iKGHduuFOq5ZlI5HIgWEYxGKVnU0BvBRZoeg5RJ9gSIu+iVCIfp2E4ziqUVE2q102kjCXDbkAoJoCIkV8F47Doq1tC26++Q6EwxG8/vorZcnIhMPEVKwSaaNwWIZtOxVPhXlpN45jkEjkKu4BMhZaWkjdpatr4nUXhiGvxVMt9twnPZMxz5+l2jaLd945he7uTqxbtwGyPPKG67okpZTPG4hGlYqlrTzYtoN0uoBQSKrIHIxXMKdd38lmNarFfcOwfe+g2Y7Lws/FcxOk5ZjIMEA8HhhmluW6Lt566zj27t0N0zSwYsUqrFu3CaJY2g3vSehXojvMmwuotGKrKPIIhSTkcsaUpsBGg+u6eOyx/0BdXQOuu+6GIf92qSOl999ojpQevH8f/GeGYYomZO4wF0rLmrrNxLIsPPHETyCKIm655UNg2fHPj54Ft9dhVslr5XmuYk6TXiSWTtNdOxSS4Tj0DmWiyCESqdy8UbXgslFFplm/UFXJdy8cDE9GZt68Bdi3bw+OHTuMd945hba2q7BgwaIxT7hk6lhAIkFf+VVRBN8CuZIIBERIklAxi9rJgOiMteDcuTPF6IOHIHDFVJALyxoggHIdKYc6ULK+AyXPc0NcTj3zskrgyJGDyOezuPrqD5RELABJWyWTeaiqWJHNeTAsy7MyVqg7mboumfEJhWSq36NsVkc8ThpgaFyvF71UY9RLE7OeXLyTJy2tL5ZliiQwehTkycgsXrwMu3fvxMsv/wonTszFu971bkQikWGPJ9bBsi/ORxOiyENRxIpaIHtinQCQSEy9dMxo8FJZixcvxKlTbyGXS4PnY77KLu3rJL5ALoDhGxDHsb77pKqKYBjP7tiCrltU2s1zuRwOH96PefMWYs6cuRP+fTIEbCMSIcKrtPXxPJimjWxWRySiUL9fdN2CLAtQFJFawwohLQPBoEQt8s9mNf87M1txWdRcaA4wBQJSScq8AJGRueWWD40rIxMMEvtY2m3HPM8iFJKQTlfO94VlGcRiAViWU5SOmV5i8ex46+qIxpbrAtFoAxzHxYkTJ1EoGEXf+qm9Ttt2oGkmMhkN/f05JBJkeJTjOMRiAUSjKhRFKKvjad++3bBtBxs3vmvSaxgG0SoLBqWK1mF0vTJDkACpJalqee/lpSCfFUttct8w7FnfOTarycVLb9DK/XuF3YmQ1XgyMqJIfNRpe6Z4efRMRqtYisMbisznjWn3fFFVEfF4AIGABMuyfVfKfN6AogQQCoXR01M9w5ReNJ3NaujryyKf18HzhGgiEaVoNFX6et3dXTh16i2sWrUW4fDw6HgisCwyYS/LQsUm7IHKDUE6jltsI6bfPUZTd2w6vzNTgVlNLgA9YgGIHP1kpvuB0WVkHMdELke/7djrOquULTHPs76Z2HQV7gesjlVfdDOZzKNQGK4b19TUgu7uLjhOddSCLoVh2MhkCNEUCiYEgfMVjsc7gZPW49chyyrWrFlP5Xq8OoynVl0pZDIFiCJPfQaGtBEzVFufNc0Ez9OLXogSwOzVHJv15ELrdCCKHBiGgaaVl4ceLCNz/vxZ/PCH/4a9e/dR3fQCAQmO41Rs0xcErpiX16bFTMzzL5EkAYWCib6+HHI5fcxia1NTC0zTpOI0WmkYhjVI4dgtunDKo25qb799HH19F7F+fVvJnYmlwHXhq2RHo2pFis9E5Zik4WjP21RCQp9EL/TeY02bvZpjs5ZcXJdeER8AFEWkVrvheR4bNmzC7/7u3WhoaMa+fa/jqaceR1dX+ba8gsBBkviKSU2IIufbLFcqKhoNikJIRRRJu3Y6XSj5M25ungPXdWeUFAxRODbQ35+DZdkIhxVEIsqQoT7TNLFvXzvi8XosXbq8IteRyWgwTQvRKH0VYoDUo7JZnXqEZJo2DMOimsoi0QtHjQinSn5pOjBryQWgp+XjzUHQPKUTx0cV27a9H9deez10Xcfzz/+8LBkZT8a+UrMKksQjFCIzClM5GKkoAurqAhAEDqlUAen0xOtIgUAAkUhkRpGLB08Pz1OQDgQkRKMKeJ7FoUP7oWl5bNp0VUXbWnM5A7puIRKh6zXvQdctWJZDfco+l6MvoV8oGAgE6EUvhjE73SpnJbmQllB6raY02xoBFKe8SWMAwzBYuHAxPvjBj5QtIxMKSUU/cPobvyQR+fRkcupmWDxdMkHgkEwSUilnzoD4u3TCtqdPMaBcePbGxI/IwNGjh7Bo0VI0NzdX/LnzedJpF4lUpoU2k9H82SBa8PTUaBb3CwW60Us2OzvdKmcluTAMM+nC+6VgWVIUpN0YcOlQpyAIl8jIvIxnn/15yTUCWRbAsmxFOlAEgfN7/KdCzZh0uskIBEgUVi6peGhsbIFt2+jtvUjhKqcXmmbhV796CQCDbduug6JURtb+UpDallsxgiGimhI4jl545Eno02ytLhTo1V4cx52VkjCzjlwGhibpnE4VRSyeEqksB0ni4boYtVYQj9dh+/bbcNVV70EqlcLTTz+BPXt2wTBGj5w4jkUgIFbEYpnjWL/GMhXEoigCYjEVluVQ1yVraWmZcXWX0XDhwjmcPXsKq1ZdCcsiLfKxmErd+nckeGlX2iksgNRf8nmDehtxNqtTLcQXCiZEkWbtRZ910/qzjlwAQNdpKR+TiIBmSiwQkMYNgz0ZmQ9+8C4sXrwcR48ewpNPPorTp0+OeLoJh2XkcgZsm+7Jh2UZRCIKslm94jUWb2ZGFHkkk4WKOPcpiopoNDbjycVxHHR0vA5VDWL16rVwHGJRncsZiESUKYli0mnNV/CmjULBBMMwVNNjtu3AMGyq700+b1IjLG+ocjZhVpILrdSQLIu+BwMNqKoI07RLrlnIsoJ3v/ta3HTTbZAkCS+//Cu88MIzQ2x7AwHJn/6mCeL7oqBQMCrebizLAqJR8lyVTr01N8/BxYvdM7rucuLEm0gm+7Fx4xbw/ECqxzBIPYYIIypUJ9RHQipVAM9zFRm0zGY1BAKVaCOmlxrTNKMYvdC5SC99N1swq8iFqNI61FJYiiJQO0EzDANFESZFfKPJyLiuA1muTNtxOKz4PhmVgmflTGyP81MyM9PU1AzbttHT013x56oENE3D/v170djYgoULFw37d887xTRtxGJqRfxTBoNYGdMfgrQsB4ZhUSUu23Zgmja12ovXxUer1ZlWnbhaMKvIBaAXtUgS70um04CiCGUJFI4mI3P06FvUTzuhkOx32VQKJA0W8CfBaaf0RkNTE/F36e4uf6ZoOvDGG3thmvq4rcf5vOFrhFXScXLwECTtek8up0MUiao0vTUNqqmxQsGAKPJUIizHGW7vMJMxq8iFFMrppDtUld7QJEDIhUYU4MnIbN9+C1iWwTPP/AI7dryAbDZL4SrJdXIcWxFPGQ+SxCMaVZDP6xUlsJEgyzJisTp0d1ePzlipSCYTOH78TSxevBz19fXjPt5rivBqZ5WqF9u2g0xGRzhMd8jSdVGU0KcbvVgW3ejFMCxIEp31psJ6fKowa8iF5kS+55RHq4gtywJMk14UxDDAihXLcOutd+LKKzfh3Lkz+PnPH8XhwwfLkpHhOBaqKlaUWBRFRCBA2pqnQzoGIKmx3t6eYerUo8FzpPScJ4kPR4UvcgS0t79eVHdoK/l3SGRBOv2iUbVidRjDsKDr9FWOvWifbiGebvSiaSZkmRa5lH4Afeyxx7BixQrkcnRMEGlj1vi5MAxDjfXpRy0i1UEprzEAYLFu3UYsWrQEu3fvwt69r+HkyePYvPmaSQ3VhcMyslm9Yl0rgYBY7AbLT2tnTFNTC44dO4zu7i60ts4FwzC+CoP3f5ZlwbLwT+JeusL7+2A3yqEOlAPmYzSHTc+ePYPOzrPYsGELFGXiLobZrA5FERCNqhVrmvC61Wh/fzIZDbGYCl03qdw33mcjywKVRhjTtP3DB4331TRtCAI341uTZw25OI5L5cvMcWSjoXWqFsUBF0IaIGZl4hCzsnA4guuvfz/eeecU2ttfw/PP/xxLlqzAxo2bIculDbsFg5LvxlgJkJw8mbSf7pxyS8uc4om+F2vXrgDDMH66xLad4mnZgeOUpljrRTOeTbIg8FAUQlCWZQ9xoJwMbNtGR8cuhMMRXHHF6kmtAZBTseO4iEYVpNNaRdrLPSIo5/VeCsdxkc8TCX1aUXU+T9J4tLosveiFRs03nzcQjc58G+RZkRajmRKTJKFs5ePBoC0dM5pZ2WAZmZUr105IRkYUif1vpWQoQiEZHMcilZo+l0oyaCohFlPR3BxDY2Mjzp49i2Qyj76+LJLJPLJZHYWCWbQhLr2w6h1sdN1CPm8UFY3z6O/PolAwwDAk2qyrCyIclifcWfXmm4eRyaSxceMWcFx5xW1dt5BOawiH5Yp0kjmOi0xGQygkUz15FwoGVbn7wdELDei6CVku7/3s6NiDrVvb0NnZ5d97H/vYx3DFFVcgnU77j7vtttvwzW9+0//7uXPn8KlPfQrr16/H9u3b8dxzzw1b+4c//CFuuukmrFmzBjfeeCMeeuihIf/+7W9/G1u2bMGBAwdw55134sorr8THP/5xnD17Fn19ffjv//2/Y8OGDfjABz6AXbt2lfR6ZgW5MAxDtUuM1umdtuBlKWZlgiBg8+ar8IEPfLAkGRmWJWKX6bRWERtkr8jrSbdPJbwh2GhURSSiwHXdomdKDvX1Tejp6YGuV66A6jWY5HKkc6u/P+vb8NbVBREKyUMUjkdCoZDHwYN70dIyD/PmLaByXaZJ3CZDIcmvL9KEYdjQdYt6lxpts658nt7Uvm2TMYjxPs+xsGbNWvA8jwMH9hXn4WwcPnwYgiBg7969AIBkMokTJ05g06ZN/u998YtfxLZt2/DAAw9g4cKFuPfee4corD/yyCP4i7/4C2zbtg3f/e53sX37dvz1X/81/vmf/3nI82uahj/+4z/GPffcg3/4h39AZ2cn/uiP/gj33nsvNm3ahG9/+9toamrCF77wBRQK40eQs4JcSAqj/J2L41gwDAPLoicdQztqKTWXXVdXX5KMTCgko1Awqb3mwQiHZbiuW9EGgZHAcSxCIRnxeBCCQFw++/tzRY94kjptbGwB4E5pS7LrksjBIxrTtKGqEmKxwKgn6H37OmDbNtratlC9Fsty/AimEpIxuZwOQeCokhdtsy7LIvUxWjM6mmaVFQlJkowVK67AgQP7UCgQW+U5c+bg+uuvR3t7OwCgo6MDDMNg48aN/u998pOfxN13342tW7fi61//OhzHwYsvvgiA7I3f/va3ceedd+K+++7D1q1b8Yd/+If4rd/6LXzve9+Drg8cyjVNw/3334/bb78dN9xwA/7Lf/kv2Lt3LzZv3oxPf/rT2Lp1K+6//34kk0ns3r173Ncz48nFdV3oOp2NkWbUQlvwUhA4sCw7ofVGk5E5dYrIyBArXaYiUitkuppBJjN1iq+ea2IkohStjrNFL5Lh90dzcwtcF9PWkuzZbyeTeWQyGkSRQ11dAKoq+umk3t5enDx5DCtWrEI0GqN+DaZJ3C8jEYW6URdApuyr3WqYZqeXrpsQBL6sdOC6detx4MB+GIYF27bxu7/7u9i8ebNPLu3t7Vi5ciWCwaD/O1u3bvX/HIvFEI/H/cilq6sLPT092L59+5Dnufnmm5HNZnHs2DH/Z0Q8d6ATccECEilfddVV/s/mz58PAOjp6Rn3tcx4cqGpgCxJAjVdMiJ4aVBVC5hsFHSpjMwrr/wKv/rVMzDNfEU2f0URfEOvqQAhFQXhsALDsNHfnytaHY/+O4IgoL6+AT090z9MaVk20mkNyWQeLMsgHlehKALa23dBEERceeXG8ReZJAzDRjarV0QuxjBs2LZN2bmRvtUwz3NUXrs381JO7WXduo04deptZDIZnD79Dt773veira0Nhw4dgq7raG9vH5ISA4BQKDTk76Io+hmKixeJAnhdXd2Qx3h/HyolFQDLDryvgkBINxwOD1kbwJCIZzTMeHLxplrLBUmJgUrH2YDgJR2i4jgGgsCVHQV5MjIbN16Fvr4e/Pu//xAdHXtKnvcoBaLIQ1HEKamxMAzpQotEFBiG5ZtplYrm5jno7e0dU3F6KmHbLrJZHYlEHqdPn0Rvbzfa2rZAkio3YQ/Ab0SohJWx1wJNU0Kfptw9QCIOWkOQ5UZCa9eug+u62LevAz/60Q8xd+5cLFu2DIFAALt27cKRI0eGRBfjoaGhAQDQ19c35Ofe3yORyKSvdTzMaHIhpmC0Bh15alGLJAlUBS9J7YbOtbEsi3Xr1uPuu38Xra3zcfDgXvziFz/F+fNny16b5zmEQhLS6ULF51hEkUcsFgCACZOKh8bGFjCMi64u+qkxr5ljMjAMA6+88gpisTg2blw3JSKUmmZC0+gPQZI2YroS+rTNukithE7dxTRtMAwz6WsLh8NYvHgJHnnkYTz11C8BwK+xPPjgg7Asa1jkMhaam5vR2NiIZ555ZsjPn376aQSDQaxYsWJS11kKZjS5AKBW0yApMVrtzPRqN0R6nF4UBJDTPsMIeO97r8e2bSQX++tfP4MdO16Y9LQvkRiRJ2VBPNHnCYcVBAIi0mkN2aw+6QipqakJAFOR1FgoKIFnbEQjMmRxYu6Khw8fRD6fxcaNW5BKaTAMC7GYSl0c8lLk8ySNS1vluBIS+jSthskBlaGWais3elm3bgP279+LFSuuQD5fgOM4aGtrw549e7Bw4UI/GikFLMvi85//PB5//HH8zd/8DV555RV885vfxI9//GN85jOfqWhUPOOHKGls4jzPwnXppMRYlgHPczAMOvUGInhpUpsP8b7g3vvW2joPTU0fxqFDB3D48AFcuHAOV165CVdcsXpI/nU8eF1nlfR9EUUOwaAMTTORTpefyuJ5AQ0NTejqouvvwnEscpk8vnnv3yEUDWHRFYuwbusGzF82H5pmwrJHH/jNZrM4fPgA5s1biJaWVgBkczYM259NyWYr0zYOAJlMAbFYAJZlUx2ozWY1P31J49qJGrFIbSqezKkIVLTuNM1ELKZOajzCdV0sWrQEjuNAUSR8//v/jM985jN+Kmxwl1ip+OhHPwrDMPCDH/wA//7v/46mpibcd999uOeeeya81kTAuNM9Lj1JeI6T/f3l6+oEAhJc16XSNSXLAgSBo1Yor6sLUFUNjscDxehiOAmkUins2bMLnZ1nEY3GS5aRUVURgsAhlapcAV9VRciyMGr312Sxf38HDh7ch4985Hcgy3RSN7LM4/Tht/DT7/5kyM9D0RA2XLsRm69/Fzieh+0A+iWb7csv/xpnzpzG7bffhVAojEsRDEoQRR7pdKFiESLPs4hEFOpq1aGQDMtyqLXnK4oInmepfNdYlkEsFkBfHx0B2FgsgEymtM9I0wo4f/4cOjvP4cKF89B1Uq+Mx+vR2joX1157NRSlMrbSlcSMjlzoTeXz1DZGWeaptfYSwUub2hdcVUVYlj1qnSoSmbiMDM+zUBQBiUSeyjVeCuL5Qp47kaA/4d/U1IKDB/ehu/sCFixYTGdRx8GpI28P+3EmmcFvfr4DL//iN1i4chG23LgFS9YshaZZ0A0LnZ1dOH36baxevW5EYgFIgVwUbUQiCjIZndp3YDAsy0EuZyAUIgRDC6RpQKFGLppmIh4PUFmLqCzY1FLahmFBFHlY1vDX6jgOenp60NV1DhcunPMHnEVRxJw5c9HS0oo5c+ZBVYkEjCTRt5OeCsxYcqE1n0FSYi6V0JroS3HUZP8VRaQWATEMWS+ZHDvS82RkWlvnYf/+Dhw7dhhnz76DDRs2Y9myFUO6ibyNP5OpjNilJxVPptwrI83f0NAIlmXR09PlkwvPe+rHpIPQcRzAdchrdwEXZDMyrZFfMy9wOPvW6A0Sruvi1JsncerNkwhFQ7jhozfhio1X4O1cEqoaxNq1G8a8ZsOwkEw6RadQpiKGbppGPOIDARG5HB0yGLAaplNDJJp9FjVC8GoltMhl8NBzLpfD+fNn0dl5Hp2d52Ca5PXX1zdg7dqNmDOnFfX1DSOmom3bBsPMPCHLGZ0W6+0tP4SlmRIjLZccFY0uUeSgqhK1k6OiCOD5iafr+vp6sXv3q+jt7UZDQxM2b3436uqIlwgxFXMr4snCsgyiURWaZlZkyNMDwwCHDx9AXTyGhQsXEVHQvhTSyQySfUn09ySQTmaQSmRQyBXA8Swa5zTg/Xdej7w2/BDBMAzCIRFf/29/OaEoq2FOA97/ie1omt8C22FLSv1VmnwZhszcJJP0VJSJSZyCvj46MvGk9V2glnmoqwsikciVfViybRu6nsabbx7HhQvnkEj0F0cUVLS2zkVz81zMmdNaUipWUQR/KHkmYUaSixdp0EjFxGIqMhk6HU7RKCni0agJhEIyTNOm1g1Hai2Ty9O7rosTJ45h3749ME0DK1asxubNmxGLhYeoM9MCx5Gcfz5vUHv9l0KSeDBwISsizrx9Dm/uP4bTx8/g3OkLsMyxT64Ll8/HJ//gE9D04e+lKPJIdHXjoa//f5O6rpUbr8Bt99wOFww0wx63+O1Fj55gJG3IsuDbUNNCOCxTtdCuqwsgkaBj4xAMSn779ESRTqdw4YIXnVyA45C25IaGZsyZ04qWlrmIx+smTBIMQ0hvppHLjE2L0Ug9ERMollqXGMcx1IrNpCuIrmXzZF8nwzBYvnwl5s9fgL1723H06EGcO3cabW1XYe7cBVRveo9Ycjmduvw/yzIQBRaSJOD0W2fwyrO78NaRkzAmON8ky9Komz7LACcPDa+3lIqje9/EycNv4/0f347VW9YiX7DGjBpcF0ilCohEFASDEvUo0ksV0fI+AQZ8X2iRi6fpRSPC1XWrZA0/yzLR1dWJzs5zOH/+LDIZolysqkEsXrwMCxcuwIIF86Hr5ZGe62KIl9BMwYwkF4ZhqAw8CgJHbQiT9pyMZdnUiteKIlKRyPFkZNasWY2dO3+Dl156Hs3Nc/Gud72byqSvl+ahTSyCwIFjyf937+jAK8/tQv/F5ITXkWQRtu1AVkdPZTBwcebEmTKuFjB0Az9/6EmcOfEObrn7NhR0a9zDVDpdQCSiIhCQqKfIMhkN0agCXbeo3JODrYZpEIymmX6kWy5M0/YFbC99ra7rIpVK+p1d3d2dcBwHLMuiuXkOli9fjTlz5iISiYBhiMdPIKBC18uP7m3bKRrUzRyCmZHkQibzy482eJ6jFmlIEk9V9p+m4CXD0In0AEIAixbNRzj8QRw+fAhvvNGBX/zip1i9eh3WrFkHnp/cLcUwKJ5mDWrEwnEsRIGFoet49vEXsf+1gzCN0d9XlmXRMq8JC5fNR8v8ZsTqo4jEwwiFA5BVxT89chwLwzARCHJwHHeI+6Ssirhw6jyV6z+w8wB6zvXgt//wbsgSB20MgVYSweQRjapwXbpOkLbtQNOIhD6t1Fs+byAcphO92DZRRRcEOt9n07Qgihx03YJhGOjsPIfOzvM4f/4c8nlS5w2Ho1i+/Aq0tMxFc3MzeH740KSXpuM4puyOT9O0wfP07REqiRlXc6E53+Kddsq9IUmPvEqlSMkwQDweRH9/lsqwGRFztKiRVSgkw7adIV0w7e2v4cyZkwiFwti8+d1obZ034XUjEQW27VBL6wgCC1ni8cyjL+DVX+2GM0pqKVYfxar1K7Cm7QosWDrPT0ExLOdvWh55uK475DMZ7EDp2yMzgJbX8Pbht3H49YN46+BbZZ/21ZCKj3/htxFvqkdBG3sI0WuEqERasZy63UiIRlXk8zqVg89kG1Yuheu6yOVSuHDhPE6dOoWenm4ALnieR0tLa7FNeO6oreKXglbtlONYam3XU4UZSS66blE5QdXXB9HXV/4mTnNwUpJ4SJJARVGYdmeOpz48ErGfP38Wu3e/imw2jfnzF6Gt7WoEAqV9GYhrIZBO0ytICwIHnnXxV/f+A4xLDMEYhsGKK5fifbe+B/MXt5IUJFjIsoD+/lzZZOB9hq5jwbEdtP96D/b+pgPJ3uSk12Q5Fh/47Zux5qorkcuPnZ7yPvdUiu6gpSwLlGfCPPXs8j930tkWmNShjAwxnkdX1zmcP38Oul4AwzCIROJ+Ib6pqXlSLqCyzEMQeGr71UxKi81IckmnC2WfdnieRTAoU+mCodnZFQ4r0HWTyqmznM6XkRCJkLz7aK/TsixfRoZl2ZJkZCSJh6qKFRnClCUO+17djyd/9DT5uyrjXe/ZiOtu2QpRFOCAGTLDEQ7L0HWL6olfkniIAolqOt/pxG+e3IG3Dp6Y9Ho3fPQmbHpvG3LjWAqIIo9gUEIikaMqFUMzeqEfpZf2+TmOg4sXe/yZk95eIksvCEJxiHEuVq1aBtfly36dXiRJI9MSjwcq4rtTKcw4cgGA3t5M2TcjmUlhqaRh4vEAUqnyZwFof9lotmiOFbVcilQqhd27X0VX1zlEo3G8613XoKlpuIyMl06kOUcxGAzDIBQU8f++9iCWrlqMm+7cRgbvLHdEgqR5T4yEQEAExwIXL1zEL//tF7hwenJqzB/4nZux5qp1yBfG3kQDAQkcx1CNCEm0wVPz6qF5MBsrg5DL5XDhgiexMjDEWFfX4E/FewO1AHnvHMeloiZA9ofypXQ8bbmZEr3MOHKhNTxJ65RKU5OIpFN4KpuBIHAIBOgNYRJdqNJnE1zXxenTp9DR8RoKhRyWLFmJjRvbhsjIRKMqdN2syIS5B1UVoCgidN2EaTpjft4cRwi0ErM7gxEKSYDj4M2ON/HcfzyDQq70jVqURPz2H96NuuYGFEpwYPUGUWnOC9GMXmjep4O/i7Zto7u7y9frSiT6wDCAJCn+EGNra+uoskY0hzNpEagsC0VF8xq5UAfN4Ulap3pR5CHLdGokkYgCTaOXErNtOicv70s7mYjKMAwcOLAXx44dhiCIvoxMICBVXOzSE3mcSHGbZrQ3GjzFXEnkANfFT7/3KE4cOD7u7ykBBZ/8359CIBaGNoI6wEjw6i80XxPNWglAL/LPZNJIpXrw1lun0Nl5vmiCx6CxsalYO5mHurrShhi9LAKNQ6MsC+D58iNihmFQXx8c/4FVghlHLoZhlX1TcxyDSIROHpRm+FxXV50pMc/fo5xW676+XuzZ8youXuxGY2MzbrzxenBcgNosD8OQL5/juMUIhCjwTlSevhJ1l8EgFtADRXFJ4iFLHF59eid2PPHSqO9HKBrCp77y+xBkacyW5EshSbzfzUYzPUaLEAAiqMowzITvL8sy0dnZ6QtAptMpAAyCwRCam+f4xXjPmneioKXeQTM6m0lF/RlHLrmcXnYahWZ3VzSqIpvVyx7G5HkWoZBMJSqjeTN7JzgaekuejMwbb7RD13UsX74a69ZtnPSX3wPLMgioAliWhV4UDMxmJ9eKS06ZdPThLsVoWl0cxyKg8Dj71hn85DuPQNeGbrLxpjg+9eVPw2U56CUSC8+zUCQOlmECHAdFlZHNatTmnVRVBMsyVOpTHEeK3uN1NY41xNjU1IKWlrlYsGABWlubqETEtA6OXicbjShoJhX1ZxS5AEBfX7bsTY5mEbG+PkilBkSzmBwMyrBtOtpNtOYHPBCzMhsvvvgbvP32UShKAJs2XYWFCxdN6kTGcSxUlccv/vM5zF88F+s2r0a+YE76tOnJz9CIai9FMEhkY0Y7oYeDIgq5Av7tbx9Cf3c/AKB5fjN+948+Bct2oZdIDLLEQeAYPPeDJ3H60Nv4/W98AbbLQlVFaq+L5mwXMLounzfEeOHCeVy4MHiIMYI5c0jtpKWlZcgQI60RA5p1F1qZhGhUBc+zMyJ6mVHkQquYH4uRgmS5IT2JEEQkk+XffDTTMbSUXQG6wp7AULOyrq4u7NmzE8lk/6RkZBiGQTAg4NF/+wXqGmLYdvPWsojFQyXqLl7tg8zRjP64UEiGY5p48C/+GcFIEJ+493eg6w6MEgZ9BYGDInE4+cZx/OqHT0ErNgosb1uFG+/5oD8YSrM1nbhkln/PktQY8avp6+tDZ+dZXLhw3h9i5DiuOMBIUl3h8Oj3iaf0UG6URpNAaQ1sB4MSZFmokQttOI5D5YOmFW14Xwgafhf0Ggw4qCodwqN9ilcUEYIwNPfvOA7efPMwDhxoh+u6E5KRURUeO3+1G4VcAdvvfB9y+bFFHktFKCTDMOjWXcabERqMQEAEHBscz5dElgwDyCIHxnXw9IOP4fTh4cKZv/XlTyPa3Ag1II5LcKWC1sCvpmno7r6Aixc7cerUaWhaHq4LxGJ1kxpinGwNZySQOmj5g7WkwcYpO5sgijzCYXlGkMuM0RYjnWLlfyOI5zYdPhUEjlo3luuCyklZEHhqeXVaJkweVFUYRnosy2L16rVYsGAROjpex8GDe3H69FvjysgoMoe3j57C6bfO4J7/8bFx1YMnAtO0IYr0Xrso8mBZpuQ0bC5nIKCKxArZHnuDFEUOisTjyK4D2PHIczD1ke/HnY//Ch/8Hx+HYdiQZZHKfavrFoJBGSzLTOjeHTzESJwYyRCjoshobm4pep3MLVnh4VKYpu03oZQL23bA86X564wFyyLrlAvTtGcEsQAziFwAUNk8CLnQ2YRoCV/SEtzz1qInoCkgk6En9WGazqjvfTAYxHvfez3On1+O3btfxa9//Qzmz1+Mtrarhm0yksQhnUjj+Sd34H985fegGw619w8gwoWqWl6TwWBMRvAxlzcAhkE4rIyY82dZBrLIwtINPPrAw7jw9ujOlwBw9uhp5FIZiMEQAgE65AIAum5CkoRx18vn80UnxqFDjMSJcQNaWlqxePF8WNbYs0ilYEDZGGVHaJZF1ir3/rJtp1hvLA9E325myO/PKHKhkfcnCqV0/FsuFTKcLGiSC41TlrcOw9B5zwHSGFBKs0Jr6zzcdtuHfRmZCxfODpGREQQOLOPi37/7KP77/74Hlg3qhmJeZEtDzVZVRViWPanPJJfTEYkow2T0JYmDLPLY+8Jr2PXkS7BL7FTc9eRLeN8nboFp0pS7txAKScPIxbZt9PR0+8X4/v5ef4hx3rwFIw4x2rZLLWK0bQccV75Xkxe5lAsSudBRNa6RC2UwDEPFe4XGDQeQzZdWBCQIHJUNkvjT0LkmkhKjs2mLIgfXRckbLM/zWL9+ExYtWordu1/F3r2v4eTJ49iyZSsWL56Hf3vgP/GxT30QvCAgS8nf/VKYpg1B4GHbk38PWJaBoohlTfyn0wXEYgEYBkn7KRKHfCqDx773KHrPdU9orePtR7DtEzf7hlg0yMWybF8dOpVKFSVWzg8bYtywoW3cIUbTtKlFjIQUyv8+WJYDUaQTcQAY0SdmonAcFwxT/QQzY8gFoBW5sFRORrRIipgK0VmLZgQkSfR8yRVlcmmYSCSCG27Y7svI5HMJvHkgj0g8jOa5jchkK0MsAEmNCUJ5vjqBgARNM8qqpbkuMesKqCJcx8GuJ19C+3O74DoTv18c28HuX76Ctg9cC9ct3//Esix0dXXijTe68M477yCZTAAAFCWIhQuX+BL1klRa/YMYYmHCNZyRr82hMg9CK3Iha9lUMgtkUJjKJVUUM4ZcvFxjuaBVc6EZAdFyw+R5OhEQyzJgGDo1LpZlwPMcdH1yRMUwDBYtWowFC+YjFJTx7a89iM/f//swTPpCl4NhGOUVhXmepPASifLng0zThmVZOH3wBPY8s7Ostd7Y0YF3f/B90HWzWAcr/d4jQ4wpXwCyu7sTtk1qEnPmtGLRouVobZ2LaDQ26VO1YdgQBK7sA6Bt22UP5wJekw1DqX7jUKvfCEL1s8sMIhc669A4FQF0IyCa6TUaw450IyCeyhxEQJXw3M9ewvW3vQdgGASDIjiOpeq4OBiOQ+ppwaDk296SKBN+Z59n16vr1rB7KhiUkcvp1O7bfMHE0vUr0LyoFV1lOF0amo6DL3dgxZb1EJXxv/5kiPG839mVy2UAAKFQGEuXLkdLy1zMmdOKxsYolQl0L1LQy+xJoRW5eNfEceVbotOKgiqhIF4JzCByKf9bSotYALoREK11yIZIo52Zbnotny9vp+B5FrZl49RbZ3DzXdcjk9VRKJA22FiMyO/Qul4y8S9CFHm4rguWZVEoGD7ZkHw3aaHmeRKVxWIqbNuFrhP1YS9HT7ON23EA22Fww9234od//r2y1jry6gGsvmYDTNMe1m7uui76+/v8QnxPTxdc1xtinINVq9Zgzpx5w4YYHccpRuHl1zhkebhl8EThOK4fgdOIOGhkGGjVbyzLqfp6C3CZkQvNKIEWUfE8i8I4vhylgBTz6bUz00qvcRxTvrEbx+D5J36Dmz98PWyHbLQAMY0TRd6X88lm9UnfJxzHIhAQIQgc8nkT2WwWosgXI6+h109IxoZlAYCFbFaHIHCQZQHxOEnFVELtOZvTUNdSj6aFc9A9SS8YAOh+pxOO7cBxrGJtLYsLFwacGAeGGONYuXINWlpa0dzcMuYQI2mAKL+ATuoSdGZUvOiFxjXRqt/QWIemu2glMSPIxXVdKhs5LUKo1giIljsgrQYDGkOYLMtAlHicePMUbvvYTUimhqb9DMNCf7+FQEBEPK4ilzMmTIyKIkJVBeTzxhD1ANO0EQyWttGZpu0/3iM8mrI5ACE12wWuuu29eOLbPy5rrRN7j0BtiaFj7x5cuNAJgDgxtrTM9X3ig8HS5d29KKjcDjTbJhEHDXhpKBrtyLQ6xmhEHDNl1mVGkAtAZ3qdpI6qJ5UFkM2TlvKAN5hWDuhGQOV1WwGAKHDY99ohbN66fsxNgpCK5WsvZbPjb+wMA4RCClgWI0rvOI4Lxyn982ZZBpIkIJHIQRA4RCIKMhl6SsQAmX1ZtHoJwnURpPtSk17nRPsRXPWRbbBtB+vXb0BDQysaGwecGCcKy3KgqvRqHLRSbCTaKrc5gE7E4brknrtcMDO0mwEqpEBrI5/NERAt1QGADlEJIoudv3od737fZmjjREG27SCVKqBQMBAOK0XXvtEfH4mocBwHyWRh1M/BNC2IYmmdOcGg5NdndN1CKlVAKCRTqSF4cByyaW7efk1Z65w7cQbNLc24444PY8uWq9Hc3DxpYgHobcAAzTZiOuksxwG1KIEWwcwERcgZQy60Tve0IpdqWoesRUd5gMaJkVwPW3Y6UxR5XOzsQ3NrI1zXLfm6dN3yBxdjscCIshvhsALbdsZVDfBqCeNBEDjwPDeke82yHCSTeaiqSEX6w0NBt7Bm6wawZWyclmGir7MXrutSSfkA9AiGXleVSynicKlFHDRTY9WOGUEuxGGQzsAirYiDVgRUTZEUQC8CotFxxjIu9ryyD+9+32aAmVhfv+sS+fZ0ugBFERGJKP5G40U0pbRtk7mL8TffYFAakahs20UqVfBbmmnAsohG29zlC8pa59SBY4DrUhwSpCeVQificFFGMDYEtCIOr4uNxvVUO2YEuQDV1dtNLy1GJ3Ih68w+chEEDm8fO415i+agUJhcO7MXPei6hWhUQSgkQxT5kmXiSfQ19qYpywIcxx11nseLkMJheVKv4VJwHAuW57B04xVlrXP+rTOA4/jW0OWC5lQ8vYiDVjqLXsRBs6hfzZgx5EIje0Sj552sU74+EEBHGHFgHTo1KZokVW69xXVd/M/7fx+maZX9Pmmaif7+vJ8CKiUa8TBWaoxhiP/KeOk1XS9qgykTr78wDEkRBoMS4vEAIhEFrgssXrd8wmsNRvJiwtffqqZ0VjV2QlUjuVQ7Zgy50HgzaZECLdC6HlqRC80IiIawZzZnwgUD26Gz0cgyD9O0iVZXQEQ4rJSUohgrNaaqkk8c4yGXM6AopUmS8DwZ5oxEFMTjQSiKUGxYyKO/P4d0WkMwEkIgUnq78KXI9KUgyIKveVUuaEUctFJHNNeqxnWqHTOGXGig2iIXWtdDIo7ZaUdAZm7odK8pioh8nkzzJxJ5WJaNWEwdd8MfLXLhOBayzJfsROrJxYzUPcYwDCSJzMfU1QUQChG3wXzeQF9fttgFZw6J4EzDROvS+SU990iwTAumZlAlhVrEMd46dDrPqumQPBpmxJwLvTeSAVA9pFBt10OzxZqW2yctawOeZ4d1nOXzZOAyGJQhy6PLyAyuuwz+/WBQQj5vTOj+zOcNhEIKNM0Ez7MQRR6iyBfnlCwYho1cTi/pc2BYDtHGeMnPPRIyyQykUIhajYNWxOGtVe796K1jl3k+cRxQaQ6g1WRQI5cqw2wlBXqRFK1aEp1GBXLCo0N4kiSMqBbgOKXJyHipMcsiUYoocmBZZkIT6UQhmgXHMairC8JxHBiGhVxuctpoLoB4S/2Ef28wUhcTaAqHq66DaSAKKtf7hNZcCc0IiM5AZrXjskqL0UK1kQIt0KsB0VKeppOmA8aXoiEyMjk4joN4XB2WujJNe8gwZSAgl2QnLQgcAgEJsZiKWCwAQSB1n3xeRyKRRy5nTLqrznEcxJrqJvW7HvovXATL0BwSrL700Wxdp9pxWUUutEAvAqIDemRHL7KjsY4o0IqAvFRdaUX3kWRkTNNCKERaib3i+kiyLizL+KkuQeCKj7OG6IzJslCs4ZQnjWNZLkJ1kfEfOAaSFxNwHIfakKCXPio/DUUnfUSzgE6j6YFms0K1Y0aQS3VtnNVX0K++CKj8kxXLMggEFeRz5asLT1TU05ORkSQe4bDip648kyZVFZFM5v3HiyIHQSCEwrIkhabrJjKZwoifr207VCb2bdtBJDz5bjEA0LJ5oNh8QeN+HDiZl18rqbZIoboisrKXqDhmBLnQQLVtwED1XVM1kab3BaSRn55smk7XLRiGVUxrBWBZDgIBEbpu+9EJmROxYRg20ulCSdERzQ2PLRqZTfZzc4sk4F1TuZ9/tW3m1QYaB6+ZgsuGXKoRtL471UQKxZXguuWls7z3phz9rMHXM9mTtOsChYIJx3GhKGIxxebCMFwUCiZMc+ToZCxcTrMOk0W13dPVdj0zAZcNuVTnzVFt11Q9XXDe77sUai4TOQUzDFGGFgTOF6N0HBeWZReHDbni4xhYlj3tG4VjO/gvf/u/4Fg27OI12t6fTQu2ZcEyLViGBcuyYBtm8e8mbMtGrLm8brNLUX3fs/IPOkD1fcdmQvRzGZFLdd0cQDV6O7ggr6/MVSikNLxTOY2C/ljXw7LMECLx7GxN00ahYMA0HbhFcUev/qLrFjiORSymQtOsCc+60JTZYTkWFniA58EKAAsGIuPdW4x/jw2kGcnP/XvYdWGYdlWSQrUcdIorobqup/oxI8iFXvqo/DUqIYZHI89Nb1CMRrqm/IEz7z2hseENTkPxPDuETBhmwEVS08xRC/+BgFSU03chSTzSaQ2FgglVJQ6YhYI5RG5/LNCaA/JIika79mzdhKuNNGnOpFU7ZgS50EA1SlPQHRSjFXGUvQy1QTEA4HkewORYk2EYCAIhE5ZlUF8fhG07ME0bum4hmy1tEp7nOXAcC00zwTAMAgHSkuy6LnI5HYWCgUCAiEp6U/9jgZYlNc0IiBbobsLlr0MLtOw6aKHKtrIRcdmQS3VGHNVICtWRFvMgySKQKU1un+NYPyIRBNbXJTNNG5bloFAwxhykHA2BANEkA8hrs20yUOnNuTiOi0xGA8+zCAQkKIqAXE4f1d5YFPmSBjDHAy2hUbpt+jTTPtX12qrpeqrtoDwSLiNyocf2tUGxqbmebCaPYEgd9d8Hp7cEgYPrun6Kq1AwhqSLHIc4Lk6UXEjUw0LTBn5P1y2IIj+MPCyLzMeIIlckGRLZDI5SOI4BxzFUrKRpee/Q8hUCZnMaqtqup0YuVYXaoNjUrEPLfMotNheIIg/LsocQiSci6dVKslltzFO8rpN5lYl+uQdHLR4Mw0IkogIYOfowDBuGkYcskyFMy7KLQ5juqBpnkwHPkc/Me38mG8VwHJ2UTzUOKtNC9ZFU+WtUGjOCXKovnUXLqpTiMB2FEIjW67JtZ9LrWJaF3t5e9PZ2Q1UlbNmyGaGQBAAwTUImkxF6dF0Xuk4K8KWmpASBA8Mww8jAtl2/g2ys2ommWdA0C4oiIhpV/YinVBfM8cAAOP76AcTnNKJ+XjM4joOuGwDDwnZQMuHM7gioukiBXmt09bPLjCAXgM5N4qVryj2l0WoOoJvOokEK9HSPPI+Q8TatQiGPnp4uXLx4Eb293ejr64XjkPbflpY52LJlMwp5DflC+WmkfN5ALBYouXV4oENsOG644QZIkgieJ14wn/3s57Fly9UAgDNn3sFf/uWfIZVKIRKJ4P77v4r58xcgHJZ97TFPXXmyIOk1Fjseftrf9QKxMBoXtKBpYSvmLF+A+nlNYFgWhmYCLAfbcWBZzrD7n1aDAc0IqBr18qqr5lL+GpXGjCEXGjWOaksf0Yw4aFwPLdMogNQfLvVicV0XiUQ/Ll7sRm9vD3p6upHJpMEwDBiGQTxejxUrVqG+vhGNjc1QVVJvCQRV5AuZsq/Jcdyif4uETEYb87GiSNqUR0thua6Lb33r/6K+vnXYv/3d330dd975Ebz//Tfj2Wd/ib/927/CAw98DzzPIpnMQ1HEkjvLRoOiiOh558KQnSqXSONUIo1T+4/5PwvGwmhcMAdNi1sxZ9kC1M1tAsMwMIwi4RQ/cxqpOpalFwHRUsOutqYHGun0gXWqGzOIXFjYZbILzXRWNa1Dahy0Ig6XSprEth3YtoXz58+ht7fHJxTT9PxQJDQ2NmPZshWor29CfX1Dse14KDLpPEJhdVzJ/FKRy+mIxcZfLxCQxnWYZJjh7cCJRD+OHz+Kb37zOwCAG254P775zW/AsgrI5wVYljNCZ5kBw5jYa2NdB0de2Tfu47KJNLKJNE7uP+r/LBiPoGnhHDQuIoSjzG2CKvMwWBcFffKfO730Gr22X1paXjRrQDSWYVmm6glmRpCL67pFp77yyIVeOovesCGN+8Oy6EUctm1PepPIZjPo7u4uprd6kEgk4LokDRONxrBgwWLU1zeioaEJkUikpM/CuwyBZ6GX370LAEinNUSjStF2ePjrFEUerotxN/wvfelLcBwXa9asw2c+8zmEQiF0d3ejvr4RHEdkYjiOQ2NjIy5cuIC5c2X/d73OMkHgEAxKUFXRl/cfDxzHgOM5vNXx5gRfOUG2P4Vsfwpv7x34/XBDDHd/7X9AM/KT3vx4nkWhUP4BgBZJkXXoEALxFqJFUuVfT7UTCzBDyAWgNV1fXQZEjuNQSYuRtVwqXwAvnWWMUxKwbRv9/X24eJFEJRcvdqNQyAFgwHEc6usbsXlzG2Q5gsbGJsiyPPaCo8A0bTiOA0WVkC3Rq3482DaJHiIRBZmMNqylOBAYv+j/ne98H/PmtYLjgL/4i6/hm9/8Bv7kT/5i2OOCQdKMMFoUZJo2Eom8L+8/uLNsNKiKiHcOvw1To8S2AERZgqEZZW181UYKJAKqrgYDWtc0A7hl5pALjZN5tc2V2LZDZa4E8KIXDrZd3snRth2I4vDbQtM0n0QuXuxBX99F2LYN13URCATR2NiE+vomNDQ0oq6uHixLtLcGm2RNFrmcjlBIKW76dAjGMGykUgVEIkrRIIzUPiTJi1qGEs5TTz2Jn/zkPwAAn/jE3bjppg/AMGzU1QVx550fwf/+3/cCAJqamtDb2wPHsRGLBWHbNnp6etDY2DTm9eg60Swb3FmWy43ceMC4Dg7vaKfxNvhoWTIPVhkbulc3o0EKJEtRnpGatw49R9Tqi4CqHTOGXKrJv5qQCx0fbFodbESxd/yIYzxYlgNFYZBMJtHT0+XXS1KpJFiWhPTxeB2WLl2BurpGNDU1IRgMjbiWYdhUOqO8jZ5SkOfDshwkk3mEwyoEgUMup0NVJWSzw4v9t9xyO2655XYAQKFQQDabRTAYhGGYePHF57F06XIAQCwWx/LlK/Dqqy/h/e+/GY899jMsW7YCsVispGsqFAxomgFVJXIyhYKBQmEgovCsls8cOUnhHRjA3FWL4TIsJiu1IwgclcFQgJ69Na11qrHFeiZgxpALlaE8al1VNsUah5eGKu+LaVkjRxyl/a7ptwL39pKopFAgsxiCIKKhoQkLFy5BQwOJTARBGGdFAs9oq1RBx9HgOK4/rW9ZxEeFFmzbRSKRQzgso64uCMuyYVljfxb9/X24//4/guM4cBwHS5cuxR/+4X0QBDKZ/9WvfhX33XcfHnjgOwiFQvjjP/7qhK7JdTFEs8xrn9Y0E5LAof2Xv6FiReCB5TnMX7UEmTKiQkHgxn3fSgXN9BqNJhBaLdZ0W7VrkQsVMAxTVV1V5OBBJ+IYKMaX98WcSBtxLpfzoxJCJr0AXDiOi3A4jIULFyIWa0A83oBoNDbpG9k0CQnTeJ9Mi/y+wLOgM4I4FOm0hnicg227iMcJyWiaCcOwh500W1vn4l//9WFyPQKHcJg0BzCMN0vTjO9976Gyr2m4ZpkIU9Pwxq93l732YCy6cjks0yrrM/Iiv3Jxaft6OaAnEFpdLdYzgViAGUIuAJ031KtL0IBHCo5TPikIAgegvNP4aPUbx3HQ399fjEq60dPTg2w2UyRsFnV19bjiijXF2ZImKIoKVRXBMAyVzULXTciyUHb0YlkOspkCgiEFqu2Wvd6lkGUBtu340/OSxEOSeASDMgAXtu3CcRy/tuAdeLyBT103qUZUg+F1loVUHq8/8SIsg+7zrH7PJlhued8vni+/m5OsQzO9Ri8Cmmir+Eig1WJNq05bacwgcil/De8ESiPv6W3m5X4RLMuGLJeWZhoLXv3Gtk10dnYNmS2xLAvEh0RBY2Mzli9fhYaGRtTXN4xItoZh+11O5ULTTIRCChUy0A0bTE6DJJVPVpdCVcUhsixegR0gmwL5j4UX4ZH324HrAooiUEuTjnV9ej6PQzs6qK4rBxS0Ll+AZHrsodKxQFJidKINQeCqaiMHaHfBlb8Oz3NUlccrhRlELgyVKVmv8F0+KdDp9CpnKt51XWQyab+Dq7//Ivr6+vz3KRqNY9GipWhoILMloVC4pBvSskg6iwYJk03HBc+Xn5N3HBf5vAme56GqIjWCURQy3DjaBuk4bnGjGvnfdd1CLKYim6XXGjwYLMtA5Bk894MnqdZaAGDp5tXQNLOs7xXNYn41ptdorUUrAqr0QYYWZgy5AHRyqF46q9wvg207kOXy3z7XHZjUH++kZds2ensv+lFJT083dL0AgAHP82hqakZb22aEQnE0NjZBFMVJX5dpWhBFjkpBVNMsyDKPbJbOBpTJaIjFVF9ev1woiohUavKVHI98xhOynCyCqoBDOzpw7ugp6muvee9mlNsZK0k8MiV67owFr65KI+IQBJ7KvUE6JF0qg480I6CZgBlDLkSFtvzwm9ZsCc36jRe9XFq/IaKO3T6ZDBZ1DAZDmDNnTlE6pQnxeByCwCMSUdDfnyv7mgzDmpT/yUjQdROxWGDUuY2JgkRsGkIhGYlEvqw1SdRil/2l13ULklR+2/WlCAZEpHr68OpPn6e6LgBEGuOINsaQTE+eGLwIl0anGM2OM1oREC1CGFiLziBmtafEgBlELgCdQlY5LbuDQTY0mh1jDHp6+otkQoYV0+l08TTHoK6uHsuXX+GLOgYCgWHreB1LNK5J120EAjKVVKTjkIK3otCrlXg+LuGwPOmog2FILSOZLL//zDAshEIytSFPgFwbCxe/+PaP4VDa4Abjinevh15mmoaW5htAN71Gq8GAVseZRwa0pvxnAi47cqE/FT+5jjHTNH3plETiIi5e7IGmkaIqEXVswpIly9HQ0Iz6+nrwfKmzJWRwcbJqux6Iq6MFSRLKXgsYkLsfPBBIY81wWEYwKE2q3qEoIgyj/KgFIPcCwzDUJrAliYfIM3jqO/+JXLJ8RehLIUgirtz2LuS08jZgSRKQydBpDhcEjsq9RrvBwDSrRy9tJmHGkIvXOlsuyImeodYxVmr9JpvNoru7C319hFD6+0nh3XFcRCJRLF26FMFgfEKijiPBMEh6hsaXVNOIuRaNtQaiF3qFeIDUX6JRdcLSMAxDUmLJZJ7atXipxHJbkgWBgyJxeOUnz+Es5Ul8D+tvuhqm7ZS14ZGUGKid7FmWTpRAs51ZELhhTqSTAT3VAXZGpMSAGUQuAL1wkF4b8eizJX19vbh4saeY4upBLpctnmw51NU1YM2adaira/RFHWnpcJE24smJRI60VijEUjuNk+hFpRq9uC6QTBYQC4sQwxISJdYPBqIWelIchmFBVcWyyIVlGSgSh4Mv7cGhl+jqh3mQVBkb3/9uZPPlkaAs89B1OjM3ksRT6aQC6EVApLYBKvcIrY4zUZwZbcjADCMXb3it/PZYm2LHmABN09DT012MSsjUO/GecaEoATQ2NuGKK9aioaER8XjdiI0ApmlTCedd1/UHM2mc3jTNojZXQqIXC6oqUSm2eggoHJBPgmVYxKNhJFL6mOTlRS2JRGlRy0jOkvPmzR/2OELG3KTvUY5jEYkoMHQLq7ZuxJs796P/wsUJrzMeNrz/3Th9+h3kNQutrfMmvY4kCWV12Q1dq/yIz4MgcOOawZW6Dr0aEEflO0QGrmcGZhS5uK5LZciqnLqL67pIpVL+gGIy2YuLF3uLLYsM4vF4SaKOl8I0bUiSQOUL5qVn6JCLiUiEzhAkQDSz4vEAdN2kkgIJqDxEKwfr1ScA1wW/5VbEI/VIZsxRT4qqKkLXS5c7GclZ8h//8bsjPpbUqTho2sTuUVHkEQqR2pGukzbwO//oU3j06/+CZHffhNYaC6G6KK68fgse+cmjuHixGy0tc7F+/WbU19dPaB1J4ouGcHTMwXieg2GUT1QcxxZbh2m0M9NNr9HohKPVoToVYNwZJNHpusSmttxhNUHgoKqlzTZYllWcLen2C/C6rhXXEdHaOgexWD1isQY0NjaVLOp4KYjNbwB9fdlJ/f5gcByDaFRFX1/5LckAEI2qyOf1ssU1PUgSD0URy653BBQeklOA9cpjgNcCzDBgl7eBX7IeuYKFwiWbvPc+JxK5ksglkejHxz9+J5566ldFSwMbt9xyPX7848dHVDr2ZGPSE5h4DwSk4u8UhhCuKHIQWBc/+asHkb6YKHm9sXDL5z+OhkXzkM3pOHr0CA4d2g/LMrBw4RKsW7cJoVC4pHVo3hOyLFCLNmiuFY2qJRu4jQWeZxEMylTqe/X1wRmREgNmWOQC0BkgGmsqPp/P+6KOPT3d6O8fKurY2jrPd1OMxeIIBKTi75V3sqeZzrJtt+jLwlH58ufzRALeMOgUv3XdgiwLUJTJR2oBhYfkarB2Pj5ALADgunCO7YHZcxaBzdshidKQOQ6vQaHUqGUkZ8n6+gb09HSPSC6GYZVc8xJFHorIAhyLRCI3LJVnGDYYkcNd930aP/nL7yPTnypp3dEwZ/kCtC5fiHTWAM/zWLPmSixduhyHDh3AsWOH8c47p7B8+SqsXbt+THM3QeDAMMM9byYLWeapRca0og2GAbWhWFpRy0xRQ/Ywo8iFFMTpdIyRD8lFX1+fH5X09HQPE3VcuXINGhoa0NjYDEVRh61lmjYVWXmAdjqLbOA0NgAinS9STRNks5pvijXRmRxV5iDDgLnzccAcOYp1E10wfv0w+A3bUN8wD7pFUnKyLCCRoBPRjfi8LqnpieLoBWqOYxBQRLCMi2O/2Yvl124cdT3dsCGJHO76yu/jkb/8PnKJ9KSuS5BE3Ph7H4J2yf0gyzLa2rZg5cpVOHCgA8eOHcLbbx/DmjXrsXLlavD88C2CNC3QIQOWJU0utIhKFHkqMjy0O85ozAIJwswp5gMzjFyA8jrGDMMoFt4vIpG4iK6uLpgm+ZIQUccmLF9+BRoamlBXVz/iF+tSmKZNbW5mYBCv/LV03UQgIFEzJ8rnibcIrdZdu6hsHA4rE1pTlXkorAnz5ccAY5zUh2XA2vMM2KYFENdeC07li7bJpb8fnrMk8fDhfAmesZwlvUPCpeTCcQwCqgiOZXDmwDHs/o9noWVykEMqmtcsQ2GUmROPYD7y5U/jkb/8PvKpiadOb/i9O8CKIgr6yM8RDIZwzTXXYeXKNdi3rx379u3GsWNHsG7dRixZstzf0DiOBcexE64pjQaaQ5jEmG64RcJkQLveQoPwaAx/TyWoX+1jjz2GL3/5y9i7d++IU+Qe7r77bsRiMfzjP/5jSeu+/vrr+MIXvoBdu3aVFK66rotsNoOengFr3mSy3584j8fjWLZsOaLRugmJOo4Ey7Kp3IyW5fgKvOVO2BOrXqLpRaNJwOvyovmlKxRM32CrlO4xReahcFaRWEov/jrd78DpOQN27goIK9+FuqgIzSSEOd4+FIvFsXTpcrzwwrN4//tvxgsvPDuusyQRshSRLXIAx7EIKDw4jsWp9sM48PPfINuX9B//2sNP486vLRnzvdUNG7Io4K4vfxo/+csHUciUfgJZ855NmHvFYmRy498HdXX1uOGG7bhw4Rz27t2DXbtexptvHsLGje9Ca+s8anNPHiRJoNY5SFstgEY2guMYX7G8XPD8zCnmA9MYufzpn/5pSZHBYPT398M0iT/IpScB27bR19c7RItL0/IAmGKevAlr124Y5FsiIxyWS25HHQveVDyNTZdoVAlU0g6aRqIXWi2e+bxeciNEqSAilAFYlj3mxqBIHFTeJsSiT+Izc104Z4/COXcM7JylkJdugBKLwrEd6JY75gDml770FXzta3+Kf/3XB0tylvSELEMhGYxjg+M5nNi5HweffgX5EabtLd3Ab77/U2z7Hx9H2rJHJTzNsCFLMu667/fwk796EFpu/M+hfl4zrvno+5Gd4EY5Z85ctLS04uTJt3DgQAd+/etn0NLSive9773g+dEPjRMBzxMjOVqHFVopMQBUVLwBegKawMwaoASmkVyWLl06qd8rFApQlAA0rYDu7gE3xd7ei76oYyAQREvLHNTXN/qijpdO99u2A5al45JIM52laRZCIYkKuZimXcxp0xngqkT04rpAKlVANErcHEeKSGWJgyq6hFi0Mt9k14Vz/gSc8ycAOQC2ZTHk+VdAiUfhWDZMh4Fh2jAMy9/kFyxYiO9//wdjLsvzLESRB88zgO3AdRx0Hz+JU68dxLmDJ2CNM2zYdfwdvL3rAOa3rUF+jJSTpluQFQUfvu/38OjX/wV6fvTUoKhIuO1/fgIFzZrUICDDMFiyZBkWLFiEY8fexJtvHsDDDz+MBQuWYP36TQiHIxNeczAUhV7thoiG0kmJ8Tzre/WUvxa9BoMZxCsASiCXXbt24Z577sFvfvMbNDWRPPPHPvYxvPHGG3j99dcRDpPWxdtuuw3btm3DggULAADnzp3DX//1X2Pfvn1obm7Gvffei5tuuslfd6S02NGjR/Gtb30L7e3tsG0bS5Yswf/6X/8L11xzjf+YRCKBnTt34gtf+AJUVcWGDRtw3XXbiqKOTWhsbBozHTcYpmlRKbbRTGeR0xJDrVNF04hgJK0TXS6nIxiUqER8HmzbQSajIxxWkEoVhhChLHEIiAzMVx4DCuW3aQ+BloNz6iCcUwcJ0TQtAB9vgdS0AG4w4KczHMfxDcI41gW8j9hxwHAseIGHlskjfb4LvafP4/yht9H91hk4Ezz5tj/6POZeuQyiIMIYY0PSdBtKIIA7/+hT+Onf/H8wCiN/tjf9/ocBjocxSp2lVPA8j/Xr12Pz5g145ZVX8eabh3DmzCmsWOF1likTXpNlmWKkUX7LMABqkkdkLYFqeo0GgUpS+YaCU41xyWXDhg0QBAEdHR24+eabUSgUcPjwYQiCgL179+K6665DMpnEiRMn8KUvfQm9vb0AgC9+8Yv46Ec/ik9/+tP44Q9/iHvvvRcvvPACmpubR3yet99+Gx//+MexaNEifPWrX0U0GsWhQ4fQ2dk55HF///d/jy996Uv4whe+iP379+LFF3+FT37yv2DVqjUTfvHeVDyNG4mWYCQwYA1MgxA0ja7cPanjCFRPnd66uRwQiZACv+O4kCQOAYkhcyz5yXVJlQwtB+edI8A7R4CrbkNeri9Gfqx/cOA4BlZBxxu/fBmO7UDL5JDq6kOmNwGXQmRomxZe+u6j2P7F34VlO2MeVAq6DSUcwoe+eA8e+8a/wtSHfhbrbrgKzUvnly3x4iEYlJHLadi48V1Yvpx0lh09ehhvv30cq1ZdiVWr1pQsrgqQqKVckzIPDEPSTzRmWwBCVDRSv54VNh3Zl5lVzAeAcducZFnG6tWr0d5OdI7279+PQCCA66+/3v9ZR0cHGIbBxo0DLZWf/OQncffdd2Pr1q34+te/Dsdx8OKLL476PN/5zncQCoXw8MMP45ZbbsE111yDz3zmM7jrrruGPG758uWYO3cufud3fgd/9md/hVgshh07Rl93LHiEQANehxANaJpJ7aTiCUaq6uSNwy5FNqtBVQXq0t+6bqFQMBCJqJAlDkGZhbXzcbi58uY7Jgo2FIdlkc3dskiKTNNMGIaNQjqHYzs6cOKVfTh74DjS3X1UiMVD3zsXcORXu6FI4xdvC7oNNR7BHV/8JHhx4H5ZtmUNrrpj25jptYlAUUTYtuO3CweDQVxzzXtxyy0fQkNDEw4caMfPfvYTnDhxDE4JTpkMQ4YdaR1OvHonDaLy2n1pEAJtC4GZVG8BSiAXANi0aZNPJO3t7Whra8PmzZuH/GzlypUIBoP+72zdutX/cywWQzweR1dX16jP8dprr+Hmm28ec3gLAK666ioAgCgK4Hkec+fOx8WLPaW8jGHwbiCOK/9DMwyLmu6Pt6lJEh2yyucNyLJA7eb07IZDIToCmYNRKJiwTAtBhYO182dws0nqzzEmOB6MJE+rPPqBn78EI5ODVArBaDYijXW4497fBSfwWLJpFbbdfTuy+dIHRccCyzJQVWHE9FU8Xofrr9+OG264GYqi4rXXXsZTTz2Os2ffGTNKlmURhjHx+abRQNJY9AQ0aabEaJmfzRQPl8EoiVw2b96MEydOIJ1O++TS1taGQ4cOQdd1tLe3Y9OmTUN+JxQaqqkliiIMY/STSjKZRENDw7jXEg6TlmFBIJfO8zwMY/LpI1oRh+t6+mD0ohdZph290MvbFgoGWJah9no9iAIHkXNh7vwZ3Ew/1bVLAROKwzbotdpOBo7t4KXv/QSKxI+7qaiqCEESEW6ux0e+8vu44VN3IJsfXVdtogiFZOTHIaqWllbcfPMHsXXr+2BZFl566Tk8//xTox76aJrGkb2gfL1BDzRrN7QiF1HkZlzUApRILhs3boTruti9ezcOHDiAtrY2LFu2DIFAALt27cKRI0fQ1tZW1oVEo1FcvFi6AixRSC7rKQHQTY3RJARdt8DzHLUTC4leRKodJ5mMVhzUpLOeKHAIBXhYu56Em6Yn1jgRMKE4rCowdUpeuIg3nnoZ6hjRi6dJlkzmkS9YkCNh5Ar0iEVRSCq1lPQVwzBYtGgJbr/9LmzadDUSiX4888wT2LHjV0inB9KaNAUvyTWSqIVWSsy2XWoRH8fRabMWRYFKvXSqURK5RCIRLFu2DA899BBYlsWqVav8GsuDDz4Iy7KGRS4TxdVXX42nn34aul56FEKjLmGaFrXhJMOw/N59GtB1+rUXb8OgActyoOsWlfSYILADxJKiLzNfKphIAyyXjuJCuTj07KvI9SUhX3L4YRggHFYgCCySyby/8Wi6Tc2BkedZqKow4SI5x3FYtWoNPvSh38Lq1etx/vwZ/Pznj+L113dC0wrUpJI8lKNPdylopsRkmV7H2ayOXACSGtuzZw82bNjgi/i1tbVhz549WLhwYUkprbHwuc99DplMBr/927+NX/7yl3j11Vfx4IMP4tFHHx31d2ikZAa0oOgQjKfpRWctepEQQKIXRaEbveRyOliWLes6BZ5FOCDAev0XcJOTq5/RAhNtrBo7Wtd1seOfH4Uscb6mHsexiEYDcBwHyWSBmunaYHjklcnokz7Fi6KIjRs344Mf/CgWLVqO48ffxM9+9ghee+11FAp0urpkWYBp0ouCCLlUF1ExzMystwATIBcv7bV58+ZhPxvcJTZZLF68GA8//DBisRj+z//5P/jc5z6HZ599Fq2trSM+nmEYihFHdabGLIsMhdK6Ns+si2b0AgCZTAGBgDgpjTVB4BAOirB2/xJu/+gNH1MFJhildvqngczFBNp/+gJUiYMsC4hGFeTzOrW5pZEQDMowDItKHSMQCODd774Wt912J+bNm4fXX9+Fxx9/BMeOvVlSZ9lYoNkOTzMl5k3S00iJzcT5Fg8zys9lJPT1Zcu+ITwHwP5+Omq5sZiKbFanlG/loarle594YFkGsZiKZDJP1eJXFHl/uLLUW4rnWUSCIqw9v4Tbe57atUwaogLhhrvRlyAzDnfddRtEUYQoEluF++//EyybMxe/+MvvT/mlfeBL9yC+oAWZrE71c7sUksRDVSXqytFebe7EiVPYt28P+vp6EA5HsWHDZsybt2DCaR9R5KCq9IRUg0EJtu1QSbGpqgiGYahopkWj6oxsQwZmoCryYLiuC0URy/4Q7eLAGi3/Ey96oUEuntw9rWsjbcQGgkGZqkaYYVjQdRbhcGnr+sTS/kx1EAsAJhyHbQ7dXL72tb/B4sVEqkgQOFipqZ258bDj+z/FHV/9775VRCUgCByCQQnJJL37AiCHN1nm0d+fR0vLHDQ3347Tp0/hwIE92LHjeTQ0NGPDhs1oahp5wHok0B7ilSR6VgySRG+gc6YSCzCBtFi1gmbrL60QVNNIezOteyKXI2ZdtFAomGAY+m3EnvhjMDj2tXrEYu99Du7Fs1SvoRyw4TqMlxFz3elJmeWTGbz28C9LGq6cDDiOHAzSaY16zSkYlIoK1IQUSWfZYtx2213YvPlqpNNJPPfcz7FjxwtIlUDePE9k/2lL9dNMidFIrc5kYgFmeORC5BXgy+iXgwH/k/LXcl236KUuUOmZr5RZVySiDBFopIF0uoBIRIWqiiN2BXFckVj2vQCn+x16T0wDkUZYztAv81e/+scAXKxdux5/8Af/Cxylwb/J4OTrB7H4XWsQXdA6qi/LZMCyDCIRhVoqdzCk4qzOSOkmjuOwcuUaLF68HIcPH8Cbbx7C2bPvYNmyFbjyyo0jmvMB9KOW0e7VyYBux5k4o8zBLsWMj1wA0o5YLjz/E5rRiyzT427PrIsWLMuBpllU1wQGVI4lSRj2uXAci2hIhH3g13C6TlF9XhpgIvVDTpzf+c738YMf/Bjf//6/AXDx6KP/MX0XV8TL//oEBI5eM4vXGaZpJrVNcfDagYCETGbstLUoitiwgXSWLVmyHCdOHMPjj/8nDhzYC/OSNKUneElz0JFhGIpDmPTUAmZqC7KHWUEu9AiBXqeXYVhF1z5aMy9WUaCPXlokn9chijzVNQESuaVSeSiK6BMsxzGIhgRYb7wE58LbVJ+PFthAGLY9cHL3agCiKOJDH/oITp58e9rbQvVsHjt/8CQCMp3PLBxWYFk21dkTD17XWakSKIFAAFdffS1uvfVOzJkzF2+80YGf/ewRHDt2xO8sI2Zl45u8lQoyJ0PntZM0FqikxDyrjJmMmX31IKkxWh/CYP8TGiBy9/Tafkn0Qm891wWyWX3cGslk4DiEYFRVIi20IRH2oVfgnj9B/bmoQA3DtQc8PAqFArJFK0nXdfHCC8+itXUugOk/SZ7ZfwznD71Vdv0lHFaKjq3025oliQfPs5NaOxqN4brrbsSNN96KYDCI3bt34sknH8XZs+9AFOk4RALkwCMIHEWpfnpzMqoqzsip/MGY8eTigUZqDBiQu6eBfJ40CdCb2LfAMCzVSMMwLNi2Q5W0PNi2i0xGQ1DhYB95Fc7Zo9SfgxbYcB0sayA10t/fh89//r/ik5/8Ldx998dw9uwZfPSjn5jGKxyKXT/8BTjGndRsEcMQawPXdZFO0+lqGgyWZRAMSmWv3dzcgu3bb8d73nMDGAbYseN5/Md/PILOTjrzUKR2Q9eyWaOkRE272WY6MPNfQRFEwrv8G0XTTESjKpUeddd1/eiFlk94Pq8jEKDX3w8AmYyOWEyFYdhUC7osyyCk8rDe3EW8UqoZ4TrYYAGQ19/aOhf/+q8PD3mIIHAwk8mpv7ZLwPEc1t68FbwowDUnds8zDCneW5ZdsUHMcFhBPm9Q6TpjGAYLFizC4sWL8c47b+HVV3fh+ed/jnnzFmL9+s2IRqOTXleSBGqzbTzPwnVB5TUT/6CZf+6fFeRCMzVm2y5sm97MS6FgIBYLDGnFLAfehL0s0+lEAwgJZjIaQiHZN+oqFyzLIBoS4Zxoh3PqEIWrrCzYWBNESUS9IsFxXH/2yXWJA6XrumBZBtY0Z8Ual87Dez59JxhRQCozsXvK6wrTdasiNRZgIJ1DMyIACGEtXrwCTU3zcfjwGzhy5A2cO3cGS5eSzjJVHbmzbDQMCF7SST155mc0oKrSjO4S8zAryMWDqgrIU3De8wr7tIYWNY2YddGKXjIZDdEo2SRofTlM04amEY+WcocrGaZILG/thfP2firXV2kwoTiSRYtlr+7Gsoyvvk1LhXuyiDTXYf3t16F1zTIUdAuGNrF701OhKBQM6hu/B0EgEjU0LbABkpVwHLfomSRg/fpNWL78Crzxxl689dYxnDx5AqtWrcXq1esgCKWltBVFoKp6QSyb6dhwS9LM7hLzMKvIRZZFKuQyMPPCUNm8aUcvtu1A00wEgxK1SWCANAxEIgoCAWnSREiIRYBzcj+ct/ZSu7aKguXAyCrsHNlsHMeF4wzfvIlL4dReWnxuE9Z/8H1oWbkQmm4jndUnfA2iyCMUkpDN6tTbjT0wDPF+yWY1qoVohmEQCIjDVANUVcVVV23FypVrsH//Hhw8uA/Hjx/F2rXrsXz5Fb647kjw1DNoyegoikDNsnm2pMSAWUQu3kAlyzJlp3W8mRdZ5qmc8gabdXlT7OUilzMQjweoDlYCZAgyFgvAsuwJb0QMA0RDAvDOITjH26ldU6XBBGNwJli7qDQaFs/Fhjveh/qFrdANG8n05MheVUkKNZUqVFSQk6TbTCrR/mAEAiI0zRq1lhGNRnHddTeiu7sL+/btQXv7Lhw7dhjr12/GggWLRowAFEWkdigjls0iNemYYFCeFSkxYBaRiwcytFX+jeNFBrRSCPm8F73Qy/NmsxqCQZmqyKA3BBmNKrCs0uXMCbGIwNk3YR99ndr1TAWYcLz0jbfCoUvzioXY+KFtiLY0QDcdpMYZQBwNLMv4PjsTEROdDEIhGbbtUjs4eeB5FqLIl3R/NzU14/3vvxVnzryD/fv34OWXf4U332zEhg3vQnNzi/84UeThui41+2GSPqdn2TzTBycHY1aRi6eXlcmUv5Zp2nBdcjPSmN6tRPRiGDZk2aYqXwGQtFs2qyMSUUoq8PvEcv447COvUruOqQITqS8ahNE9dZcKORTAgo0rseK9bQjEI9AtF6ns5D9PQeAQCsnQNLNihXsPgYAEjmOoi10C5BSfy5WeBiSdZQsxb958nDhxFG+8sQ/PP/8LzJ27ABs2bEY0GkMgICGbpZdKVhQR6TSd107Tu6kaMKvIxQOtTi+v7ZeWNMRA9EJvwjibJW3Euj566mAy0HWr2F2kDnE7vBQMA0SCAtD5FuxDL1N7/qkEE2mccmtjORTA/A0rsPTdGxCf2whdM2G5DNK5yUfKRG5FhihyyGQ06jphl0KWBYgiR7Ut3kMgIMFxnEnViFiWxYoVq7B48TIcOXIQR468gV/84jGsWLESW7ZcBcehMyfmWTbTSjeqKv1Zs+nErCQXVZVgGOXf8IZhQ1XpRy+KQi/SGJDQl6hK6AMD6snRqFIkmOGPiQQFMD2nYL+xg+pzTyWYUBxWtjKFbv85OBYNi+Zi7pXLsGDDSiiRIM6dPQepLo5EqvyTtCQRPx1Ns5BI5CreeDDYZ4j2cwkCB0niy+46EwQB69ZtxPLlK3Hw4D6cOHEMJ04cxxVXrMHq1esgiuVt5uR7TKcDlBTymVmTEgNmIbkQh0qWWqdXZaIXFZpmUsvTFgpECYDm7IuHfN4oDt6pw06o0ZAApvcM7P0vUn3OKYUggeEFOA6d940TeIQb4wg31SHcVIf4vGZEW+oRaojBNCzYLmDZLna9vhcdHbtw++0fRSQSmfzzcSyCQdLZWOmivQeeZxEKkcMMrXvYA8OQWlEmQ6/rTFFUvO9927Bx40bs3LkThw7tx4kTR7F27YZxO8tGAxG8BLUGBtoCstWAGe9EORJcl9j50uoIiUZV5PM6tRtJVYklME3pDeKtriCZLFTEAz4YlMFxjB8dRYIC2P5zsDueR6XMq6YCTLwF7KbtSBQjlwce+BZ27Pg1Ojsv4N/+7T98o7AzZ97Bk0/+FP/zM5/F8Rf3gOU4cAIPluOgxsKQ60KINtUjEAnB0HS4LgOwLFwAluXCtu0hJ/x0OoUnnngEGzZswZo1V078uhlyclYUAfl85WZXLoU3L5PNatQ7wwAgHPaaA+ipBxD31QASiRwcx0VPTzf27duDnp5OBINhrFvXhkWLFk8oagiHiV0FrcNcfX1wVkUtwCzSFhsM2kZY+Txds6583gDHcRBFehphXhE+HJaprTkY3vxCOCwTYkl2wt47s4kFAJhLDMKuvfY6PPDAPw/pMAKAv/u7r2P16rWQgkHUbVqOZITBypuuwfIbrsbud47gZE8nbFbEIz95HL//mc+gYDgoaBY0jagCX3qEC4cjiEbjOH9+Yp42DEMOJ/F4ABzHIpHITxmx8Dw5wORy9A5agyHLAliWpUosAIpdn4YfZTU2NuGmm27Be997IziOw86dv8bTTz+Jzs4LJa3HcSwEgaVGLLOtkO9hVpKLB1piloZB5O5pkoHXRkwTum7Bshy/BZU20mkNPOuCS3fDbn+24m25UwEm2gBzELmsW7d+mN1uItGP48eP4j3v2YaCbiMcbcBX7v8KLnRexIUL3fi///dbWLVqHRzHxfXX34Tjx48ikUiM+9xz585HT083NG38WtmlpJJM5pHJaNTTUqNBEDhEIgoyGa0ig5gcxyIQEJHJ0K0biiIHnh+upMwwDObPX4hbb70TW7Zci3w+hxdeeAq//vWzSCT6x1yTyPTTI/TZVsj3MKvJheaHRttq2DSJSCTtXGsmo4Hn2YqoqoYDApDohrX7aWCa7H5pg4k0jDup3d3djfr6Rj83z3Ec6usb0NPTPea/jYfW1vkAXJw9e2b062MYn1RYlkEiQUiF1nR5KRBF3rdArkTEApB0WC5nUH9dgYA8Zusxy7JYvnwl7rjjI1i3rg3d3Z34xS8ew6uv/mZEOReWJYKXtMhFFDnfGnm2YdaSC5nYZ6lFG170QlPuPpvVIcs8dVOgdFpDMChNSo59NIQCPPhcH6zdT80aYgEANhCdkiL4SGhoaIQsqzh/fji5kA1dGUIq2aw+ZZGKB68LLZUqVKy1ORCQfEkjmlBVEbZtl0SIPC/gyis34EMf+hhWrFiFU6dO4Mknf4KOjt3Q9YE0HTErozcIHQhIM963ZTTMWnIBSGGfZmRA22rYdclUM+001kD9RaFyIgoFeAiFJKzXfwE4s4dYoASLqsdjf7mbmprQ29vju1Tato3e3otobGwa89/GA8MwmDt3Pi5cOAfLMsHzLAIBCXV1AV+1t68vOy2kApBaQCAgVbQLTZL44uAzXV8ZlmWgKMKEbQVkWcG73vVu3HbbXZg7dwGOHDmAn/3sP3HkyCEALiSJp9Z+zHHMrI1agFlOLp4UfzVbDXunNdpFPV23oOtW2QX+kMpD0NKwXvs5MIKY40wGG6qDXYKmWCwWx9Kly/HCC88CAF544VksW7YCsVhszH8rBQsWLITj2Mhm+31nyEQij1SqUDGRyVKgqqI/x1KJ7kOAfI+8qIj24T0UklEoTL7dPxyO4D3v2Ybt2z+IWCyOjo5deOKJn+CNNw5TI3raNddqw6xsRR4MT0eIljyFJPFFuW56hUevjbi/n74GFDGGcibVgRNUeYhmFtbOxwF7+ja6SoFbugHGgvXI5Qde27e+9bfYseNF9Pf3IRKJIhyO4Ic/fATvvHMaX/vanyKTySAUCuGP//irmD9/IQCM+W/DnpMjTqKiyEEQeBiGge9///tYuHAxrrrq2il41WPDUzdmWQapFF2F48Hw7vl0mr6SgKIIkCR6kvqu66K7+zz27WtHb28vYrE6bNy4GXPmzJ30mgwD1NXNvvbjwZj15AKQm6O/P0ftxBGLqcjlDGqDlQBRf2VZlnp6gEzYq9C0ic1CBFQekpUjxGJVl2IwLfCbt0OPtJZ1wh0N3jAvx7FD/u8pbnsNHY7jYseOX6G7uxMf+chvT+tmw3EswmEFpmlVzKUSKBrJFd1eaUdnHmklEnRM7zzEYioyGQ1vvvkmDhzoQKGQQ0vLPGzY0Ia6uvoJrxcKyZAkflaTy6yb0B8N4bBMLdrIZMg8SSJhUQvnKyWh77ouUqk8olG1KD8z/pc5oPCQ7AKsnT+btcQCAEy4vig1IvhWDZ4DpeM4RQdKABhwo/Q+b4bBIDOxAekOz2gMACzLhm0TZWlP+22kDW/u3Hk4c+YUuru70dzcPOzfpwJe4b6Sni9AUYsuoqBQMCvyPOGwTL1GJUk8XBewLAfLlq3AokWL8eabh3H48AH88pc/w6JFS7F+/SYEg6GS1mMYzHpiAS4TciGnSI6K1wtANg3DsIoKq/ROeJ7VMG2JdMchBBOJqP7JeTSoCg/J1YsRS2UVdacVDAtGCSDZN5A64TjSYegZNnkEAgx3o3Rd+DbIjuPAsgYIyLKcCX1+pCWZwfnz70wLuQSDEgSBr5i6w2CQyMhGoUD/3goGJVjW5MQuRwMRA5WGKB/zvIC1a9dj2bIVOHhwP44dO4J33jmJlStXY82a9ZCksZt+KjWHVm24LNJiAPnSm6ZNTdyRYYBYLIB0mm4njaqKEASOugglQCasI5HR89yqzEFhTJiv/BQw6Kbnqg1MKA7u3R9Cf7o6CPS5555CoZDDBz/40Sl7TpIGk2FZTlGBobLPFwySWg4tifrBEEXO9zai+TqIIy3GPERmMmns39+O06ffhiBIWLNmPVauXAWeH352ZxgGdXWBWR+1ALO8W2wwGIaBIHDFk2j5cF0gl9Opd3x4k8SVmNq1LAeplIZwWB42A6PKPBTWgrnzsVlPLIBnEFY93W9z5y5AOp1CMpmckudTVRHRqIJCwSiKRFb++YieHn1i8YzR0mm6r4PjWMgyP67/UigUxrXXbsMHPnAH6urqsW/f63jiiZ/g7bdPDItgKyXPVI24bMjFA80PV9ctuK5LTWbGQyajQVEEqi3PHizLRjqtIRJR/NqAIvNQOBvmK48BOv0vfzWCCXsGYdWBefPmw3WBc+cmpjU2UQgCh3g8AJ4numSaVvkuQEUZsFquBLy2Y9qHhWBQQi5nlJzirK9vwI033oxt27ZDFEW8+uoOPPXU4zh//iwAQoJETXn2Ry3AZUYuXu2F5uR6NqtBVUVqERFAcvle/aUSN6Jp2shkiNOkqvBQeYekwnT6pk9Vi2gjrCmUUBkPoVAYsVhdxcjFk7IPhYgcSjo9NbpkgYAIWebHNJwrB4oigGEY6o6bXsF9MqoBra3zcOutd+Ld734PNE3Hr3/9DF544Wno+nA5mdmMy4pcPNAsqNm2i0LBRDBIVyPMMGzoulmxMNowLJiGCVVwCbFo4/uUzyawobg/VV8tmDdvPi5e7EGhQJfkZVlAPK7CcRz09+cqpg92KQYaBei2BXvgeRaqSs9m2INXxC/HDplhGCxZshx33PERbNjwLvT2XkQqlbhsohbgMiQXb2pfFOlK8tOW0Afg53orYSQkSxxExoHx8mNA4fI6UYETwAjSlIo/loK5cxdgPCHLiYDnOUSjKmSZDP2OVzugiVBIBsexSKXoO1UC3rCnUhFpHM8ckEajDs/zWLNmHT71qXuwYsWKIf/22GOPYcWKFcjlZufB7rIjFw+02wErIaEPAOl0wddfogVJ4hCQGFg7HwPyaWrrzhQw4Thsszq6xAajrq4eqhocUchyIvDk8cNhGYWCUVEJl5HgadpVQtbFQySiwjAs6rMyoshDFHmqnjKkky0Alr28ttvLYs7lUpDQ1IWq0vOyHyyhT/PGdF0glSogGiUyLuVuEpLIISizsF55HG4uRekqZxaYcN2westoDpR33XUbRFGEKJLo8bOf/Ty2bLkaAHGn/Mu//DOkUilEIhHcf/9XMW/e/MlfV1HI8u23jxeFLCfWKCIIXLH+xyKfr+ww5EhgGEIsXs2wUiBulZOTNBoLpOuMvtZZKCTDdd0pTYm5rgvDMMaduakkLi8qvQS0230rJaHvqRxHIuWpHIsih6DCwdr5M7jZ8c2sZiuYSAMsZ+hnNJoDJQB87Wt/g4ceehgPPfSwTywAcae8886P4D/+4zHceedH8Ld/+1dlX1tr63zYto3z58+V/DuCQNJfwaAETTORSOSmgVgYRCIqbNupKLGQuROmIs8x0HU2uQNcR8cebN3aht7ei/7PXnrpGViWNcQb5rbbbsM3v/lN/+/nzp3Dpz71Kaxfvx7bt2/Hc889N2ztF154AXfeeSfWrl2La665Bt/4xjdgDhJd/fa3v40tW7agvb0dH/7wh7F27Vo8/fTTAID29nb8zu/8DtatW4ctW7bg/vvvH9GrhjYuW3LxNmmaBXPXdStmNazrxK+bEMzEf18UOIRUDtarP4ObGdtpb7aDiTTCuiQCHMmBcix47pQ33PB+AMANN7y/ZAfKsdDSMgc8z5eUGpMk3ieVQsFAIpGfFiVljmMQjVZek0xRBIgiV5FZGUUhB81yMhlr1qwFz/M4cGAfAEDXddx666148MEH0dHRAQBIJpM4ceIENm3a5P/eF7/4RWzbtg0PPPAAFi5ciHvvvRddXV3+v//yl7/E5z//eVx55ZX4p3/6J3zuc5/DI488gn/4h38Y8vyapuG+++7DRz7yETz44IO48sor0dHRgXvuuQf19fX4x3/8R3z5y1/Gjh078JWvfGXSr7NUXJZpMQ8Mw0AUefA8A8uiEwfrugVRHNBpool83iieEJUJ6aSJAodQgIf16hNw031Ur2kmgg1GYKVK30S++tU/BuBi7dr1+MxnPodQKDSmA2WpcvsjgeM4tLbOw7lzZ+A4zrA8Pc9zkGUekiTANG3k83QFVCcKUeQRCpF5ENpmX5c+j6KIxZZmumuTrjMBiUR5XXqSJGPFiitw4MA+XH/9TZAkBplMBqdPn0Y+n8d1112Hjo4OMAyDjRs3+hHKJz/5Sdx1110AgNWrV+Oaa67Biy++iI9//ONwXRd/+7d/izvuuAN/9md/5j+XKIr48z//c/zX//pf/fvNI5cbbrjBf9wnPvEJbNiwAd/61rf8nzU1NeGee+7B8ePHsXz58rJe81i4bCOXwQiHVarrZbMaBIFuEd5DLqfDtl1EIkpJjxcElhDLrifhpi6O/wuzHZIKl2FKnrn4zne+jx/84Mf4/vf/Df9/e2ceHUd15/vvvbX0Ur1qs61dxsYG43iTMWBhTJiJjRPyWGzzwgsBHgk8YkJIAEdwYBIfOCx2Jn7YkIQxJw7J8WRIAslkQhJy/AaSEDtgYUwMTsB2jKSWZANau9VrddX7o1SlltRqtayqXqT7OUfHrV6qbstSffve+/t9v4CKnTu3Wzs+AFVVdYjFYkZUMqVa1LHfL8Ht1qrcensHMTAQyauwOJ2ikcdipbDwPIXbrfl7me9ere0TBYPmVJ0tWbIUb799BDxPUVrqxy9/+UssXboULS0tALQlqoULF8LlchmvaWpqMm77/X6UlJQYM5dTp06hs7MT69evhyzLxtdFF12EWCyG48ePp7wXgjVr1hjfRyIRHDlyBFdeeeWI165YsQKCIODdd9+d8vvNxIyeuQB6HDJM3dxXVSAYjMDrdRi26mYSDGoWLnqu+XgIPIVHEiC//muofR+aOoZihXiyCwjT0ZfKRFHENddsQnPz14fuH06g5DhuUgmUE1FdXQNCCM6cCWDBgrngeQ6xWALBoHWJkJNBLwMmBKabrI6GUjJ08Y9a8t5dLjvicdk0kV6yZDl++tOfwO2245133oEgCGhsbMSjjz6KWCyGlpaWEUtiAOB2j3RTFkUR8bh2LdKXWW+77ba05+vq6jJue71eiOLwPvLAwACSySS2bduGbdu2ZXytFcx4cdFxOkVEInHTptxaQFccHo/DtNCiVHQLl/GW3wSB04TljZeg9pxOc4SZCfWUIK5kt2kViUSQTCbhcmlxyPv3v4x587RlhNQEynXrNkw6gTIdeoiY3+9EbW0N2to+QDR6MWIFZMnD8xw8HjtiMdn0aq3R6EUC2tKf+Y2fNhsPnufQ22ten8nixUvw4IMPghBg69at2LFjB+bPnw9JknDw4EEcO3YMt956a9bH8/l8AICHH34Y55133pjHq6vHDyxzu90ghODOO+/EZZddNubxioqKrMdxNjBxgfZLrKrqpPcyJiIaTUAUOdPLk3W0EmXnmOPz+ozl0G+hdneaft6ixjcLyTTikppAeffdW+DxePHEE9/Bgw9uhaJoJeD19Q24555m4zX33fcAHnnkm9i791kjgTJbCNEu1IIw/CXLCuJxGcFgDOXllWhtbcWZMx/B5zt7wTITh0OE0ykgGIxa3uWv577EYglLltwoJcaSnpn4/V5s2rQJP/7xj/Hhhx/i/PPPN/ZYnn32WWNZKlsaGhowa9YsdHR0YPPmyTlmO51OLF26FKdOncKdd9452bcyZZi4DKH7jokiZ+ofTjAYhd8vQZaTllTy6EFgqqot6/E8hdclQm75HdSPsy9nnSlQbxnokEN2anjX3Xffh7vvvm/M8/fu/fdxj1VXV489e57LeD5CtE360amUhBAkk4qRbTIwkBwxa66pqcOhQwfR3v5B3sVFdx3Wl8Gs9iTThMUJWU6a7hmm4/HYEQ6ffdnxeHi9TnR1deLxxx/H6tWrjYKPxsZGbN++HfX19SgvL8/6eJRSNDc3Y+vWrQiFQlizZg0EQUB7ezv279+PXbt2weEYf//13nvvxc033wxKKdatWwdJktDV1YVXX30VX/va19DQ0DDl9zweTFxG4XY70N1tXg242U2Q6Y7f16fNYADAIVIkD/8e6kftpp5nekBAnG7QWBJOpwiOo2MSKJNJxUic1PcSRt7WHhsviVLfw9NjjgFNRPRUynB4/ETKVFwuN0pKyhAItGHx4mVW/2DGxW4XIEkiIpGEZRf6VCjVqiHjcdkyuxqnU4SqwvTAMt3A9uTJk1BVFStXrjQea2xsBAAsX7580sfdsGEDJEnCM888gxdeeAGUUtTU1GDt2rUQhMyNto2Njdi3bx927dqFrVu1WXhlZSUuvfRSlJVNPp55MsyYsLBs0ZIEk6YujwHa+q4k2UwPM9IRBA5elwD5rf8Hpesf5p9gGkAkH7hLr0PPqDLk1ARKfVahJ08CGHVbe0wXnOE0StUQHv12NiKSiSNHDuPo0cO47rob4HSaW9E4ERxHhyySVASDsZzYx1BK4PM5EYkkLEmqBIb/Ds0205xJIWDZwmYuo9CXx+x2wdS13lhMHtoMdZi+zstxQ3ssR15hwpIB4ilBMk3mRzKpFpxDMgBUV9fi6NE30d7eigULxm7mWoUk2YyQLCtLjFPhOC0lNRy27pyCwMHlsqGvz/ySZp8vu9aAmQTrcxkHl8tm+qcQfdNdksyzneE4Ap9bhHz0D1A6T5h23OkI8ZQhoRTPr3xpaemQkaW1AWI6oqgFiVFK0NMTzpmw8DyFz+fA4GDMsnPqkc4DA1HTZ2GSJBozXsYwxfOXlkP0XxIrPo0MDERhswmmNFhSqglL8p0/QQ28b8Lopjm+CiRzEJBlFoQQ1NTUoqurc4SPlNlovSR2SJIdwWB0KPY4Nz8n3cE5GIxaZl2j7+OEQjEkEubOUHmewuEQmbCkgYnLOOi5L2abW6qqiv7+CCTJNqVMGUoJfB4RyWMHoLT/3cQRTl+op7QgmhAnQ1VVHRRFMaJyzYQQDHX+OyHLCnp7B02/+GZCFDljNmFVabNe0hyJJCwRL683t3thxQQTlwwQQoaqisz9VJJMKhgYiMDttkEQJh8wps9YlL+/DqX1mKljm7ZwPIjNntNcEzOYPXsOBEGYcsZLKrqolJRI4DiKvr5wTirBUrHZeLjddvT3RywVNI/HYZR7m41uIstmLelh4pIFepmvmciygoEBzcZFK1nNDkNYjrdAOXXU9HFNV4jLj2Q8N3sIZjLayHIqpIoKpRS9vWEEg9GcJ3I6neJQxZa1djZajgoscWq22QQIAseEJQNMXCZA713I1ihyMiQSSQSDmo1LNhkwhBD43AKUE4ehnDxi+nimM1pAWHHNWnSqquoQj8dx5szZ2fgQQiBJIkpKXKCUoLc3jFAoankz5NhxaM2Loshbno6p9zFZYc9PiBYqxsgMK0XOAjLU0e1wCIhEzP30G48njSCwTLX3hrD8469QThw2dQwzAeItg6xSAMNLMP39fXj44X9BR0cAoiiiqqoG9933APx+f8aUSbMTKCdCN7IMBFoxZ05l1q/Tl3XtdgGxmBYilmtB0dGrtRKJJAYGzPfaS8Vm42G3T91Cfzz8fm0lg81aMsNmLlmiffqzTWoJK1tiMRnhcBw+nxOUjv2FJQTwuQWg9R0o7x8y/fwzAeKrGPNJmRCCG274An7ykxfx3HP/gaqqanz/+7sBZE6ZtCKBMhOiKGL27EoEAm1ZVXEJAge3246SEmnIsmUQoZA5lvJngyjy8Pm0HhYrw8SA4V6W/n5r3Jq9XofhxsDIDBOXSWJVdUg0qnUlj44y1oRFBNr/huTfX7fk3DMB4vKPWd/3eLxYvrzR+H7Rogtw+vTpjCmTViVQTkRNTS1CoQH09qZPEeU4felLgiTZkEgk0dMTyquoAFpDpm4QaXVKpiBo1Wf9/dbsIzmdbJ9lMjBxmQS69Yc+LTYbvVxyuAplSFg63kfy2AFLzjkjEO0gHJfxIqsoCn7xixfQ1LQmY8pkpsespLq6HqoKBALDVWOEaN5fPp9zqOiEoL8/gr4+rQEyn8ZOupULxxH09g5aXgKeWtYsp3FhmCqCwMHpNL+xejrDxGWS6P0vmu+S+YTDcchyEh6PA16XAHSdRPKdP1lyrpkC8ZRCnqBSbOfOHXA6HbjuusnZmucKSZJQVlaOQKA1ZdnLBVHkEA7H0N09OJRSmv+iBVHk4fc7EYslMDAQtVzkrC5r1ntlGJODbeifBYQQ2Gw8ZNn8DX5AK50s9dqgfvgB5L++avrxZxrUXYpEhmvuU0/9XwQCbXjiiZ2glE6QMqlalkA57vgpgSjymDfvHLzxxutQ1QRkmSIUiuWskz5bXC6tObi/PzepmXa7AKdTRF9fxDJh9fslAGwDf7KwmctZom/wi+LkmyAnwucSoHz4AeQj/236sWckvnLI46RPPvPM03jvvb/hscf+1YiITU2ZBDAiZTLTY2ZBiCYmkmSD3++E3++EIHCorKyFqqp4552/IRJJFJSwiCI/VECQm2UwQA8vEy0ta2Yb+GcPs9yfAvqPrrd30LQNRK9LAO3tQLLl9wDYf40Z8Gv/J4KKfcySyT/+cRJf+ML1qKmphc2mLXPOmVOJxx77NlpbP8Ajj3wTwWDQSJmsra0HgIyPndX4jCAxLayOUgpZTiIeTyKRkI0Ltaqq+MUvnofX68MVV6w/6/OZiZ7oyHEcQqFozuxjJEk0ZkhWFSy43XbYbDwTlrOEicsU0TM8enpCU15b9roE0L4uJFt+h7zuxk4zxE/fhkhMC2rTv/LRQDicRMkZtyklRoicLCsjxCQdhw4dxHvvHcPmzTcaM6184XBoS1K5ChLTcbls4HkO/f0Ry2ZvDocASWIb+FOB7blMEe2XT4XfL6GnZ/Csj+ORBHADZyC3vMyExUycHqiKJiY8T2G38ykxwyoURRmRRKl/WAD0NMrU28NplMBw4uTYJEoyIqlST7wcKSJxyPLkRa6qqhZ///u76OgIoKFhrsk/rOzgeQqXyw5VVYeWpHL3++p220EpGepjseYc+pIkE5apwcTFBPRoW5/Pib6+yXcFeyQefOgjyG/8FlDzX+0znaCeEsgJGZHI2OUa/aKv/8vzwymUQOY0SmC8JMqxt82cKelGloHABzkXF0JguHkPDsYs71sZjcejVWyZHbaXihboZ00l6EyDiYtJ6JnpXu/kkibdEg9+sAfyGy8xYbECdylkZaTti462RIac2sxPFUopqqtrEQi0GRVruUCPB47HZcuiusdD8yRzQFFUBINRy86j9eY4hs7JZi1ThVWLmYjuQZbtJx+3xEOI9EF+/dfAFB1vGekh/lmQiyggLBuqq+uQSCRw+nSX5efSw7ycThEDA9Gh8mfLT2vAcVozZjKpWCoshBBWcmwyTFxMRi8jdbkyu6a6nTyE6ADkv/wXoBTPJ+dioxgDwiaiqqoGlFJ0dpqX8TIaXVTcbjui0QR6e8OWdL5nQhQ5+HxORCIJSz3JCIHhw8aExTyYuFgAIQR2uwBJSl/N43LyEBIhyAf/E0jmdt16RkEpiF0qiK51MxEEAXPmVKKtrdX0ailB4ODzOeByaaLS0zOY870VQLPMd7m0rvto1LocHiYs1sHExSIIIXA4RDgcwoj7JScPUR6EfOCXTFgshrj8UBK5TVjMFVVVtQiHQ+jp6TblePosweWyIRLR7PnzISr6/ooockOzJes+GGg+gZJR5ccwFyYuFqJ38TudmsBIDh72ZATyn38JyMWXilhskGm4JKZTU1MPgKC9vXVKx9FFRZJsiETi6O0N50VUAK16z+eToCgK+vqs62HR8fsl1n1vIaxazGK0wCYbRJ6AxiNI/PkXgDw9P00XGsQzNiAMyBwStnHjVRBFEaKo7ZndccdXsGrVxQByHxKWCafTidLScnR0tGHp0hWTfr0o8nA6RRACDA7GEY/ndxatLyOHQrkpcdainpmwWAkTlxxACAEN9UA+9FsgYW1YEmMY4quAnKbBTw8J07Ncnn76SXz/+7tx//3/AgB45JEnMHfuvDGv00PC1q3bgJdf/g127HgUu3Z939o3kYGamlq89VYLQqEQXC7XhM/neQqbTYDdzkOWFYTD+RcVQvTGSJqThkx9KYwJi/WwZbEcwZXOAa1flO9hzCiI25+2wmm8kLBM5CskLBPV1XUgBAgEPhj3OdrenwC/3wmPxwFVVdHbG0Z/fyTvwsLzFH6/hGQyN53+hBCUlLiYsOQINnPJIcLCVZB5G+RjB8B+tS1GsIHwIhQls2NCakiYzrZtDwFQsXjxUtx++xa43e6MIWFmOiJPBp/PD7fbg/b2NixceMGIx0SRh93OQxB4xOMyQqFYQTWLao7GAoLBWE5EjlIytHnPqsJyBZu55Bh+3lLwy64ACPvRWwlxlyAZn3hva3RI2NNP78Fzz/0Ee/b8CICKnTu3WzzSs4cQgqqqOpw504VYLAaOo5AkG0pLJTidAuJxLeo4GMydW/FEaLMVp1ENlgth4TjCyo3zALvC5QG+ZgH4CzcAnDDxkxlnBfGUTNiZr4eEbdv2GCjV/hRmzZoNABBFEddcswlHj749dP9wgBiAnISEZUNDQwMAFQMDH8HrdRhmkn19kbxHHadCiOZm7PE4EA7HLbXKT4XnOdZ5nyeYuOQJblYt+Es+C4jMJM8KiLdiyFMsPelCwiKRCEKhEADNlHL//pcxb965ADIHiOUSjtMadD0eB0pLXZg7tw42mx3vvXccPT2DCIfjOXUpzgabjTcu8Lnsn7HbBeYVlkdYnkueUYK9SPzl10AkmO+hTCv4yzYjqDrTLgeNFxJ2551348EHt0JRNGv8+voG3H33fSgrKwNgfkhYNnAcgSDwEAQOgqDt9yQSScTjMuJxGaoKHDjwB7S1fYBNmz6fMyPLbKCUGBb5wWA0pz1HkmQzGpiZsOQHJi4FgBIJQT70O6h9H+Z7KNMGccOX0N1XeBnzmRgOE9P+5flhMdEFJd1SUmvrP/DHP/43Lr98Haqra3I97LQ4nZo7RTgcRySS24Zhr9cBQeCYqOQZVi1WAFCHC/wl/wPJv/4BSuD9fA+n+LFrPR9ut80I50omtVyVQhCbVAHhOD2ZkqSMVUE0KkOWY1ntS1RV1YDjOHR0tOVdXASBg8tlQzKplTznMvFT62FxglLKhKUAYOJSIFBeAF3+T5DdJUj+7XUA+b8IFit6QFgsoc0GRJEfuohTEAIjvEv/V0ujHJk0OV4a5Wj0CqSxSZRjkyr1ULLRIpJMxqdkrsnzmpFlINCGCy+8JC8X1tQgsVAoN+XFqbBS48KDiUuBwc9fDuIugXx4P7OJOUuIpxRxhSAWG7sco8UPj0ygFAR+TNLkyDTKsRcsVdXu1+OPxyZRavfrsyVdxKzabK+qqkMg0Ibu7o9RVlZuyTnSQQgMg9ZoNPdBYoDmj6anVDJhKRyYuBQg3Ox6kKZrkTj0W2CwP9/DKT7GsX0BNDGYagKlfv0qgBU2g5qaWrz+OkEg0JYTcUkVlXg8mZMO+3S4XDbY7WzjvhBhpcgFCvWUQLj0OpBZ9fkeStFBPGWWZrgML5UVDg6HE+XlFVN2SZ4IzYhVNGxUenvDCAajORcWfX/FbheYZX6BwsSlgKGiHeKqDeAWXcI6+rOFUFCna9pa7WeiuroWvb3dCAYHTD+2Fh8hGm7Cvb2DCIWyKzgwG57nUFLiGtpDY6JSqLArVhHAn7MUfNO1gNOT76EUPMTlhZKYmSFs1dX1IARobzcv/ljPJNLsU/IrKgAgSSJ8PgfbuC8CmLgUCZy/AsKaTaCVY63gGcMQd2nOs94LBZ/PB4/Hi0Bg6uJC6bCoAMi7qBBC4Pc74XCIbBmsSGDiUkRQ0Qah8VPgFq8BaOF0YhcSxKsHhM1MqquHjSzPBp7X+lRS7VoGB/MnKoBm41JaKrFlsCKDVYsVIXzDBaClcyAfeYV19Y8mQ6XY/fffg87OTlBK4HA48bWv3Yf58xdkTJgspPTJbKiqqsOxY0cRCLThnHPmZ/UaSjW/MptNAKAiGpXR0zNYEA2nPp/DcCpgwlJcMPuXIkZRklBOHEHy/RZAmZlLQaMRPnUz+sLp+0lSExv/9KdXsXfvHvzgB/tw113/B5/+9GeNhMmXXvqVkTCZ6bFCRFVV/Oxn+zBr1hxcdtkVGZ9rs/Gw2wXwPIdYLIFoNFEwhRCsd6X4mbnrB9MASjnw564Av2YjiDd3jXMFCyeAiLZxy2JTo4BDoRAIoRkTJgsxfXIiCCGorq5FZ2c7ZHlsYQPPU7hcNpSWumC3C4hGE+juDiEUihWMsHg8diYs0wC2LDYN4DylIJdeOzSLOQQohXGRyDXEM3FA2OOPP4w33vgLAODb396VMWFSVdWCS5/MhurqWpw8+T66ujpRU1MLSglsNgF2Ow+AIBpNoLd3MK/7KOmw2Xi43ZpLNROV4oeJyzSBUg703BUgs+uRfPtVqL1n8j2knEPcJZioUKy5+SEAwO9+9xK++90n8cUv3pGDkeWWysoqcByHM2cCuOCCBcayV65t77OFEAKfzwGOo8b3jOKHLYtNMzhPKfjV14BbcvmMCyIj3nLISnYXpvXrP43Dh99ERUXFuAmThZo+OR6iyEGSbCgv96GhoQFtba0Ih+MFt+yVih7LrFeCMWGZPjBxmYZQSsHXnQfhkzeA1l8wbIY1zSG+Csjj2L6Ew2GcOXPa+P611/4Ij8eTMWGyUNInx4PnKRwOEV6vlkrpcIhQFBUDAxGUlc3B4GAInZ1d+R5mWnieQ2mpBIeD2bdMV1i12Awg2fcRkkf/BLX39MRPLmKEK7+I3oF42r2Enp5uNDffg2g0Ako5eDwebNlyNxYsWJgxYTIf6ZPjwfMUgsBDFDnwPAdFURCPJ4fCxOQRfmfRaAQ/+9k+XHDBEixbtjIv400HpQQejwM8z5bApjtMXGYIqqpCaX8P8t/+AsTC+R6O+dicEK74X+jujeZ7JFNGz54ZHSqWTI4vJul4+eX/Qjwex1VXXZebgU+Ax2OHKGrbvExUpj9sQ3+GQAgBV7sQpPIcKKeOInn88LTKiyGeEhBVgc/nHLLUH/lViB+h0gmIJiIqkskkZFlBPC4jHFbOyuW5qqoOb731OgYG+uHxeC14B9khSSIcDhEAE5WZBBOXGQblBdD5y0Frz0fyxGEop45OiwZM6i5FNK4gGo8aF+mJEij1f0emTo5Oo8wO3UgxUxKlflsbEzGET5YVxGKykU5pFjU1mri0t7dh0aLFph03W+x2AZJkYyaTMxQmLjMUarODLroESsNi9L35Chw9AdBi/vv3VUBWCGRZSVsVpSdQchwxkihFkTcu+vpzRqdREkIMoRktPKkCoj8+MpUSxu1hIVOHZibWV255vV54vX4EAq05FRdNVMQRP0vGzIOJywyHOt0oufSzSA50Qzl+GErnicJLwsoC4i3L6IacmkAJTH6mlk54NCFBQXhwjUd1dS3effcootEo7HZrS9NTZyoAE5WZDitFZgDQ+mOEFf+slS/XLSoy12UC6vRYnj6pKKqxnKYtYakFLSyA5pIMqAgErEuodDgElJa64HLZRiwPMmY2TFwYI6CSF8KSyyBc8Xlw85YBvJDvIU0IkTxQkhNXT81EyssrYLc7EAi0m35srQHSNWJfhYkKQ4ctizHSQh0S6PkXg85bBuXUO0ieOgrEI/keVlqIpxTJGRoQNhG6keWpUycgyzJ4fmp/8pQSuN12CAKzwWdkhs1cGBmhoh38gkYI/3QjuKWfBPFV5HtIYyCeUiQU9qs8HtXVtUgmk+jq6jjrY4giB7/fiZISCYLAsVkKY0LYzIWRFZTnQWsXArULkew5DaX1XSgdJwGlAPLqfbOQLDCH30JizhzNyDIQaENNTV3WryNEW/qy2QS2Sc+YNExcGJOGK5kNrmQ2lEWrobS/B6X1GNRQ/jJOqKcEcmT8zfzxEig3brwKoihCFG0AgDvu+ApWrboYQPElUGaC53lUVtagvb0VF13UNKFA2O0CHA6BuRQzpgSzf5mGvPjii7j//vtx+PBhSJI0pWO99tprOHHiBG6++eaMz0v2fgil430oHSdyay9DOYgbvoiPu8c/53gJlBs3XoXt23di7tx5Y15TbAmUE3Hy5Ps4cOCP+NSnPoNZs2aPeZznKZxOG0RxuEqQiQpjKrCFakZG/vznP+NHP/rRhM/j/BUQLmiC8M83gr/oM6DV5+ak0oy4S5BMJDI+J10CZSaKMYFyIqqqagEQdHS0GffxPIXbbUdpqQt+vwRRHN5LYcLCmCpsWYxhKpRyQEUtuIpaKHICyulTUDpPQv2oHUiavz9DPCVZ5ZSMTqDU2bbtIQAqFi9eittv3wK3250xnbJQ7PYni91ux6xZs9He3oa1a9dAEDR3AlVVWSc9wxLYzKUIOHjwIBYsWIAzZ4bTJa+//nqcd955GBgYMO676qqrsHPnTuP7QCCAW265BUuXLsX69evx+9//fsRxX331Vdxyyy24+OKLsXz5cmzevBmvvfaa8fju3bvxgx/8AB0dHViwYAEWLFiA5ubmrMdNeQF89bkQL7wSwrr/Df7CDaB15wP2qS3VpUI85ZDViX+Nm5sfwosvvoTbbvsyvvvdJwEATz+9B8899xPs2fMjACp27txu2rgKCVHk4fU6cOmll2DDhnUQBA6UMkFhWAsTlyJg2bJlEAQBb775JgAgEong3XffhSAIOHz4MACgr68Px48fx4oVK4zX3XvvvfjkJz+Jp556CvX19fj617+O06eHM10CgQAuv/xybN++Hbt378ayZcvwpS99yTjPpk2b8JnPfAbl5eV4/vnn8fzzz+PLX/7yWb0HyvPgZtdDWLIWtk/dBP7SjeDObQTxlp3tjwUAQPwVk+rM1xMo+/v7jL0HURRxzTWbcPTo2wBQdAmUo+F5CpfLhpISCWVlLng8Wl9KbW0tKisrQSn7s2dYD1sWKwLsdjsWLVqElpYWbNiwAUeOHIEkSbjkkkvQ0tKCtWvX4s033wQhBMuXLzdmKDfddBM2btwIAFi0aBFWr16NV155BZ/73OcAAJ///OeNcyiKglWrVuHEiRP4+c9/jhUrVmD27NmoqKiAKIpYunSpqe+J81cA/gpg4YVQYhGo3Z1QujuhfNwBBHuyPg5x+SEHx99zCYfDCAYHDCHREyhF0WZs9Kuqiv37X8a8eecCwIgEynXrNhRcAuVoeJ7CZuMNF2jdbBNgMxNG/mDiUiSsWLHCWLJqaWlBY2MjVq5ciV/96lfGfQsXLhyxed3U1GTc9vv9KCkpGTFzOX36NHbu3IkDBw7go48+Mi5Iy5cvz8VbMqA2B1B5DrjKcwAASjSsiU1PF5SPO4FQT3ozTdEOwnFQlPFzaaLRCB56qHlEAuUTT+xET083HnxwKxRFs7mvr2/APfcML/ndd98DeOSRb2Lv3meNBMpCgBBiCAnPU8PVebSYMFFh5BsmLkXCypUrsXfvXgwMDBizlcbGRjz66KOIxWJoaWkZsSQGAG63e8T3oigiHtcuxIqi4I477sDg4CDuuusu1NXVweFwYNeuXeju7s7Z+0oHtTuBqnngqrQSYSURhzrQDQx8DKXvQyh9HwGhXqNSLPXiOpqSklL827/9MO1je/f++7hjqKurx549z035vUwFLdaYgyBwKbk0I98rExNGocLEpUhYvnw5VFXFG2+8gbfffhv33nsv5s+fD0mScPDgQRw7dgy33npr1sdrbW3FsWPHsGfPHqxZs8a4PxotvJhgKohA6RygdA70LgxFTkAN9oDwPMrKHEaOiqIokGUVspyELCcLNoVSh1ICnqfgeQ48zxl5M6lZMsBI8WBCwigGmLgUCV6vF/Pnz8cPf/hDUEpx/vnnG3sszz77LGRZHjNzyUQsFgOgzWZ0Ojo68NZbb+Hcc8817hMEwXhuIUF5AfAPb7BrCY9k6GINALxxEdZDvFLDu3Qh0oO7NBGaXPpkOnRRoJSkhJMNB5TpX6kzjnQzkfG+ZzCKBSYuRcTKlSuxb98+NDU1GT0YjY2N2L59O+rr61FeXp71sebOnYvZs2fjiSeewFe/+lUMDg5i165dqKioGPO8jz/+GC+++CLmz58Pv9+P6upqU9+XmaS7GKc2BVI6Vj3SvWb0Mlvqt5mu96nHSrdUN974GIzpBqtJLCIaGxsBaCIz+r7JbsKLoojdu3eD4zjcddddePLJJ3H77bfjwgsvHPG8K6+8Etdeey127NiBjRs34qmnnpriu8gvqR3omTrRRz9n9KxjvK+zOReDMR1h3mIMxjTHTK85BiNb2MyFwWAwGKbDxIXBYDAYpsPEhcEoMqzymgOA/fv349prr8XixYuxevVqbN++HYkU1+ndu3dj1apVOHbsGDZv3owlS5bg6quvRktLi0XvllGsMHFhMIoMq7zmfvOb3+ArX/kKPvGJT+B73/setmzZgp/+9Kf4zne+M+L80WgU3/jGN3D99ddj165dEEURW7ZsQSQSycG7ZxQLTFwYjCIj1WsOgOE1d8UVVxj3pXrN6dx000248cYb0dTUhMceewyKouCVV14BoJVN79ixA1dffTW+9a1voampCTfccAOam5uxb9++EVk20WgUDzzwAK677jpcdtll2LZtG/r6+nDo0KEc/hQYhQ4TFwajCFmxYoUhJKlec6n3TcZr7tSpU+js7MT69eshy7LxddFFFyEWi+H48ePGawVBwKpVq4zvzzlH84RLXaZjMFgTJYNRhJjtNafPTG677ba05+vq6jJuS5I0wrZfd3koRCcHRv5g4sJgFCFme835fD4AwMMPP4zzzjtvzOOF7MrAKEyYuDAYRYjZXnMNDQ2YNWsWOjo6sHnzZgtHzpgpMHFhMIoUM73mKKVobm7G1q1bEQqFsGbNGgiCgPb2duzfvx+7du2Cw+Gw6q0wpiFMXBiMIqWxsRH79u0zxWsOADZs2ABJkvDMM8/ghRdeAKUUNTU1WLt2LQRBMG3cjJkB8xZjMBgMhumwUmQGg8FgmA4TFwaDwWCYDhMXBoPBYJgOExcGg8FgmA4TFwaDwWCYDhMXBoPBYJgOExcGg8FgmA4TFwaDwWCYDhMXBoPBYJjO/wd0mqoeyWx9HgAAAABJRU5ErkJggg==\n",
      "text/plain": [
       "<Figure size 432x432 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 576x1080 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "df_sorted = get_qtype_freq()\n",
    "plot_qtype_frequency(df_sorted)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "density_plot_data(['context_length'], 'context length')\n",
    "density_plot_data(['question_length', 'answer_length'], 'question and answer length', figsize=(6,4))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.3"
  },
  "toc": {
   "base_numbering": 1,
   "nav_menu": {},
   "number_sections": true,
   "sideBar": true,
   "skip_h1_title": false,
   "title_cell": "Table of Contents",
   "title_sidebar": "Contents",
   "toc_cell": false,
   "toc_position": {},
   "toc_section_display": true,
   "toc_window_display": false
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
